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Abstract 
 
Obesity together with insulin resistance promotes multiple metabolic abnormalities and is 
strongly associated with the increased risk of chronic disease including type 2 diabetes 
(T2D), cardiovascular disease, non-alcoholic fatty liver disease and chronic kidney disease 
(CKD). The incidence of obesity continues to rise in astronomical proportions throughout the 
world and affects all different stages of the lifespan. Importantly, the proportion of women of 
reproductive age who are overweight or obese is increasing at an alarming rate and has 
potential ramifications for offspring health and disease risk. Maternal obesity is known to 
influence offspring development of obesity, T2D, cardiovascular disease and non-alcoholic 
liver disease. In contrast, the relationship between maternal obesity and CKD has not been 
clearly defined. This thesis aims to investigate if maternal obesity increases offspring risk of 
chronic kidney disease. In order to achieve this primary objective, both mouse (C57BL/6) 
and rat models of maternal obesity were developed by feeding dams a high fat diet (HFD, 
45% fat) for 6 weeks prior to mating, during gestation and lactation. The offspring’s kidneys 
were observed at various time points after birth, including postnatal Day 20, Week 9 and 
Week 32. At Day 20, there was evidence of renal inflammation and oxidative stress and the 
nuclear hormone receptor Farnesoid X receptor (FXR) was pathogenically implicated. 
Following this study, the kidneys of rat offspring of obese versus lean mothers were studied 
at postnatal Week 9 and demonstrated significantly increased markers of inflammation, 
oxidative stress and fibrosis in the offspring of obese mothers compared to control, 
exacerbated by HFD-feeding in the offspring. The glucose-like peptide-1 (GLP-1) analogue, 
Exendin-4, ameliorated the negative renal effects of maternal obesity and in particular, 
reduced renal inflammation, oxidative stress and fibrosis. We hypothesised that GLP-1 
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analogues may be useful for protecting against the deleterious effects of maternal obesity on 
renal physiology in offspring. Thereafter, a mouse model of maternal obesity, utilising the 
C57BL/6 strain, was employed and the offspring’s kidneys examined at postnatal Week 32. 
Consistent with the metabolic effects observed in the rat, mouse offspring of obese mothers, 
compared with lean mothers, had increased fat deposition, insulin resistance and impaired 
glucose tolerance as well as albuminuria and renal pathology. Furthermore, postnatal feeding 
of HFD in offspring augmented these effects. Specifically, we determined that offspring of 
obese mothers have increased renal fibrosis, inflammation and oxidative stress. Offspring of 
obese mothers are more prone to renal damage when an additional insult, such as 
streptozotocin-induced diabetes, is imposed. However, diet-induced obesity with HFD-
feeding in offspring was a very powerful means of inducing weight gain, glucose intolerance, 
albuminuria and renal damage, which may well have overpowered the effect of maternal 
obesity. We suggest that developmental programming resulting from in utero exposure to 
maternal overnutrition predisposes offspring towards CKD. Foetal exposure to maternal 
obesity should be considered as a clinically significant risk factor for chronic kidney disease. 
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     Chapter 1  
 
 
 
General Introduction 
  
  
2 
Maternal perturbations during gestation and in early postnatal life are associated with adverse 
consequences for the offspring and may increase the likelihood of chronic disease later in 
life. Obesity in women of childbearing age is increasing dramatically worldwide and 
therefore, the effect of maternal obesity on offspring disease risk is of significant interest. In 
particular, the effect of maternal obesity on kidney health is important given the significant 
increases worldwide in chronic kidney disease (CKD). CKD can ultimately lead to end-stage 
kidney disease requiring renal replacement therapy and renal transplantation, which are 
associated with tremendous cost and significant comorbidity. The central hypothesis of this 
thesis is that maternal obesity has lasting consequences for offspring kidney health and 
increases the propensity towards development of CKD. 
  
The specific aims of the project were to:  
1. Develop a robust rodent model of maternal obesity and obesity-related kidney 
disease. 
2. Determine the role of maternal obesity in the development of CKD in offspring. 
3. Investigate the underlying mechanisms involved in the relationship between obesity 
and CKD and more specifically, the relationship between maternal obesity and CKD. 
 
To address the central hypothesis, the investigations associated with this project have found 
that maternal obesity programs offspring towards the development of metabolic 
dysregulation and CKD. The results demonstrate that maternal obesity leads to dysregulation 
of renal inflammatory, oxidative stress and fibrotic markers in rodent offspring. There are 
lasting effects of maternal obesity on renal function and structure in the offspring.  
 
  
  
3 
This thesis consists of the following eight chapters:  
1. Chapter 1 briefly describes the research problem investigated in this thesis, and addresses 
the overall objectives and specific aims of the thesis. 
2. Chapter 2 provides a literature review of maternal obesity and its known associations with 
chronic disease in offspring, obesity-related kidney disease and its pathophysiology, and 
the current knowledge relating maternal obesity to CKD in offspring. 
3. Chapter 3 studies the relationship between maternal obesity and renal damage in rat 
offspring at weaning (Day 20), and specifically determines the expression of the nuclear 
hormone receptor, Farnesoid X receptor (FXR), given its known role in maintaining 
homeostasis of glucose and lipid metabolism. Chapter 3 includes both in vivo and in vitro 
experiments; and the in vitro component of this chapter includes previously unpublished 
work of Dr Muh Geot Wong. Chapter 3 has been fully peer reviewed and published in 
Nutrition and Metabolism, 2015. 
4. Chapter 4 studies the effect of maternal obesity on renal outcomes at the equivalence of 
adolescence in a mouse model. It then examines the therapeutic effect of glucose-like 
peptide-1 (GLP-1), specifically Exendin-4, on the renal pathophysiological changes 
observed in the offspring of obese mothers. Chapter 4 has been fully peer reviewed and 
published in Scientific Reports, 2016. 
5. Chapter 5 assesses the role of maternal obesity and its impact on the development of 
diabetic nephropathy in the offspring. Chapter 5 has been fully peer reviewed and 
accepted for publication in Scientific Reports on May 25th 2016. 
6. Chapter 6 compares animal models of diabetes, obesity and renal disease that were 
generated as part of this thesis. Characterisation of these mouse models formed a 
significant component of my PhD studies, which I consider will be useful to have in the 
  
4 
public domain to assist future researchers. The content of Chapter 6 has been submitted to 
PLoS One and is currently under peer review. 
7. Chapter 7 further assesses the role of maternal obesity in a mouse model of obesity-
related CKD. The content of Chapter 7 has been submitted to Diabetes and is currently 
under peer review. 
8. Chapter 8 synthesizes the findings of each chapter and proposes future directions.  
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     Chapter 2  
 
 
 
Literature Review 
 
  
 6 
2.1 Maternal obesity – A global pandemic 
 
Obesity affects almost one quarter of the adult population and is increasing rapidly 
among young women globally, with more women of childbearing age falling within 
the spectrum of being overweight to obese (1, 2). In Australia, between 13 and 21% 
of women in reproductive years (age 20-40 years) are classified as overweight or 
obese (3).  In the U.S., the prevalence is even higher at 35% (2). The 70–100% 
increase in maternal obesity over the last decade has had ramifications for all aspects 
of female reproduction, with maternal adiposity strongly associated with an increased 
risk of almost all maternal and foetal complications (4, 5). 
 
Maternal overweight and obesity are strong predictors of poorer pregnancy outcomes 
(6-13). Moreover, maternal weight predicts pregnancy-related complications such as 
gestational hypertension and preeclampsia, and pregnant women with a body mass 
index (BMI) above 30 kg/cm2 have a six-fold increase in risk of gestational diabetes 
(10).  The most common birth-related complication of maternal obesity is large for 
gestational age (LGA) neonatal size (defined as a birth weight above the 90th centile), 
which is more than doubled in neonates born to obese mothers compared to lean 
mothers (14, 15); this gives rise to the most common delivery complications which 
are caesarean section and assisted vaginal delivery in addition to premature delivery 
(10, 11). Australian super-obese pregnant women (defined as BMI > 50 or weight > 
140 kg) have a significantly higher risk for obstetric and medical complications 
during pregnancy (more than doubled), birth by caesarean section (51.6%) and 
admission to special care (16). Their babies are 20 times more likely be born with 
 7 
birth weight ≥ 4500 g, compared to babies of normal weight women. Interestingly, 
small for gestational age (SGA) neonatal size is also increased in pregnancy 
associated with maternal obesity, and neonates are more likely to have low Apgar 
scores, require special care or neonatal intensive care (NICU) admission. 
Furthermore, offspring from obese mothers are at higher risk of stillbirth (17). 
 
Maternal obesity has lasting effects on the long-term health of offspring. Evidence 
from both human and animal studies suggests that maternal obesity ‘programs’ the 
offspring towards obesity, dysglycaemia, diabetes and hypertension, all key features 
of the metabolic syndrome (18, 19). This observation evokes the concept of the 
developmental origins of health and disease (DOHaD); a concept first explored by 
Barker and colleagues, which suggests that chronic disease may be influenced by in 
utero exposure to the surrounding maternal milieu (20). There is substantial evidence 
that maternal obesity increases risk of diabetes, obesity, hypertension, cardiovascular 
disease and even premature death in adult offspring (21-24). The effect of maternal 
obesity on the risk of chronic kidney disease (CKD) in offspring is less well 
appreciated.  
 
The current review will discuss the evidence for the role of maternal obesity in the 
developmental programming of disease in offspring. Furthermore, it will review the 
current knowledge regarding the important risk factors and mechanisms of CKD. 
Finally, the evidence for the association between maternal obesity and renal disease 
will be discussed.  
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2.2 Maternal obesity and developmental programming of chronic 
disease 
 
2.2.1 Association between maternal and offspring obesity  
 
Environmental factors play a key role in the development of obesity and its associated 
comorbidities during postnatal life. Lifestyle factors, especially related to diet, are 
likely to be shared by mother and offspring. Importantly, neonatal and infant 
overfeeding are associated with increased rates of childhood obesity (25). 
Furthermore, meal behaviour related to food choice and quantity are commonly 
shared between adults and children from the same household (26). Several 
socioeconomic factors have been identified for maternal obesity, including low 
educational level, lower household income and ethnicity (10, 16). Socioeconomic 
status has been shown to influence food choice behaviours in many observational 
studies (27-29). Risk factors related to food behaviour are often shared by subsequent 
generations and they are likely to influence obesity risk for progeny.  
 
Mother and offspring commonly share the same genetic susceptibility towards 
obesity. Twin studies point towards the strong heritability of body weight. One study 
found the twin-to-twin correlation in BMI as high as 0.79 in adulthood, even in 
monozygotic twins who have been reared apart and thus exposed to different 
environments for most of their lives (30). Within the FinnTwin16 cohort (a large, 
longitudinal cohort study of monozygotic twins), just 18 of 658 monozygotic twin 
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pairs were discordant for obesity at age 25 years (31). Twins discordant for BMI 
differentiated their weight from age 18 years and predisposing factors included 
physical inactivity, sedentary lifestyle and conscious efforts to remain lean. 
Interestingly, in the FinnTwin16 Study the twin that developed obesity during early 
adulthood had a slightly higher birth weight (193'g) compared to the leaner twin 
suggesting that in utero exposure may have led to permanent physiological changes 
despite identical DNA inheritance. 
 
Further evidence for the important influence of genetic susceptibility of body weight 
has come from recent Mendelian randomisation studies. In a cohort of over 30,000 
pregnant women, genetic scores based on known single nucleotide polymorphisms 
(SNPs) for BMI were correlated with neonatal birth weight and found a 2-g (95% CI, 
0 to 3 g) higher offspring birth weight per maternal BMI-raising allele (P = 0.008) 
(32). The strength of this study design utilising Mendelian randomisation is that 
genotypes are randomly allocated at conception, and are therefore mostly free from 
confounding. It provides the best epidemiological evidence for a causal relationship 
between maternal traits related to BMI and birth weight. 
 
Genetic background and postnatal environment are key features for the development 
of chronic disease. However there appears to be a critical window during gestation 
which influences the long-term risk unaccounted for by genetic tendency and 
postnatal environment alone.  
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Epidemiological studies have suggested that offspring born to obese mothers have 
increased rates of childhood obesity and increased adiposity during childhood (33, 
34). Large meta-analyses have determined that maternal obesity is associated with 
large for gestational age (LGA) and macrosomic neonates (14), and furthermore LGA 
offspring are more likely to become obese adults (35). Early infancy weight is 
strongly correlated with adulthood weight (36, 37). However, direct evidence of the 
effect of maternal obesity on lifetime risk of obesity in adulthood is less compelling 
and is limited by study design. Studies utilising large retrospective registries have 
demonstrated significant correlation between maternal BMI during pregnancy and 
adult BMI and are summarised in Table 1 (38, 39). In a Danish retrospective cohort 
study, maternal BMI was highly correlated with offspring BMI at age 62 years and 
higher maternal BMI was associated with a less favourable body composition (less 
lean body mass and increased fat mass) among the offspring in adult life (39). 
Furthermore, gestational weight gain (GWG) during pregnancy has been shown to 
have a significant impact on adult weight in the offspring, such that the risk of adult 
obesity was significantly increased with increasing GWG (8% per kg GWG) (40). 
 
Further evidence for the important effect of maternal obesity on offspring health 
comes from observational studies of women who have undergone massive weight loss 
between subsequent pregnancies as a result of bariatric surgery. Offspring born before 
their mothers underwent weight loss surgery had significantly higher bodyweights at 
12 years and at 21–25 years than offspring born after the surgery (41). This suggests 
that maternal obesity has long-term effects on offspring body weight and BMI despite 
similarities between genetic, environmental and lifestyle exposure. 
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2.2.2 Maternal obesity is associated with metabolic syndrome in offspring 
 
Obesity is established as a well-known risk factor for multiple components of the 
metabolic syndrome. Metabolic syndrome is a construct that can be used to umbrella 
the constellation of risk factors that increase the risk of diabetes and cardiovascular 
disease (45). These include hypertension, dyslipidaemia, hypertriglyceridaemia and 
central adiposity and they are intrinsically linked to insulin resistance (46). 
Overweight and obesity are strong risk factor for the development of each of these 
factors linked with metabolic syndrome, and the risk of diabetes is increased by three 
and seven fold respectively compared to normal weight individuals (47). Furthermore, 
overweight and obesity are associated with a two-fold increased risk of cardiovascular 
disease (48). A recent, large study based in the U.S. examining over 42,297,007 
person-years of follow-up in relation to mortality and found that the number of deaths 
attributed to coronary heart disease, stroke, sudden death from an unknown cause and 
total mortality increased significantly with BMI at mean age 17 years and in particular 
this increased risk began to rise with BMI above the 50th to 74th centile (49). 
 
Observations of the long-term outcomes of offspring born to obese mothers have 
determined that maternal obesity has a lasting impact on offspring long-term health, 
separate to the effects of genetic predisposition and postnatal environmental factors.  
A large, retrospective cohort study of over 100,000 person years found that offspring 
of obese mothers (BMI >30) had 35% increased mortality compared to mothers with 
normal BMI mostly due to increased cardiovascular death (Table 2A) (21). In this 
study, statistical adjustments were made for confounding factors including maternal 
age at delivery, socioeconomic status, sex of offspring, current age, birth weight, 
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gestation at delivery, and gestation at measurement of BMI. Using a similar 
experimental design, Eriksson et al. also found that higher maternal BMI was strongly 
associated with increased risk of cardiovascular disease, both coronary heart disease 
and stroke as determined by the International Classification of Diseases (ICD) code 
systems for hospital admissions and after adjusting for confounding variables (42). 
Though it remains possible that some confounding variables are not considered, these 
large observational studies provide compelling evidence of the effect of maternal 
obesity on offspring long-term health. 
 
There is less convincing evidence that maternal obesity is a significant risk factor for 
the development of T2D in adult offspring separate to the effects of offspring obesity 
or gestational diabetes in pregnancy. Offspring of obese mothers have been shown to 
be more insulin resistant at birth, as estimated by the homoeostatic model assessment 
of insulin resistance (HOMA-IR) score (18). Furthermore, the Hyperglycaemia and 
Adverse Pregnancy Outcome (HAPO) study found an association between increased 
maternal BMI and foetal hyperinsulinaemia (50).  However, there is only one study in 
a cohort of over 13,000 adults providing epidemiological evidence for the effect of 
maternal obesity on T2D risk in adult offspring (Table 1) (42). 
 
Non-alcoholic fatty liver disease (NAFLD) is frequently associated with obesity and 
is a common manifestation of metabolic syndrome (51). It is defined by hepatic 
steatosis and mild nonspecific inflammation seen on histological examination and can 
progress to more advanced forms of chronic liver disease and rarely hepatocellular 
carcinoma. A meta-analysis found the incidence of NAFLD to be 66% in patients 
greater than 50 years with diabetes or obesity (51). Adult offspring born to obese 
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mothers are more likely to develop NAFLD according to a recent study performing 
liver ultrasound in offspring during early adulthood (Table 1) (43). Greater maternal 
pre-pregnancy BMI was associated with an almost two-fold increased risk of fatty 
liver on ultrasound, greater liver volume and shear velocity even after adjusting for 
maternal age at delivery, parity, maternal pre-pregnancy alcohol intake, household 
social class and maternal pre-pregnancy BMI. Importantly, the effect lost significance 
when adjusted for neonatal body composition as measured by DEXA.  
 
Epidemiological studies have demonstrated non-metabolic effects of maternal obesity 
on offspring risk of chronic disease. The risk of late childhood asthma is increased in 
offspring of mothers with higher pre-pregnancy BMI (52-55). Furthermore, maternal 
obesity has also been linked to cognitive function and behaviour in the offspring. In 
one recent longitudinal study, maternal obesity was associated with 3.2 lower IQ 
points and a slower time to complete an executive function scale compared with 
offspring of normal-weight mothers at age 10 years (56). Studies suggest that children 
of obese mothers may be more likely to have an autism spectrum disorder, 
developmental delay, attention-deficit hyperactivity disorder (ADHD), depression, 
anxiety or schizophrenia (57). Despite adjustment for potential confounding variables, 
these studies are limited by their observational nature. 
 
A Swedish study observed the association between maternal BMI in the first trimester 
and the development of type 1 diabetes (T1D) in 1,263,358 children and adolescents 
(age < 18 years) who were followed from birth until development of diabetes (58). 
They found that offspring of overweight or obesity mothers without diabetes had an 
increased risk of T1D regardless of parental country of birth in an adjusted model. In 
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fact, the risk for T1D in offspring is 25% higher in those of obese Nordic mothers and 
67% higher in those of obese non-Nordic mothers.  
 
The aforementioned studies mostly employ observational, epidemiological designs, 
which inherently are subject to selection methods, differences in measurement of 
study variables, design-specific sources of bias, limitations in the control of 
confounding and variations in statistical analysis (59). For example, many studies 
have used self-reported pre-pregnancy BMI rather than directly measured BMI, and 
many studies do not have additional measurements of body weight during pregnancy. 
Breastfeeding is infrequently identified as a confounding factor and is well known to 
protect offspring against risk of adult obesity and T2D (60-64). Furthermore, 
breastfeeding is known to be less common in obese mothers (65).   
 
It is impossible to design a randomised controlled trial human study in standardised 
conditions in this study population. In contrast, animal models are highly 
advantageous as the confounding effect of genetic and postnatal environmental 
influences can be minimised. Animal studies have the advantage of controlled 
experimental design and allow a specific maternal perturbation to be induced to 
determine its influence on offspring’s long-term health.   
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2.2.3 Animal studies of maternal obesity and its effect on offspring health 
 
Many animal studies have utilised dietary manipulation in rodent models to examine 
the effects of maternal obesity on offspring. Table 2B summarises the various studies 
using animal models of maternal obesity. These studies have overwhelmingly 
supported the concept that maternal obesity programs the development of metabolic 
disease in offspring, and importantly several studies have found that maternal obesity 
compounds the effect of diet-induced obesity in adulthood. Rodents, rabbits, guinea 
pigs, sheep and non-human primates have been used to model maternal obesity and 
determine its effects on offspring’s health. The largest meta-analysis including 53 
rodent studies confirmed that maternal obesity is associated with significantly higher 
body weight in offspring post weaning (66). 
 
Rodents are highly susceptible to weight gain when fed a high-fat diet (HFD) and 
they tend to develop features of obesity, insulin resistance and hepatic steatosis, all 
common features of the metabolic syndrome (67). Rodent models are the most 
common animal models employed due to their short gestation of three weeks and fast 
maturation (puberty develops at five weeks in mice, 8 weeks in rats).  
 
It is unclear whether maternal adiposity, or dietary fat per se, is the cause of the 
developmental programming evident in models of maternal obesity. Therefore, one 
study set forth to resolve this issue by feeding dams HFD ad libitum, feeding HFD 
only to caloric intake of the control animals (68). Maternal HFD consumption ad 
libitum induced hyperleptinaemia and insulin resistance in offspring, as well as an 
increased body weight that persisted into adulthood. There was no difference in body 
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weight between the non-obese chow fed and calorie matched HFD-fed offspring. 
Together, these data suggest that caloric overconsumption as opposed to the 
constituents of the diet is the influential factor.  
 
The ideal type of diet manipulation in mouse models of obesity has been debated. The 
classic HFD necessitates proportional reductions in carbohydrate content if ideal 
protein and micronutrient content is to be maintained. As a consequence, it has been 
argued that the end-organ effects may not entirely be due to the increased fat content. 
An alternative approach to induce obesity is to use the highly palatable high fat, high 
sugar obesogenic “cafeteria” style diet or “junk food” diet (consisting of highly 
palatable snacks such as doughnut, cakes and biscuits which are high in fat and 
carbohydrate). The latter tends to result in even greater adiposity, hyperglycaemia and 
insulin resistance as compared to the commercial pellet HFD and may more closely 
resemble the behavioural and phenotypic outcome in humans (69). However, the 
cafeteria-style diet has also been criticised for its unbalanced micronutrient content 
and significantly reduced protein content which itself promotes overeating.  
 
A potential explanation for overconsumption of food when consuming an obesogenic 
diet is the protein leverage hypothesis. Namely, that protein intake is prioritised over 
fat and carbohydrate intake such that the drive to eat continues until sufficient protein 
has been consumed (66). This is particularly pertinent to cafeteria-style diets that tend 
to be low in protein. Furthermore, when restricted to diets low in protein, animals, 
including pregnant females, may tend to ingest excessive energy and become obese 
but as a consequence of low protein consumption be effectively malnourished. This 
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could explain why, in some studies, offspring develop insulin resistance and visceral 
adiposity but have not all demonstrated heavier birth weights.  
 
 
Sex differences in developmental programming of maternal obesity have been 
described. The mechanisms involved may be due to sex differences in growth patterns 
and the differential effect of hormones, including sex steroids (70-72).  Female 
offspring appear to be less susceptible to metabolic disorders than males (70). 
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2.2.4 Paternal obesity and effects on offspring 
 
The concept of developmental programming relates to the in utero effects on offspring 
specific to the maternal milieu during gestation. However, some evidence suggests that 
paternal obesity also plays a role in programming offspring towards obesity. The highest 
proportion of BMI >95th of a group of young people age 7 to 20 years was found in offspring 
with both parents with metabolic syndrome and diabetes as opposed to just one parent (86). It 
has been proposed that paternal obesity induces paternal programming of offspring 
phenotypes likely mediated through genetic and epigenetic changes in spermatozoa (87). Ng 
and colleagues fed male rats HFD and determined that their offspring had low birth weight, 
adiposity, and impaired glucose tolerance compared to offspring of normal chow fed father, 
suggesting non-genetic paternal transmission of metabolic syndrome (88). This suggests that 
paternal obesity may influence offspring risk of childhood and adult glucose metabolic 
disorders, which is not necessarily linked to obesity, and invokes the possibility that 
epigenetic changes resulting from obesity may be mediated by developmental programming 
related to both mother and father.  
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2.3 Mechanisms of foetal programming by maternal obesity 
 
Animal models have been particularly useful in determining the mechanisms underlying the 
long-lasting effects of maternal obesity on offspring health. During critical windows of 
exposure, the maternal milieu may alter the development and function of key organs 
including adipose tissue and brain. The placenta is the master regulator between the maternal 
and foetal environments and therefore understanding placental structure and function is 
fundamental to unfolding the mechanisms underlying the developmental programming of 
maternal obesity. The cellular mechanisms of developmental programming include oxidative 
stress and inflammation. Epigenetic modifications may be permanently altered by in utero 
exposure to adverse pre-natal environments.  
 
2.3.1 Changes in organ structure and function 
 
There are several key differences in the developmental timing of organ maturation between 
rodents and humans. Importantly, the third trimester in humans is roughly equivalent to the 
first postnatal weeks in rodents with respect to renal maturation. Kidney maturation does not 
occur until postnatal day 20 in the rodent whereas in humans, kidney development is 
completed by 36 weeks of gestation (89). Adipose tissue develops early in gestation in 
humans whereas in rodents adipose tissue is not laid down until late gestation and early 
postnatal life, and there is relatively more brown fat in the mouse compared to the human 
(90). In contrast to humans, whose hypothalamic pathways are fully developed at birth, 
development of hypothalamic neurocircuits in rodents is not complete until the third week of 
postnatal life making maternal diet during lactation highly influential on hypothalamic 
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development (91). Given the significant differences in organ maturation between rodents and 
humans, care should be taken when applying knowledge from rodent models to the human 
situation.  
 
 
 
 
Figure 3.1. A schematic representation depicting the key players in developmental 
programming 
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2.3.1.1 Adipose tissue 
 
In humans, obese mothers have an increased risk of delivering offspring with LGA or 
macrosomia (14, 15). In contrast, rodent models of maternal obesity do not always report 
increased birth weight of offspring. Nonetheless, despite no difference in body weight per se, 
many studies have demonstrated changes in body fat distribution post birth, either by 
measuring fat deposits or by imaging techniques (92). Offspring of obese mothers are 
predisposed to adiposity, adipocyte hypertrophy and weight gain in adulthood as a result of 
upregulation of adipogenesis and lipogenesis (93). In particular, visceral adipose tissue is 
increased (including increased epididymal/periuterine, perirenal, omental and mesenteric fat 
deposits), which have been shown to have particularly adverse metabolic consequences to the 
offspring in relation to insulin resistance and metabolic risk (94). 
 
Adipogenesis, or increased adipocyte number, results from differentiation of preadipocytes 
into adipocytes. Lipogenesis occurs as a result of triglyceride synthesis and storage within 
mature adipocyte and leads to adipocyte hypertrophy (enlarged size). Offspring of obese 
dams have larger adipocytes (> 150 µm) indicating increased lipogenesis and the number of 
very small adipocytes (<25 µm) is also increased likely due to an increase in adipogenesis 
(92, 94). Key transcription factors involved with adipogenesis and lipogenesis include 
peroxisome proliferator-activated receptor-γ (PPARγ), CCAAT/enhancer binding protein 
(C/EBPα, β, γ), the sterol regulatory element-binding protein 1c (SREBP1c) as well as fatty 
acid synthesis enzymes such as fatty acid synthase (FAS). All of them are upregulated in the 
adipose tissue of offspring of obese mothers (95). PPARγ has been shown to be upregulated 
in adipose tissue of offspring exposed to maternal obesity both prenatally and up to postnatal 
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Day 130 (92, 96). FAS and multiple fatty acid transporters have been shown to be 
upregulated in retroperitoneal, omental, mesenteric and subcutaneous fat deposits (94).  
 
Adipose tissue produces adipocytokines including adiponectin and leptin which have 
autocrine, paracrine and endocrine effects and influence whole-body insulin sensitivity and 
hence the development of metabolic diseases (97). Adiponectin promotes insulin sensitivity 
and has anti-inflammatory properties; decreased circulating levels are associated with 
obesity, insulin resistance, and T2D (97). Pregnant obese dams have lower adiponectin levels 
and similarly offspring of obese mothers also have lower adiponectin levels (98).  In contrast, 
leptin plays important roles in modulating satiety and energy homeostasis. Although leptin is 
elevated in offspring of obese mothers, the offspring do not demonstrate reduced food intake 
suggesting that maternal obesity induces leptin resistance (83). The mechanism of leptin 
resistance due to maternal obesity may be permanently programmed by intrauterine 
overnutrition as a result of alterations in neural circuitry that is similar to that induced by 
HFD consumption (99).  
 
As a result of increased adiposity in offspring, particularly visceral adiposity, pathological 
processes inherent to adipose tissue ensue. Adipocytes secrete inflammatory mediators 
including chemokines and cytokines which lead to both local and systemic inflammation 
(100). These include tumour necrosis factor- α (TNF-α), monocyte chemoattractant protein-1 
(MCP-1), interleukin-8 (IL-8) and interleukin-6 (IL-6) predominantly secreted by adipose 
tissue macrophages. Excessive lipids that cannot be stored in adipocytes are released into the 
blood and ectopically deposited in the liver, muscle and pancreas. At these sites, 
inflammatory cytokines secreted by adipocytes, cause cellular functional injury. Together 
these metabolic abnormalities lead to insulin resistance and the predisposition towards 
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metabolic disorders, which may lead to end-organ effects such as cardiovascular disease and 
CKD (101). 
 
2.3.1.2 Neural circuitry is permanently altered in offspring of obese mothers 
 
The hypothalamus is important for regulating appetite and energy metabolic homeostasis in 
response to peripheral key hormones including insulin and leptin (102). Leptin receptors are 
predominantly located in the hypothalamus, which are increased in response to food 
ingestion. As a result, the expression and release of neuropeptide Y (NPY) and agouti-related 
protein (AgRP) are inhibited, whereas pro-opiomelanocortin (POMC) and cocaine- and 
amphetamine-regulated transcripts are stimulated to reduce appetite and thus inhibit food 
intake. Despite high leptin levels in obese subjects proportional to adipose tissue mass, 
weight loss does not ensue and this is mainly due to the concept of central leptin resistance. 
Furthermore, offspring of obese mothers also demonstrate leptin resistance in several animal 
models (99, 103). 
 
There is debate regarding the effect of maternal obesity on offspring appetite regulation and 
hypothalamic neurocircuitry. Many studies have found up-regulation of appetite regulatory 
neuropeptides and hormones suggesting that appetite may be increased (75, 104-106). In a 
sheep model, lambs from obese mothers demonstrate increased appetite in the context of a 
blunted postnatal leptin surge (107). However, when a meta-analysis was conducted to 
determine the effect of maternal obesity on offspring food intake in rodents, there was no 
significant increase in food consumption in offspring of obese mothers when food 
consumption was allometrically scaled to body weight (66). The authors hypothesised that 
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the juxtaposition between increased body weight and appetite in rodents could be explained 
by slowing down of energy metabolism, rather than energy overconsumption.  
 
Offspring of obese mothers have a higher propensity towards HFD-induced obesity than 
offspring of lean mothers (75, 108, 109).  When studies have interrogated differences in 
neural pathways, it appears that offspring of obese mothers have altered reward pathways for 
palatable food in the brain (110). They favour increased palatable food intake due to 
dysregulation of the reward pathway involving the mesocorticolimbic dopamine pathway 
from the ventral tegmental area (VTA) to the nucleus accumbens (NAcc). Ong et al found 
that offspring of obese dams (fed a cafeteria style diet) had increased expression of µ-opioid 
receptor (Mu) and reduced expression of dopamine active transporter (DAT) at 6 weeks of 
age, although downregulated Mu and upregulated DAT were found by 3 months. Their 
findings suggest that the normal response of the reward pathway may be desensitised in adult 
offspring of the obese mothers, which drives them towards increased food-seeking behaviour 
(111). In addition, maternal HFD was shown to alter endocannabinoid pathways within the 
hippocampus and increase anxiety-like behaviour in adult rat offspring (73). Furthermore, 
epigenetic changes mediated by maternal obesity in early life may have permanent effects in 
neural pathways within the brain (112, 113). 
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2.3.2 The placenta and programming by maternal obesity  
 
The placenta is the gatekeeper between the maternal and foetal circulation. It modulates the 
delivery of oxygen and nutrients including glucose, amino acids, free fatty acids and 
hormones such as insulin, glucagon and glucocorticoids from the maternal circulation to the 
growing foetus. In exchange, the placenta is responsible for transferring carbon dioxide, urea, 
waste products and hormones from the foetal circulation to the maternal circulation for 
clearance (see Figure 2). The placenta is now recognised as an integral programming agent 
for chronic disease in offspring and in particular, placental efficiency is a predictor of 
disease. Maternal obesity is known to modulate how the placenta forms and functions. 
  
Neonates who are born LGA usually have larger placentas, as demonstrated in a large 
epidemiological study in Saudi Arabia involving over 17,000 live births (114). As previously 
discussed, LGA offspring are at risk of a multitude of chronic diseases, including obesity 
itself and features of the metabolic syndrome. Interestingly, placental size that is 
disproportionate to the mothers’ size can also predict disease. Both small placental area in 
larger BMI women as well as larger placental area in smaller women predicted increased risk 
of coronary heart disease in their offspring later in life (115). Nonetheless, it is not just 
placental size that matters. The other morphometric differences such as shape and breadth 
appear also to be important (116).  Indeed, it is highly probable that these morphometric 
aspects of the placenta simply reflect some more important aspects of placental health, which 
are function and efficiency.   
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Figure 3.2 The placenta as gatekeeper. 
The role of the placenta as the gatekeeper between the maternal and foetal circulation, 
modulating transport of oxygen, key nutrients, hormones and waste products. 
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2.3.2.1 Maternal obesity alters nutrient delivery mediated by the placenta 
 
In general, placental function relates to how it delivers oxygen and nutrients to the foetus. 
Placental transport is dependent on a number of factors including placental size and function, 
maternal nutrient availability and the stage of gestation (117). Placental transport of key 
nutrients is not as simple as concentration gradients from maternal to foetal circulation 
although for nutrients such as glucose there is a strong relationship between maternal and 
foetal glucose levels (118). Most relevant to the setting of maternal obesity, is the transport of 
glucose and fats across the placenta. 
 
Diffusion of glucose across the placenta takes place readily and results in increased foetal 
growth. The glucose receptor, GLUT1 has been identified as the main transporter for glucose 
in the placenta (118).  In gestational diabetes, it has been demonstrated that GLUT1 is 
upregulated probably as a result of hormonally driven mechanisms such as increased insulin 
and insulin-like growth factor-1 (IGF-1). In obese mothers without gestational diabetes 
(GDM), GLUT1 expression correlated with birth weight (119). However, the placental role in 
transferring glucose from mother to foetus is yet more complex where foetal 
hyperinsulinaemia, in response to foetal hyperglycaemia can steepen the glucose gradient, 
known as glucose steal (120). This is because hyperinsulinaemia in the foetus is likely to 
accelerate glucose clearance into foetal tissues by increasing fat accumulation predominantly 
in adipose tissue and in the liver, which will consequently increase the foetal glucose steal. It 
has been postulated that even in the presence of normal maternal glucose levels, foetal 
hyperinsulinaemia will still lower foetal glucose concentrations, thus a high glucose gradient 
and an exaggerated glucose steal are sustained (120). Furthermore, in the setting of a large 
maternal-foetal glucose gradient, maternal postprandial glucose peaks may even be blunted 
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further exacerbating the foetal exposure to glucose though masking the phenomenon in the 
mother.  
The placenta is highly permeable to free fatty acids, whose transfer is gradient dependent. In 
general, the pregnant state is associated with mobilisation of lipids, cholesterol and free fatty 
acids into the maternal circulation (121). Lipoprotein metabolism is upregulated. Maternal 
lipoproteins do not pass directly across the placenta, rather lipoprotein receptors, lipases, and 
fatty acid–binding transport proteins within the placenta allow placental uptake of 
triglycerides and cholesterol and passage to the foetus. In fact, the placenta also has the 
ability to re-esterify and store lipids for later foetal use (122). Maternal obesity is associated 
with even greater increases in maternal lipid mobilisation and triglyceride. Low-density 
lipoprotein (LDL) and free fatty acids are all increased in obese compared to normal weight 
pregnant women (121).  In animal models as well as humans, maternal obesity increases the 
expression of free fatty acid transporters within the placenta, including cluster of 
differentiation 36 (CD36), fatty acid transport protein 1 (FATP1) and fatty acid transport 
protein 4 (FATP4), which are associated with increased circulating lipids in foetal serum 
(123-127). 
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2.3.3 Cellular mechanisms of developmental programming by maternal 
obesity 
2.3.3.1 Inflammation 
 
It is well understood that obesity is associated with chronic low-grade inflammation largely 
mediated by excess adipose tissue (128). Increased inflammatory markers can be found in the 
placentae of obese mothers (129-131). Enhanced placental expression of pro-inflammatory 
cytokines including MCP-1, IL-1 and TNFα, and expression of a critical signalling molecule 
in inflammatory pathway Toll-like receptor 4 (TLR4), alongside increased macrophage 
accumulation has been demonstrated in obese HFD-fed non-human primates (132, 133). 
Furthermore, cord blood levels of inflammatory markers also appear to be altered by 
exposure to an obese mother (134, 135). Dosch and colleagues found that cord serum levels 
of C-reactive protein (CRP), IL-6, and TNFα were increased in neonates of obese mothers at 
caesarean section (BMI > 35 at the time of delivery) (135). The mechanisms by which 
chronic low-grade inflammation influences placental function and how inflammatory 
mediators are transmitted to offspring and perpetuated to increase chronic disease risk later in 
life are poorly understood. 
 
2.3.3.2 Oxidative Stress  
 
An imbalance between reactive oxygen species (ROS) and antioxidant defence mechanisms 
leads to cellular damage via oxidative stress. Markers of oxidative stress appear to be 
increased in the placentae of obese mothers (136). In a study of overweight and obese 
Spanish women, reduced placental expression of mammalian target of rapamycin (mTOR) 
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and upregulation of sirtuin 1 (SIRT1) and uncoupled protein 2 (UCP2) were demonstrated. 
The implication of their altered regulation suggests increased placental oxidative stress, given 
the known role of these genes in upregulating cellular antioxidant defence mechanisms (137). 
Interestingly, in this study they did not find increased inflammatory cytokines in the cord 
blood of the neonates exposed to maternal obesity.  
 
Mitochondria are intracellular organelles extensively involved in cellular metabolism and 
oxidative stress defence as a result of inevitable free radical leakage in the process of cellular 
respiration. Mitochondrial dysfunction has been demonstrated as early as embryogenesis by 
maternal obesity (138). Furthermore, the placentae of obese mothers have higher levels of 
oxidative stress and impaired mitochondrial respiration in both rodent and human placenta 
(139-141). The outcome of increased oxidative stress and dysfunctional repair mechanisms is 
likely to be impaired placental function, which may thereby lead to detrimental foetal growth 
and development. 
 
2.3.3.3 Changes in epigenetic regulation 
 
Epigenetics is the study of heritable changes in gene activity not due to changes in the 
deoxyribonucleic acid (DNA) sequence (142). Epigenetic modification can occur via DNA 
methylation, histone modification or by the influence of micro ribonucleic acid (microRNA), 
small non-coding regions of the genome previously regarded as “junk” though now 
recognised as important regulators of gene expression itself. DNA methylation typically 
occurs at CpG dinucleotide sites (regions of DNA where a cytosine nucleotide is followed by 
a guanine nucleotide) via the action of DNA methyltransferase enzymes. DNA methylation is 
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usually associated with down-regulation or silencing of gene expression. Histone 
modification results in altered compaction of DNA around histone, preventing or enabling 
gene activation.  
 
In human studies, maternal nutrition as early as conception, can modulate DNA methylation 
of important genes. In a series of elegantly designed experiments taking place in a remote 
community in The Gambia, maternal nutritional status at the time of conception was shown 
to alter methylation status of a host of genes in the cord blood of offspring (143-145). In rural 
communities in The Gambia the combination of self-sufficient food source (without external 
influence) and reliance on stored foods during the rainy season leads to profound annual 
variations in the intakes of macro and micronutrients. First, it was established that the season 
of conception (reflecting variation in the dietary intake and nutritional status of women at the 
time of conception) significantly influenced the methylation status in multiple genes in 
children (145). Second, a randomised controlled trial whereby Gambian women were given 
micronutrient supplementation determined that particular candidate genes had altered 
methylation status as a result of the supplement as measured in cord blood of offspring (143). 
Most recently, the group has published the results of a large randomised controlled trial 
carried out in Gambian communities demonstrated the powerful effect of periconceptional 
maternal nutrition on epigenetic changes in the offspring in that DNA methylation in 
offspring blood and hair was predicted by periconceptional maternal plasma biomarker 
concentrations of key micronutrients, such as homocysteine, folate, and B vitamins (143).  
 
A very powerful example of the potential effects of epigenetic modification comes from 
animal experiments involving the Agouti mouse. The wild-type Agouti gene encodes a 
paracrine-signalling molecule that produces either black or yellow fur (146). When the agouti 
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gene is in its normal methylated state, the coat is brown and the mouse has low risk of 
metabolic disease. In contrast, if the agouti gene is unmethylated, the mouse is yellow-furred 
and obese with dysregulated metabolism. When pregnant yellow-furred agouti mice are fed 
methyl-rich diet, they produce mostly healthy brown-furred offspring. However, if fed 
methyl-poor diet the offspring are yellow furred and are at increased risk of obesity. In the 
human studies conducted in The Gambia, interestingly higher maternal BMI was 
significantly associated with hypomethylation status in the serum of offspring (144).  
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2.4 Maternal programming of kidney disease in offspring 
 
The kidney is a highly vascular and metabolically active organ, particularly susceptible to the 
impact of prenatal insults (147). Infants born prematurely, prior to 36 weeks of gestation, are 
known to have reduced nephron number and kidney size (148). Maternal factors such as 
nutritional deprivation, tobacco smoking and gestational diabetes have been shown to impact 
upon offspring’s kidney health, and importantly can have lasting effects on offspring’s 
kidney health (149).  Less is known about the influence of maternal obesity on programming 
of renal outcomes in the offspring.  
 
2.4.1 Foetal programming in kidney disease: human observational studies 
 
Low birth weight (LBW) is defined as birth weight below 2500 g and represents the postnatal 
manifestation of foetal growth restriction. Considerable evidence exists for an association 
between LBW and CKD (150-159). Indeed, a recent meta-analysis found that LBW confers 
approximately 70% increased risk (OR 1.77) of developing CKD in adult life, compared with 
normal birth weight (159).  Factors that increased the likelihood of LBW include maternal 
nutritional deprivation, maternal smoking, placental insufficiency, twin pregnancy and 
preterm delivery (149, 160-163).  Disruption in delivery of nutrients to the growing foetus 
can lead to intrauterine growth restriction, which permanently impairs renal function. 
 
Diabetes in pregnancy may also have lasting effects on offspring renal health. One study 
found that adult offspring (mean age 24-25 years) of women with T1D during pregnancy had 
reduced renal function as measured by glomerular filtration rate, renal plasma flow, mean 
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arterial pressure, and renal vascular resistances (164). In a follow-up study of the same 
cohort, the authors found that offspring of mothers with T1D had less global DNA 
methylation compared to control participants although only one gene was identified to be 
directly related to renal development (DNA methyltransferase 1; DNMT1) (165).  
 
Mothers who smoke tobacco during pregnancy can permanently damage their offspring’s 
kidney health. It is well established that offspring of mothers who smoke have an increased 
risk of prematurity and LBW (166). Follow-up studies of offspring in adulthood have 
revealed that maternal tobacco smoking increases the risk of obesity and hypertension (167).  
 
2.4.2 Mechanisms of foetal programming in the kidney 
 
The total number of nephrons within the kidney is important, as each nephron provides a 
critical filtering function within the kidney. In humans, nephron endowment, defined as the 
number of nephrons at the start of postnatal life, is an important determinant of adult kidney 
health (168). Nephrogenesis is complete by 32-36 weeks in humans and thereafter no new 
nephrons are formed. The total number of nephrons is correlated with birth weight in humans 
(151). In the context of premature delivery or intrauterine growth restriction, nephron 
endowment is reduced and thus the normal physiological mechanisms become overwhelmed 
leading to hyperfiltration and subsequent glomerular hypertrophy which may ultimately lead 
to CKD and systemic hypertension (147, 168, 169). The importance of kidney size is 
demonstrated in neonates with retarded kidney growth during the first 18 months of life, who 
have increased risk of CKD in adulthood (170). The underdeveloped kidney in offspring 
from smoking mothers is a direct result of the inflammatory and vasoconstrictive actions of 
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nicotine and results in lower nephron endowment in the offspring (171). This, in turn, is 
likely to increase the lifetime risk of CKD. An animal model of maternal smoking has found 
that maternal smoking impairs mitochondrial function, increases renal levels of reactive 
oxygen species and reduces antioxidant defence mechanisms in the kidneys of adult 
offspring. The appearance of mitochondrial defects preceded the onset of albuminuria at 
postnatal week 13. Thus, mitochondrial damage caused by maternal smoking may play an 
important role in development of CKD in adult life (172). 
 
It is hypothesized that reduced nephron number causes glomerular hyperfiltration and 
compensatory hypertrophy via alterations in key transporters within the nephron and 
alterations in the renin angiotensin system (RAS), which regulates sodium reabsorption, 
aldosterone production and vascular constriction (147). Importantly, angiotensin II (AngII) is 
a key regulator of blood pressure and fluid balance. In animal models of intrauterine growth 
restriction, alterations in the RAS have been implicated in renal dysfunction (173). 
Furthermore, renal hypertrophy as a compensatory mechanism to reduced nephron 
endowment may ultimately become pathological and lead to the cascade effects of renal 
inflammation, oxidative stress and fibrosis.  
 
Many of the same mechanisms described in relation to the foetal programming by maternal 
obesity are likely to cause kidney damage. Both inflammatory and oxidative stress are 
damaging to the kidney and are key mediators in the numerous end-organ effects of maternal 
obesity on offspring long-term health.  
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2.5 Intersecting pathology in developmental programming and chronic 
kidney disease 
 
2.5.1 Inflammation and CKD 
 
There is no doubt that inflammation plays a major role in the pathogenesis of CKD. 
Inflammation occurs as a result of cellular injury, mediated by macrophages and lymphocytes 
(174-176). The transcription factor nuclear factor kappa B (NF-κB) is responsible for up-
regulating genes involved in inflammatory processes within macrophages. The subunit of 
NF-κB p65 can be identified and measured as an indication of macrophage infiltration, and 
resident macrophages within injured kidneys can be identified by targeting cell surface 
molecules such as cluster of differentiation 68 (CD68) and F4/80 (174). These immune-
mediated cells produce pro-inflammatory and pro-fibrotic cytokines, such as transforming 
growth factor β (TGF-β), platelet derived growth factor (PDGF) and fibroblast growth factor 
2 (FGF-2), that cause migration and proliferation of resident fibroblasts. Such fibroblasts are 
differentiated to produce collagen I-IV and fibronectin to form the extracellular matrix 
(ECM) (177-179). Fibroblasts secrete various chemokines including MCP-1, IL-6 and TNFα 
that lead to further macrophage accumulation, perpetuating the development of fibrosis (180). 
TGF-β, vascular endothelial growth factors, insulin like growth factors and lipid mediators 
also contribute to inflammation and fibrosis (181).  
 
TGF-β is a central mediator of renal fibrosis due to its involvement in inducing ECM 
production and proliferation of the fibroblast and myofibroblast, as well as mediating an 
immune-regulatory function (182). In addition, it reduces matrix degradation by inhibiting 
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protease systems and promoting cell-matrix interaction by upregulating integrins, important 
receptors in establishing ECM. Without TGF-β, renal fibrosis induced by high glucose is 
significantly attenuated. In fact, antagonism of TGF-β using monoclonal antibodies virtually 
abolishes high glucose induced matrix production in mesangial cells in vitro (183). In human 
kidney 2 (HK2) proximal tubular cells, TGF-β has been shown to be integral in producing 
ECM proteins including collagen IV and fibronectin (184).  
 
2.5.2 Oxidative stress and CKD 
 
Oxidative stress is known to play a critical role in the pathophysiology of CKD due to its 
effects on tissue injury and inflammation ultimately leading to renal fibrosis in the kidney 
(185-189). Oxidative stress occurs when damaging by-products of cellular respiration, such 
as superoxide, hydroxyl and hydrogen peroxide (H2O2), outweigh cellular antioxidant 
defences including superoxide dismutase (SOD), catalase (CAT), glutathione (GSH) and 
glutathione peroxidise (Gpx) (185, 187, 190, 191). Reactive oxygen species (ROS) activate 
protein kinase C, cytokines and transcription factors to increase the expression of ECM 
related genes, leading to renal fibrosis and progression to end stage kidney disease (190). The 
excess ROS production can damage cellular lipids, proteins, or DNA to affect their normal 
function. There is vast evidence to suggest that excess glucose and lipids transported into the 
intracellular space can upset normal cellular homeostasis leading to overwhelming oxidative 
damage to the DNA and proteins.  
 
Over the past decade, the number of known biomarkers of oxidative stress has increased. 
Most reactive oxygen and nitrogen species are unstable with very short half-lives and 
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therefore difficult to capture in harvested tissues (191). Products formed from the reaction 
between ROS and various biomolecules are generally more stable than ROS including 8-
hydroxy-2-deoxyguanosine (8-OHdg), 2-isoprostane, nitrotyrosine, and thiobarbituric acid 
reactive substances (188). Increased ROS that outweigh anti-oxidant defences will lead to 
cellular injury initiating the inflammatory signalling cascade (192). Furthermore, oxidative 
stress can be amplified by pro-inflammatory cytokines. Thus, inflammation and oxidative 
stress can act synergistically during the development of CKD to establish a vicious cycle of 
injury (193).  
 
2.5.3 The role of lipids in CKD 
 
Lipid deposition within the body is primarily within adipose tissue and thereafter in the liver 
and other organs, including the kidney. In the normal kidney, approximately 3% of its total 
weight is from renal storage of lipids (194). More than 50% of the lipids in the kidney are 
phospholipids, which are the major constituents of cell membranes. Approximately 20% of 
lipids within the kidney are triglycerides, and about 10% are free fatty acids, which are 
efficient energy sources, particularly in the tubular epithelial cells where metabolic activity is 
high due to their role in filtration, especially with respect to sodium transport.  
 
Fatty acid beta-oxidation is the catabolic process by which fatty acid molecules are broken 
down in the cytosol and in the mitochondria to generate acetyl-CoA, which enters the citric 
acid cycle in order to produce adenosine triphosphate (ATP). The cellular mechanisms to 
ensure orchestrated fatty acid uptake, oxidation and synthesis are tightly regulated to avoid 
excessive intracellular lipid accumulation. The latter has been shown to have direct toxic 
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effects on the cell by generating fatty acyl-CoA, diaclyglycerols and ceramides (194, 195). 
Fatty acid oxidation is first initiated when long chain fatty acids are actively transported 
across the membrane by CD36 and then manoeuvred to the mitochondria for metabolism. 
The enzyme carnitine palmitoyl-transferase 1 (CPT1) conjugates fatty acids with carnitine, 
where fatty acid oxidation can take place. The transcription factors, peroxisome proliferator-
activated receptors (PPARs) and PPARδ coactivator-1a (PGC1A) regulate the expression of 
proteins involved in fatty acid uptake and oxidation.  
 
Renal biopsy samples from both humans and rodents with CKD have lower expression of 
genes responsible for fatty acid oxidation, suggesting that lipid metabolism is impaired (195). 
Furthermore, the expression of PPARs and PGC1A are lower in CKD versus normal kidney 
tissue. In vitro studies demonstrated that TGF-β is intrinsically involved in blocking fatty 
acid oxidation pathways, mediated by PGC1A (195). As previously described, this is another 
mechanism whereby TGF-β plays an integral role in initiating and perpetuating renal injury 
and fibrosis.  
 
 
2.5.4 Epigenetic memory in kidney disease 
 
Epigenetic changes in the kidneys are increasingly understood to be involved in the 
development of CKD (196-198). All major epigenetic-like changes including DNA 
methylation, histone modification and microRNA regulation have been implicated in the 
pathophysiology of renal fibrosis. In fact, microRNAs may even hold promise as a diagnostic 
tool for identification of early changes associated with kidney disease via their measurement 
in the urine (199). Given that the amniotic fluid largely reflects the properties of foetal urine 
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in the third trimester of pregnancy, it is also possible that renal transcripts related to early 
epigenetic changes could be measured in utero or at the time of birth in amniotic fluid (200). 
Furthermore, understanding the epigenetic changes involved in development and progression 
of CKD is likely to be an important precursor to the development of new therapeutic targets.  
 
DNA methylation in the promoter region of gene RAS protein activator like 1 (RASAL1) 
which encodes for an inhibitor of the RAS oncoprotein, is associated with fibroblast 
activation and propagates renal fibrosis (201). Moreover, RASAL1 activation takes place 
when TGFβ-1 is upregulated, which in turn silences the expression of RASAL1 gene and 
thus contributes to fibroblast activation and extracellular matrix deposition. A similar 
epigenetic modification is the hypermethylation of the Krüppel-like factor 4 (KLF4) 
promoter, DNA methyltransferase 1 (Dnmt1), in the setting of renal fibrosis whereby KLF4 
expression is decreased in C57BL/6 mice with renal injury and in HK-2 cells stimulated with 
transforming growth factor TGF-β1 in vitro (202). 
 
 
Histone modification has been demonstrated as an important epigenetic modification in 
CKD. In a mouse model of diabetes and using an in vitro model of mesangial cells, De 
Marinis and colleagues showed that high ambient glucose could inhibit the repressive histone 
marks in the promoter of the thioredoxin-interacting protein (TXNIP) gene (203). Levels of 
TXNIP protein are augmented by high glucose, which in turn promotes oxidative stress and 
renal fibrosis (204). Siddiqi and colleagues provided further evidence for the importance of 
epigenetic modification of the TXNIP protein (205). They showed that the histone marker 
H3K27 and the microRNA, miRNA-101, are two epigenetic modifications associated with 
diabetic kidney disease  
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A number of microRNAs have emerged as important mediators in the pathogenesis of renal 
fibrosis and microRNA-based treatment strategies have the potential to arrest the progression 
of renal fibrosis (198, 206). It has been shown that miRNA-200b suppresses TGF-β1-induced 
ECM proteins such as fibronectin by directly targeting its 3'UTR mRNA expression, 
independent of TGF-β1 signalling pathways (207). 
 
It is likely that new epigenetic modifications that initiate and perpetuate renal fibrosis will be 
discovered in the future. Hydralazine, an anti-hypertensive compound that has long been 
known to possess de-methylating activity, was used to induce DNA-de-methylation by 
reversing aberrant promoter CpG island methylation, and in particular reversing RASAL1 
promoter methylation (208). It remains to be investigated whether this medication or any 
other de-methylating agent may be used as therapeutic agents to treat CKD. Furthermore, 
new technologies such as lentivirus and nanoparticle vectors may be potentially used to 
deliver miRNAs specifically to kidney cells to turn on or off particular genes and abrogate 
the progression of renal fibrosis. 
 
2.5.5 Final pathological consequence of CKD: Renal fibrosis 
 
Tissue fibrosis is a common outcome in any organ as a result of disease-related injury. The 
pathway from injury to fibrosis is complex and is known to involve cellular constituents 
including inflammatory cells (e.g., macrophages and T cells), epithelial cells, fibrogenic cells 
(e.g., fibroblasts and myofibroblasts) and endothelial cells (209). The fibrogenic cells 
produce a variety of extracellular matrix proteins, such as interstitial collagens, cellular 
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fibronectin, basement membrane proteins, which themselves further perpetuate the fibrotic 
process. Renal fibrosis is regarded as the central event in the progression of CKD (175, 186, 
210, 211). In response to renal fibrosis, the kidneys undergo a self-perpetuated pathological 
process resulting in end stage kidney disease (ESKD) manifested by glomerulosclerosis, 
vascular sclerosis, and tubulointerstitial fibrosis (212).  
 
Injury at any site within the kidney including the glomeruli, tubules, interstitium and 
capillaries will inevitably trigger the deposition of extracellular matrix. Especially important 
to the development of renal fibrosis, collagen type I, III and IV and fibronectin are the major 
constituents of extracellular matrix (ECM) in the kidney (213). Fibronectin which is an 
adhesive glycoprotein involved in extracellular matrix has been extensively shown to be 
increased in both animal models and human patients with CKD (214-216). As the severity of 
kidney disease advances, the ECM expands and the levels of collagen and fibronectin 
increase. 
 
Irrespective of the initiating insult, the hallmarks of renal fibrosis are glomerular sclerosis 
and interstitial fibrosis. The prognostic characteristic that best correlates with the progression 
of CKD is tubulointerstitial fibrosis (217). Glomerular fibrosis, regardless of the cause, 
diminishes renal blood flow, leads to hypoxia, triggers cellular stress, further nephron 
collapse and tubulointerstitial fibrosis ensues. Ultimately, the increase in ECM production is 
accompanied by loss of renal parenchyma; contraction of the fibrous scar takes place, which 
further amplifies the kidney injury (218). This is reflected in end-stage kidneys with reduced 
size.  
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2.6 Obesity and chronic kidney disease 
 
2.6.1 Epidemiological Studies Linking Obesity with CKD 
 
Independent of major risk factors for CKD such as diabetes and hypertension, obesity is 
closely associated with CKD (219-222). A meta-analysis examined the impact of obesity on 
the incidence of CKD over a median period of 12 years, which included 19 studies and over 2 
million participants, and found that being overweight was associated with a 40% higher risk 
of developing kidney disease (pooled RR = 1.40 (1.30–1.50)), and obesity with an even 
higher risk of 80% (RR=1.83, 1.57–2.13). Most reviewed studies have been adjusted for 
potential confounders, such as age, gender, ethnicity, smoking status, alcohol use, and 
physical activity. Within this meta-analysis, some studies were also adjusted for diabetes, 
dyslipidaemia, and hypertension although there was no sub-analysis on adjusted models 
within this meta-analysis. 
 
More recently, Cao et al showed that increased BMI is associated with increased risk of CKD 
regardless of whether or not there is co-existing metabolic syndrome (220). Meta-analysis 
some years earlier also concluded that each individual component of metabolic syndrome is 
associated with CKD, including elevated blood pressure, impaired glucose tolerance, elevated 
triglycerides, elevated LDL and obesity itself (223). A greater number of the components of 
the metabolic syndrome corresponds to a greater risk of reduced renal function (223). Taken 
together, this evidence suggests that while the presence of the metabolic syndrome confers 
some additional risk of CKD in overweight and obese individuals, the effect of increased 
BMI on CKD risk is independent of the other factors.  
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Cao and colleagues showed that the cumulative incidence of CKD increased stepwise with a 
higher BMI category, independent of the presence of metabolic syndrome. To further confirm 
this association, MacLauglin showed that the risk of CKD was over 2.5 times higher in obese 
participants compared with normal-weight participants in a fully adjusted model (224).  
 
Microalbuminuria is one of the best biomarkers to indicate early development of renal 
impairment, and is defined by urinary albumin excretion (UAE) of 30–300 mg/24 h in a 24-h 
urine collection, and urinary albumin concentration (UAC) of 20–200 mg/l or albumin to 
creatinine ratio (ACR) of 30–300 mg/mmol in spot urine samples (225). Microalbuminuria is 
also a predictor of both progressive renal impairment and cardiovascular disease (226). The 
analysis of a cohort of youth with diabetes from the SEARCH for Diabetes in Youth Study 
found that insulin sensitivity was significantly associated with albuminuria in children and 
adolescents with newly diagnosed type 2, but not type 1 diabetes (227). Furthermore, the 
prevalence of microalbuminuria is increased with increasing BMI in the population of 
Sheffield (228). The risk of having microalbuminuria is increased exponentially with a rising 
BMI value.  
 
Not only is obesity an important risk factor for CKD, it also increases the likelihood of the 
progression of this disease. In an UK based study, Othman et al. found the deterioration of 
CKD over 10 years was 62.5% in overweight and 79.5% in obese compared to 44.7% in 
normal weight individuals with CKD (mean GFR 36.2 ml/min/1.73 m2) (229). Interestingly, 
no significant difference in the rate of progression (fall of eGFR ml/min/1.73 m2/year) was 
observed between the three groups.  
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One very large study of more than 320,000 patients who had undergone screening health 
check-ups between 1964 and 1985 found that the long term risk of ESKD was strongly and 
independently associated with being overweight or obese, with an odds ratio as high as 7 in 
extremely obese patients (BMI ≥ 40kg/m2) (230). Furthermore, renal transplant recipients 
who are obese are also at higher risk of delayed graft function (231). Paradoxically, in terms 
of predicting ESKD and mortality in CKD patients, BMI shows a relatively consistent U-
shaped association with clinical outcomes, with the best outcomes observed in overweight 
and mildly obese patients, while low BMI is associated with worse outcomes in all patients, 
independent of the severity of CKD (222). The largest study of over 400,000 patients 
maintained on haemodialysis revealed a survival advantage with increasing BMI (232). In 
this group of patients, low BMI may be a quasi measure of malnutrition and reduced lean 
muscle mass, which has been shown to be an independent predictor of poor outcome in 
patients with ESKD (233).  
 
Metabolically healthy obesity (MHO) is a unique phenotype that apparently protects from the 
metabolic complications of obesity and is characterised by normal insulin sensitivity (234, 
235). A recent study investigated the association between obesity and CKD by examining a 
group of individuals with MHO and found that, over an 8-year period, the incidence of CKD 
was 2.6% (56 of 2122 participants) in the metabolically healthy non-obese group, 2.6% (8 of 
302) in the MHO group, 6.7% (30 of 445) in those with the metabolically abnormal non-
obese group, and 10.9% (29 of 267) in the metabolically-abnormal obese group (236). After 
adjustment for confounders, compared with the metabolically healthy non-obesity group, the 
odds ratios for new-onset CKD was significantly increased only for the metabolically 
abnormal obese group and not for the MHO, nor metabolically abnormal non-obese group. 
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This suggests that the association between obesity and CKD is intrinsic to the metabolic 
disorders most commonly associated with obesity. Importantly, the levels of pro-
inflammatory and pro-fibrotic cytokines are increased in individuals who are obese (237). 
Thus the expression of inflammatory mediators and insulin resistance is higher in the 
glomeruli of patients with obesity-related nephropathy (238).  
 
2.6.2 Pathophysiology of obesity-related kidney disease 
 
The pathophysiological and cellular mechanisms underlying the associated between obesity 
and CKD are not fully understood. However, insulin resistance together with inflammatory 
responses, renal lipotoxic effects and dysfunctional secretion of hormones such as 
adiponectin and leptin are key regulators of metabolic disorders in obesity. In addition, 
hyperglycaemia, insulin resistance, hormonal changes, activation of the RAS, endothelial 
dysfunction, mesangial cell proliferation and oxidative stress associated with obesity are all 
known to mediate inflammation within the kidney, synergistically promoting renal fibrosis 
(239). Animal studies have helped to elucidate the molecular mechanisms of obesity-related 
kidney disease. 
 
2.6.3 Role of insulin resistance in obesity 
 
The pathway by which insulin resistance and compensatory hyperinsulinaemia contribute to 
renal injury is not fully understood although epidemiological evidence strongly supports the 
association between the development of CKD and obesity, metabolic syndrome and diabetes. 
Insulin has important trophic effects on vascular smooth muscle cells and can exert important 
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proliferative effects on renal glomerular and mesangial cells (239, 240). Insulin does this by 
stimulating the secretion of insulin-like growth factor 1 (IGF-1), which has been 
demonstrated to inhibit apoptosis of mesangial cells and increase ECM protein synthesis 
(241). Insulin also instigates the release of several cytokines and growth factors from renal 
mesangial and tubular cells, including TGFβ (239, 240). 
 
2.6.4 Role of inflammation in obesity 
 
Obesity is often regarded as a pro-inflammatory state (237, 242-244). Inflammation within 
adipose tissue is mainly due to complex interactions between adipocytes, macrophages and 
other immune cells, involving both the innate and the adaptive arms of the immune system 
(244). Adipose tissue macrophages play an integral role in inducing the systemic pro-
inflammatory status by release significant amount of pro-inflammatory cytokines, such as 
TNFα. There is an abundance of pro-inflammatory M1 macrophages in the obese state. The 
presence of M1 macrophages correlates with insulin resistance and states of overnutrition. 
Adipocytes themselves have immune-cell-like functions that lead to CD4+ T-cell activation, 
potentially triggering inflammation independently of macrophage infiltration. As such, 
inflammatory mediators from adipose tissue enter the circulation and can lead to 
pathophysiological changes in the kidney.  
 
In addition, hyperglycaemia, insulin resistance, hormonal changes, oxidative stress and renal 
fibrosis itself are associated with the obese state and are all known to mediate inflammation 
within the kidney. 
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2.6.5 Role of hormones in obesity  
 
Adiponectin levels are inversely correlated with low-grade albuminuria or microalbuminuria 
in obese and overweight individuals. In contrast, in patients with established diabetes or 
CKD, adiponectin is positively correlated with albuminuria and as eGFR declines, 
adiponectin increases (245). 
 
A direct role of adiponectin on the kidney has been suggested (189). It is known that 
adiponectin receptor 1 gene is expressed in the mouse kidney to a similar degree as in the 
liver, although protein quantification can be technically challenging (189). In an adiponectin 
knockout mouse, elevated levels of albuminuria compared to controls were evident and 
indeed treatment with exogenous adiponectin attenuated such albuminuria and renal structure 
change (246). Furthermore, genetically modified mice with inducible podocyte injury have 
worse renal outcomes when systemic adiponectin is lacking, while the overexpression of 
adiponectin can protect from renal injury. Adiponectin appears to exert its effects by 
activating several key pathways in autophagy, the system by which a cell maintains 
homeostasis and regulates programmed cell death (189). Sharma and colleagues found that 5' 
adenosine monophosphate-activated protein kinase (AMPK) plays a central role in mediating 
the effects of adiponectin (189, 246).  
 
Leptin, another hormone produced in adipose tissue, may also be involved in the 
deterioration of renal function in obese individuals (240). Leptin is primarily cleared from the 
circulation by the kidney through glomerular filtration, via leptin receptors and metabolic 
degradation in the renal tubules. The renal functional decline in patients with CKD results in 
reduced clearance and increased levels of serum leptin (247). Leptin also plays an active role 
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in the kidney remodelling. In vitro studies have shown that leptin stimulates the proliferation 
of endothelial cells and hypertrophy in mesangial cells and increases renal production of 
TGFβ-1 and collagen type I and type IV. Infusion of leptin into normal rats results in the 
development of glomerulosclerosis and proteinuria (247). In addition, leptin also has an 
important role in progressing inflammatory and oxidative stress pathways, thereby 
propagating CKD progression. 
 
2.6.6 Role of lipids and fatty acid metabolism 
 
Given the association between renal lipid accumulation, lipotoxicity and progression of renal 
injury, lipid metabolism is increasingly recognised to be a key mediator of obesity-related 
kidney disease (194, 195). The main pathophysiological outcome of lipogenesis in the kidney 
is via the AMPK pathway to increase the expression of acetyl COA carboxylase and fatty 
acid synthase (248). AMPK activity is reduced in obese animals, associated with reduced 
acetyl CoA carboxylase phosphorylation and thus increased acetyl CoA. Indeed, recently 
Mount and colleagues have showed that lipid accumulation is associated with reduced 
activity of AMPK in the kidney, leading to reduced phosphorylation and increased activity of 
acetyl CoA carboxylase which can thereby trigger oxidative stress. 
 
HFD-fed rodents develop renal lipid accumulation and renal injury (194, 249-251). In some 
animal models, lipid accumulation is indicated by the unique appearance of lipid vacuoles in 
proximal tubular cells (194, 251). This pattern of lipid vacuolation has been observed in 
proximal tubular cells in mice with an AMPK-b1 subunit deficiency, providing further 
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evidence of the connection between the development of CKD and the AMPK pathway, 
obesity, and lipid derangement (248).  
 
Jiang and colleague exposed C57BL/6 mice to 12 weeks of HFD and demonstrated increased 
renal lipid accumulation and glomerulosclerosis. The pathway identified in that study was via 
the SREBP1c pathway, which is important in the regulation of fatty acid synthesis (252). 
With increased SREBP1c activation, they found increased kidney expression of inflammatory 
mediators, collagen IV and fibronectin. Another study using long-term HFD-fed Wistar rats 
also found increased renal expression of SREBP-1, tubular lipid growth factor secretion and 
tubular interstitial fibrosis (251). Furthermore, there was increased lipid droplet formation in 
renal tubular cells but not in the glomeruli (251). 
 
Fatty acid synthase (FAS) is a key multifunction enzyme that plays a central role in 
catalysing fatty acid synthesis in the cytosol, to form long chain complex fatty acids from 
acetyl CoA, malonyl CoA and nicotinamide adenine dinucleotide phosphate (NADPH) (253). 
FAS activation increased triacylglycerol and ECM deposition in the kidney and was mediated 
by SREBP-1 (251). In the setting of FAS upregulation, TGFβ-1 is also upregulated by 1.4 
times. Furthermore, insulin had a powerful effect on upregulating the FAS-mediated 
pathways (251). 
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2.6.7 Role of nuclear hormones in obesity-related CKD 
 
Nuclear hormone receptors are ligand-activated transcription factors that regulate gene 
expression and are involved in many developmental, metabolic and endocrine functions 
(254). The most important nuclear hormone receptors known to have a role in the 
pathogenesis of kidney disease include vitamin D receptor (VDR), Farnesoid X receptor 
(FXR), and peroxisome-proliferator-associated receptors (PPARs).  
 
The Farnesoid X receptor (FXR) is a nuclear hormone receptor critical in bile acid, glucose 
and lipid metabolism (254-259). Although FXR is predominantly found in the enterohepatic 
system, it is also found in several other tissues and in particular, is highly expressed in the 
kidney, with expression detected in glomeruli, mesangial cells, podocytes and proximal 
tubular cells (PTCs) (260). FXR activation is associated with improved glucose metabolism 
and insulin sensitivity (257, 261). Within the kidney, FXR activation downregulates 
lipogenic and fibrotic genes and reduces diabetes and obesity-related changes including 
glomerulosclerosis, tubulointerstitial fibrosis and proteinuria (250, 262-265). FXR knock out 
mice are at increased risk of developing diabetes and obesity-related nephropathy (263-265). 
The FXR ligand (6-ethyl chenodeoxycholic acid) has been shown to have anti-fibrotic, anti-
inflammatory and anti-apoptotic effects in cisplatin-induced HK-2 cells (266). Its in vivo 
effects require further investigation. 
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2.7 Association between maternal obesity and CKD  
 
There is strong evidence for a causal relationship between obesity and CKD and there 
remains no doubt that maternal obesity causes developmental programming with life-long 
metabolic consequences for the offspring. However, the relationship between maternal 
obesity and development of CKD in offspring has been poorly characterised. Based on the 
available evidence, it is highly plausible that maternal obesity will increase the risk of renal 
disease in offspring, especially when a further renal insult supervenes. Several studies have 
shown that offspring born to diabetic mothers are at increased risk of hypertension, 
hyperfiltration and CKD (164). Likewise, we hypothesise that maternal obesity can increase 
the risk of CKD in offspring (see Figure 3). The limited evidence for this risk factor of CKD 
will be discussed. 
 
A longitudinal study of over 5000 births found that overweight and obesity in early infancy is 
associated with increased risk of CKD in adulthood (267). A large population-based, case-
control study with 1994 patients with childhood CKD (<21 years of age at diagnosis) and 
20,032 controls confirmed that maternal overweight and obesity are associated with a 
significantly increased risk of CKD in these young children (24% and 26% increased risk 
respectively compared to the controls) (268). Low birth weight, gestational diabetes, and 
maternal overweight/obesity were significantly associated with obstructive uropathy in 
children (268). These data suggest that prenatal factors may impact the later risk of CKD.  
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Figure 3.3 A schematic representation of the key mediators in the development of CKD and 
the mechanism by which maternal obesity may increase the risk of CKD in offspring 
 
In animal models, there is some evidence for an association between maternal obesity and 
CKD. Jackson and colleagues reported glomerulosclerosis and increased albuminuria in rat 
offspring exposed to a maternal diet high in fructose and fat (269). In a rat model of maternal 
high fat feeding, Armitage and colleagues (2005) reported no change in nephron endowment 
in offspring, but they have abnormal renal renin activity which may underlie the increased 
blood pressure observed in the offspring of the obese mothers (270). Similarly in another 
study, offspring of HFD-fed rats had increased renal renin mRNA expression until postnatal 
Day 90 (271). Offspring of female mice with severe maternal diabetes (induced by 
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streptozotocin, STZ, administered during gestation) demonstrated kidney injury with 
evidence of fibrosis, increased oxidative stress, and enhanced lipid deposition which was 
exaggerated when the offspring themselves were fed HFD (272). A limitation of this study is 
that STZ during pregnancy is likely to impact both the mother and developing foetus. There 
is a paucity of data investigating the effects of maternal obesity on renal lipid deposition, 
inflammation, oxidative stress and renal fibrosis, which forms the rationale for undertaking 
the current research described in this thesis dissertation.  
 
  
  
 
59 
 
 
 
     Chapter 3  
 
 
 
 
FXR Expression Is Associated With 
Dysregulated Glucose And Lipid Levels 
In The Offspring Kidney 
Induced By Maternal Obesity 
 
Sarah J. Glastras, Muh Geot Wong, Hui Chen, Jie Zhang, Amgad Zaky, 
Carol A. Pollock and Sonia Saad 
 
Published in Nutrition and Metabolism, 2015, 12(40): 1-13. 
  
  
 
60 
3.1 Abstract 
 
Background: Maternal obesity is associated with dysregulation of glucose and lipid 
metabolism with consequent exposure of the foetus to an abnormal metabolic milieu. It is 
recognized that maternal obesity predisposes offspring to chronic kidney disease (CKD). We 
aimed to determine whether the nuclear Farnesoid X receptor (FXR), known to play a role in 
maintaining homeostasis of glucose and lipid metabolism, is involved in renal injury in 
offspring of obese mothers.   
Methods: Maternal obesity was established in a rat model by feeding dams with high-fat diet 
prior to and during pregnancy and lactation. The offspring’s kidneys were examined at 
postnatal Day 1and Day 20. Human kidney 2 (HK2) cells were exposed to high glucose with 
or without the FXR agonist GW4064 or when FXR mRNA was silenced. 
Results: Glucose intolerance in the offspring of obese mothers was evident at weaning, with 
associated downregulation of renal FXR expression and upregulation of monocyte 
chemoattractant protein-1 (MCP-1) and transforming growth factor-β1 (TGF-β1). HK2 cells 
exposed to high glucose had reduced FXR expression and increased MCP-1, TGF-β1, 
fibronectin and collagen IV expression, which was reversed in the presence of GW4064. 
FXR-silenced HK2 cells had amplified pro-inflammatory and pro-fibrotic markers under high 
glucose conditions.  
Conclusions: Maternal obesity influences renal expression of pro-inflammatory and fibrotic 
factors that predispose the offspring to CKD. This was associated with the downregulation of 
the renal FXR expression suggesting a potential protective role for FXR.   
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3.2 Introduction 
 
Obesity is increasing in pandemic proportions worldwide, both in Western countries such as 
the United States and Australia but also in developing countries (273, 274). Obesity clearly 
presents a personal risk for a range of future chronic disease, but when occurs during 
pregnancy and lactation has been shown to increase the risk of future chronic disease in the 
offspring (21, 65, 275). Developmental programming is increasingly recognized as an 
important determinant of offspring health (65, 275-280). Indeed, offspring born to obese 
mothers are at increased risk of cardiovascular disease, stroke, diabetes and obesity itself (5, 
21, 65). There are many factors that influence disease risk, which include genetic 
predisposition, postnatal diet and lifestyle as well as maternal factors that affect the in utero 
environment. Animal models are a useful means by which to examine the effect of maternal 
obesity during pregnancy and lactation on offspring without the confounding factors of 
genetic background and adult lifestyle.  
 
Nuclear hormone receptors are ligand-activated transcription factors that regulate gene 
expression and are involved in many developmental, metabolic and endocrine functions 
(254). The Farnesoid X receptor (FXR) is a nuclear hormone receptor critical in bile acid, 
glucose and lipid metabolism (254-259). FXR is found in several tissues outside the 
enterohepatic system and in particular, is highly expressed in the kidney, with expression 
detected in glomeruli, mesangial cells, podocytes and proximal tubular cells (PTCs) (260). 
FXR activation is associated with improved glucose metabolism and insulin sensitivity (257, 
261). Within the kidney, FXR activation downregulates lipogenic and fibrotic genes and 
reduces diabetes and obesity-related changes including glomerulosclerosis, tubulointerstitial 
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fibrosis and proteinuria (250, 262-265). FXR null mice are at increased risk of developing 
diabetes and obesity-related nephropathy (263-265). FXR is also important in the regulation 
of urine volume, and its activation increases the ability of renal tubules to concentrate urine 
(281). 
 
Maternal obesity is likely to affect future kidney health in offspring. Several studies have 
shown that offspring born to diabetic mothers are at increased risk of hypertension, 
hyperfiltration and chronic kidney disease (CKD) (149). Maternal obesity is yet more 
complex with dysregulated glucose, lipid and hormonal changes. Despite one report of a 22% 
increased risk of CKD in offspring of obese mothers, more conclusive evidence is lacking 
(230).  Obesity itself may lead to glomerulosclerosis and proteinuria (222). Obesity related 
inflammation plays a significant role in the development and progression of renal damage in 
obesity (282-284). There is also significantly more renal lipid accumulation within the 
kidneys of obese animals (264, 285).  
 
In this study, we aimed to investigate the effect of maternal obesity on the risk of CKD in the 
offspring in a rodent model and determine whether dysregulation of FXR expression is 
involved in this process. We hypothesized that FXR may be an important mediator of 
inflammatory and fibrotic pathways known to be involved in CKD and that maternal obesity 
may modulate these pathways. Therefore, we exposed HK2 cells to high ambient glucose to 
determine the effect on FXR expression, and investigate the effect of FXR activation and 
silencing on fibrotic and inflammatory mediators in those cells. 
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3.3 Materials and Methods 
 
3.3.1 Animal model of maternal obesity 
 
Twenty virgin outbred female Sprague Dawley rats (8-week old, Animal Resource Centre Pty 
Ltd, Perth, Australia) were maintained on 12h light/dark cycle, 20±2°C. They were randomly 
assigned to one of 2 groups with equal average body weight: (1) standard chow (11 kJ/g, 14% 
fat, Gordon’s Speciality Stockfeeds, NSW, Australia) or (2) high-fat diet (HFD, 20 kJ/g, 43% 
fat; Specialty Feeds, Perth, WA) [8]. After 5 weeks, females were mated, and, housed 
individually. The same diet was maintained during pregnancy and lactation until weaning. 
The study was approved by the Animal Care and Ethics Committee of the University of 
Technology Sydney (ACEC# 2009-350), and the “Australian code of practice for the care 
and use of animals for scientific purposes ” (NHMRC, Australia) were followed. At birth, 
litter size was adjusted to 10 pups per mother (gender ratio: 1/1). An intraperitoneal glucose 
tolerance test (IPGTT) was performed at postnatal day 20. AUC was calculated for each rat. 
At postnatal Day 1 or Day 20, tissues from male offspring (n=8) were collected. Day 1 
offspring were killed by direct decapitation. Day 20 offspring were anaesthetized (Pentothal® 
0.1mg/g, i.p., Abbott Australasia, NSW, Australia) after overnight fasting. Blood were 
collected through cardiac puncture and blood glucose was measured immediately (Accu-
Chek®, Roche Diagnostics, NJ, USA). Plasma was stored for lipids and hormonal 
determination. Left kidneys were snap frozen in liquid nitrogen and kept at -80°C for mRNA 
for protein quantification. Right kidneys were embedded in paraffin and sectioned for 
immunohistochemistry staining.  
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3.3.2 Biochemical analyses 
 
Insulin concentrations were assessed using a radioimmunoassay kit (Linco, St Charles, USA). 
Plasma non-esterified fatty acid (NEFA) was measured using NEFA kit (WAKO, Osaka, 
Japan). In order to examine effects on renal function, Cystatin C was measured by 
immunoassay as per manufacturer’s instructions (R&D Systems, Minneapolis, USA).  
 
3.3.3 In vitro cell culture of HK-2 cells 
 
HK-2 cells of a human proximal epithelial cell line from American Type Cell Collection 
(ATCC, USA) were used as previously described (286). Cells were grown in 10 cm tissue 
culture dishes (Becton, Dickinson, NJ, USA), in keratinocyte serum-free media (KSFM) 
supplemented with bovine pituitary extract and epidermal growth factor (GIBCO). Initial 
‘dose-response’ experiments for FXR agonist GW4064 (Sigma Aldrich, USA) were 
undertaken to determine the concentration at which GW4064 maximally stimulated FXR 
protein expression, with minimal cytotoxicity. Exposure of HK2 cells to 1 µM of GW 4064 
resulted in no cell toxicity. When the HK-2 cells were 60-70% confluent, they were exposed 
to the following experimental conditions for 24 hours prior to RNA extraction and 48 hours 
before protein extraction: 1) 5 mM D-glucose (ICN Biomedicals, Ohio, USA) (vehicle 
control); 2) 30 mM D-glucose; 3) 1 µM GW 4064; 4) 1 µM GW 4064 + 30 mM D-glucose 
and 5) 5 mM D-glucose + 25mM L-glucose as an osmotic control (ICN Biomedicals, Ohio, 
USA).  
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3.3.4 Gene Silencing 
 
Gene silencing was performed using small interfering RNA (siRNA) strategies. Twenty-
seven-mer double-stranded RNA molecules were chemically synthesized (Shanghai 
GenePharma Co, Ltd, Shanghai, China). The complementary oligonucleotides were 2’-
deprotected, annealed, and purified by the manufacturer. The sequence specifically targeting 
human FXR (NR1H4) (accession no. NM_005123) was 5'-
GAUUGUUACUUCAACUCUATT-3', 5’ UAGAAUUGAAGUAACAAUCTT 3’. HK-2 
cells were plated in a 6-well plate. FXR siRNA (80 nmol/L) was introduced into HK-2 cells 
using Lipofectamine 2000. In parallel, cells were transfected with a non-specific siRNA 
which served as a control. Twenty-four hours after transfection, both the control and the FXR 
silenced cells were exposed to 5 mM or 30 mM D-glucose for 48 hours. Silencing was 
confirmed by mRNA and protein expression.  
 
3.3.5 Relative quantitative real-time PCR (RT-PCR) 
 
RNA was extracted using RNeasy mini kit (Qiagen, Valencia, CA, USA). cDNA was 
generated using Transcriptor First Strand cDNA Synthesis Kits (Roche Diagnostics, 
Mannheim, Germany). Real time polymerase chain reaction (RT-PCR) was performed using 
an ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA, 
USA). SYBR GreenER qPCR Supermix (Invitrogen) with unlabelled PCR primers was used 
for the animal experiments (Table 3A). Taqman Gene Expression Master Mix (Applied 
Biosystems) and gene-specific expression assays containing two unlabelled PCR primers and 
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FAM dye-labelled Taqman MGB probes was used for in vitro work (Table 3B). Results are 
presented as fold change compared to control after normalization to β-Actin.  
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Table 3.A.  Real time qPCR rat primers 
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
FXR TGACAAAGAAGCCGCGAAT  TGTAATGGTACCCAGAGGCCC 
SREBP1c CATGGATTGCACATTTGAAGAC GCAGGAGAAGAGAAGCTCTCAG 
MCP-1 GTTGTTCACAGTTGCTGCCT CTCTGTCATACTGGTCACTTCTAC 
TGF-β1 AGGACCTGGGTTGGAAGTGG AGTTGGCATGGTAGCCCTTG 
Collagen 
IV 
CCATGGTCAGGACTTGGGTA AAGGGCATGGTGCTGAACT 
Fibronectin CAGCCCCTGATTGGAGTC TGGGTGACACCTGAGTGAAC 
β-actin GTGGGGCGCCCCAGGCACCA CTCCTTAATGTCACGCACGATTTC 
 
Primer sequence for rat Farnesoid X receptor (FXR), sterol receptor element binding protein-
1c (SREBP1c), monocyte chemoattractant protein (MCP)-1, transforming growth factor 
(TGF- β1), collagen IV, fibronectin, and β-actin genes are shown. 
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Table 3.B. Real time qPCR human primers 
Human primers Assay 1D Amplicon length 
FXR (NR1H4) Hs00231968_m1 85 
SREBP1c Hs01088691_m1 90 
SHP (N20B2) Hs00222677_m1 87 
Collagen IV 
(COL13A) 
Hs00193225_m1 66 
Fibronectin Hs01549976_m1 81 
MCP-1 Hs00234140_m1 101 
TGF-β1 Hs00998133_m1 57 
Human β-actin 4333762F 171 
 
Primer assay ID and amplicon length for each human primer is listed for Farnesoid X 
receptor (FXR), sterol receptor element binding protein-1c (SREBP1c), small heterodimer 
protein (SHP), collagen IV, fibronectin, monocyte chemoattractant protein (MCP-1), 
transforming growth factor (TGF- β1) and β-actin genes. 
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3.3.6 Immunohistochemistry (IHC)  
 
Formalin-fixed paraffin kidney sections were deparaffinised and incubated with the 
polyclonal primary antibody anti-FXR (1:50 dilution, Abcam Ltd, Cambridge), anti-
fibronectin (dilution 1:1,000, Abcam) and anti-collagen IV (dilution 1:1,000, Abcam) 
overnight, followed by horseradish peroxidase anti-rabbit Envision system (Dako 
Cytochemistry, Tokyo, Japan) the following day. Staining was developed with 
3.3diaminobenzidine tetrahydrochloride (Dako Cytochemistry, Tokyo, Japan) before 
counterstaining with Mayer’s haematoxylin stains. Antibody against rabbit IgG was used as a 
negative control. Images were analysed using an Olympus microscope (Olympus, Japan) and 
Image J software.  
 
3.3.7 Immunofluorescence (IF) 
 
Formalin-fixed paraffin kidney sections were deparaffinised and epitope was retrieved by 
boiling the tissues in sodium citrate (pH 6.0) for 20 min. Cells were permeabilised using 
0.2% Triton-X100 (Sigma Aldrich). Tissues were then blocked in 10% blocking solution 
(Dako Cytochemistry) and incubated with SREBP1 primary antibody (1 in 100 dilution over 
night at 4oC) (Abcam, Cambridge, USA). The expression was visualized by means of anti-
rabbit Alexa® Fluor 488 (FITC alternative, green fluorescent dye, Dako Cytochemistry) at 
1:2000 dilution in serum for 1 h.  
 
3.3.8 Western blot analysis 
 
Protein was extracted from HK-2 PTCs lysate and western blotting were performed as 
previously described (287). Briefly, 15 mg of total cell protein was mixed with 6X Laemmli 
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sample buffer containing mercapto-ethanol and heated at 95°C for 10 min. Samples were 
then analysed by SDS-PAGE in 2.5 to 10% Novex Bolt mini gels (Life Technologies, 
California, USA) and electroblotted to Hybond Nitrocellulose membranes (Amersham 
Pharmacia Biotech, Bucks, UK). Membranes were blocked in Tris-buffered saline containing 
0.2% Tween 20 (TTBS) in 5 % skim milk for 2 hours. Then primary antibodies against FXR 
1:1000 (Abcam); fibronectin 1:1000 (Sigma Aldrich), collagen IV 1:5000 (Abcam) and 
SREBP1c 1:1000 (Abcam) were added and incubated overnight at 4 °C. Membranes were 
washed and incubated with horseradish peroxidase-conjugated secondary antibody for 2 
hours at room temperature, and washed. The membranes then were reprobed with β-Actin 
1:10000 (Santa Cruz, CA). Protein bands were visualized using the enhanced 
chemiluminescence (ECL) detection system (Amersham Pharmacia Biotech). The bands 
corresponding to fibronectin (220kDa), collagen IV (250kDa), FXR (69kDa), SREBP1c 
(120kDa) and β-Actin (42kDa) were captured using LAS 4000 (Fujifilm, Tokyo, Japan), 
corrected for β-actin as a loading control. They were then analysed using ImageJ software 
(National Institutes of Health, USA).  
 
3.3.9 Statistical analysis 
 
Results are expressed as mean ± SEM. The differences between the two groups were 
analysed by independent Student’s t-test. When there were more than 2 groups, one-way 
analysis of variance (ANOVA) was used, with post-hoc Fisher’s protected least-significant 
difference test (Prism 5, GraphPad Software, USA). P < 0.05 was considered significant.  
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3.4 Results 
3.4.1 Effect of maternal obesity on the offspring of obese mothers  
 
Offspring of obese mothers had no difference in body weight at postnatal Day 1, compared to 
offspring of lean mothers (6.65 ± 0.42 vs. 6.68 ± 0.57g). Similarly, no differences in blood 
glucose or insulin levels were found (blood glucose: 5.15 ± 0.58 vs. 4.47 ± 0.49 mmol/L, 
plasma insulin 0.21 ± 0.05 vs. 0.18 ± 0.04ng/ml). However at postnatal Day 20, offspring of 
the obese mothers had significantly greater body weight compared to the offspring of lean 
mothers (p < 0.01; Table 3C). In addition, offspring of obese mothers had increased 
adiposity; there was a 3-fold increase in retroperitoneal fat (p < 0.01) and a 4-fold increase in 
epididymal white adipose tissue (p < 0.01). The liver and kidneys were also heavier in 
offspring of the obese mothers (p < 0.05).  
 
After overnight fasting, blood glucose levels were higher in offspring of obese mothers (p < 
0.01, Table 3C). Likewise, plasma triglycerides and NEFA were increased significantly in 
obese mothers’ offspring at Day 20 (p < 0.01).  
 
At Day 20, offspring of obese mothers had significantly higher blood glucose concentrations 
at 15, 30, and 90 min during the IPGTT (p < 0.01, p < 0.05, p < 0.05, respectively, Figure 
3.1A). The AUC value was significantly higher in offspring of obese mothers (p < 0.05, 
Figure 3.1B), suggesting impaired glucose metabolism in offspring of obese mothers. Insulin 
resistance, as measured by HOMA-IR was elevated in offspring of obese mothers (p < 0.001, 
Figure 3.1C). Renal function, as measured by serum Cystatin C was not altered by maternal 
obesity (Figure 3.2). 
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Table 3.C. Weight measurements and blood test parameters at postnatal day 20 
 Control Obese 
Body weight (g) 59.3 ± 0.5 71.5 ± 2.8  ** 
Retroperitoneal fat (mg) 71.5 ± 3.8 287.9 ± 24.6 ** 
Epididymal fat (mg) 95.5 ± 4.9 483.4 ± 45.5 ** 
Liver (g) 2.80 ± 0.04 3.48 ± 0.17 * 
Kidney (mg) 347.3 ± 5.9 375.3 ± 11.4 * 
Fasting blood glucose (mM) 5.54 ± 0.16 6.11 ± 0.09 ** 
Plasma insulin (ng/ml) 0.37 ± 0.07 0.60 ± 0.07 * 
Plasma triglycerides (mM) 0.21 ± 0.03 1.29 ± 0.24 ** 
Plasma fatty acids (mM) 0.94 ± 0.05 1.41 ± 0.14 ** 
 
The data were analysed by Student’s t-test * p < 0.05, ** p < 0.01, N = 8-10 per group. 
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Figure 3.1. Offspring of obese mothers have reduced glucose tolerance at weaning 
Intraperitoneal glucose tolerance test at postnatal Day 20: (A) AUC depicted in (B). (C) 
Insulin resistance measured by HOMA-IR. N = 8 per group. * p < 0.05, ** p < 0.01, *** p < 
0.001. 
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Figure 3.2 Serum Cystatin C in offspring of obese and lean mothers 
Cystatin C was measured as a marker of renal function in offspring serum from control and 
obese mothers (N = 4-5 per group). 
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3.4.2 FXR and SREBP1c expression in the kidneys at postnatal Day 1 and 
Day 20 
 
Renal expression of FXR mRNA was reduced in offspring of obese mothers compared to 
offspring of lean mothers at Day 1 (p < 0.05, Figure 3.3A). This effect was sustained to Day 
20 (p < 0.05, Figure 3.3A).  Renal FXR protein change was consistent with mRNA changes 
at Day 20 (p < 0.01, Figs. 3.3C and 2D). FXR activation is known to inhibit sterol regulatory 
element binding protein-1c (SREBP-1c) expression (288). Although renal SREBP1c mRNA 
levels were not changed in offspring of the obese mothers at Day 1 or Day 20, the levels of 
SREBP1c protein expression were upregulated in the kidney from the offspring of the obese 
mothers at Day 20 as expected (p < 0.01, Figure 3.3B, E and F).  
 
3.4.3 Offspring born to obese mothers had increased renal MCP-1 and 
TGF-1 mRNA levels 
 
Renal monocyte chemoattractant protein-1 (MCP-1) was increased by four times in the 
offspring of the obese mothers compared to the control at Day 1 (p < 0.05; Figure 3.4A). 
TGF-β1 was also increased in the offspring of obese mothers at Day 1 (p < 0.05; Figure 
3.4B). There was no statistically significance in MCP-1 and TGF-β1 expression at Day 20, 
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Figure 3.3 FXR was downregulated in the kidneys of offspring of obese mothers at postnatal 
Days 1 and 20  
mRNA expression of FXR (A) and its downstream target SREBP-1c (B) at postnatal Days 1 
and 20. IHC staining (C and E) and quantification (D and F) of FXR and SREBP1c at Day 
20. Images are shown at 400x magnification. N = 5-7 per group, * p < 0.05 and ** P<0.01. 
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Figure 3.4 mRNA expression of MCP-1 and TGF-β was upregulated in the kidneys of 
offspring of obese mothers at Day 1 but not at Day 20 
Collagen IV but not fibronectin mRNA was increased in offspring of obese mothers at Day 1 
but not at Day 20. However, cortical protein expression of fibronectin and Collagen IV was 
increased in offspring of obese mothers at Day 20. Renal mRNA expression of MCP-1 (A), 
TGF-β1 (B), Collagen IV (C) and fibronectin (D) at postnatal Day 1 and Day 20. Protein 
expression of fibronectin (E), and Collagen IV (G) in offspring of obese mothers at Day 20. 
Graphical quantitation of fibronectin and Collagen IV staining are shown in (F) and (H) 
respectively. N'='5–7 per group, *p'<'0.05, **p'<'0.01 
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3.4.4 Renal markers of extracellular matrix accumulation in offspring 
 
There was no change in in fibronectin mRNA expression at either Day 1 or Day 20 in 
offspring of obese versus lean mothers (Figure 3.4D). Interestingly, there was an increase in 
collagen IV protein levels at Day 20 as measured by immunohistochemistry staining (p < 
0.01; Figure 3.4G and 3H). There was an increase in collagen IV mRNA expression at Day 1 
but no difference at Day 20 (Figure 3.4C).  At the protein level, there was an increase in 
fibronectin levels at Day 20 (Figure 3E and 3F). 
 
3.4.5 High glucose down-regulates FXR expression and regulates its target 
genes in human HK2 cells 
 
Exposure to high glucose (30 mM D-glucose) significantly suppressed FXR mRNA 
expression by half and 2/3 at 24 and 72 hours respectively (p < 0.05, p < 0.01 respectively, 
Figure 3.5A). This effect was not observed in cells cultured in 25 mM L-glucose + 5 mM D-
glucose, which served as an osmotic control. The same effect was seen at the protein level by 
Western blot, whereby FXR was reduced in culture exposed to high glucose at both 24 and 
48 h (p < 0.05, Figure 3.5B). Given the known reciprocal relationship between FXR and 
SREBP-1c and small heterodimer protein (SHP) activation, SREBP-1c and SHP were 
examined. At 72 hours, SREBP-1c mRNA was markedly upregulated in the HK-2 cells 
exposed to high glucose compared to those exposed to 5 mM D-glucose (p < 0.001; Figure 
3.5C). SREBP-1c protein was significantly increased at 48 h when exposed to high glucose 
compared to control (p < 0.05, Figure 3.5D). No difference in SHP mRNA expression in low 
or high glucose at 24 hours was seen (Figure 3.5B). However, 72-hour exposure to high 
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glucose was associated with down-regulation of SHP mRNA compared to cells exposed to 5 
mM D-glucose (p <0.01; Figure 3.5E).  
 
Figure 3.5. Effect of high glucose on FXR expression in HK-2 cells 
HK-2 cells were exposed to 5 mM D-glucose (white open bar) or 30 mM D-glucose (black 
solid bar) for 24 or 72 h. mRNA expression of FXR (A), SREBP-1c (B) and SHP (C) is 
shown at 24 and 72 h. Protein expression of FXR (B) and SREBP1 (D) is also shown at 24 
and 48 h. N'='3 per group, *p'<'0.05, **p'<'0.01, ***p'<'0.001. 
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3.4.6 FXR agonist inhibits high glucose-induced fibronectin and collagen 
IV expression  
 
The extracellular matrix proteins fibronectin and collagen IV are commonly overexpressed in 
the early stages of CKD. To determine the effect of high glucose on the expression of 
fibronectin and collagen mRNA, HK-2 cells were exposed to high glucose for 24 hours. This 
resulted in an increase in fibronectin and collagen IV compared to the vehicle control (p < 
0.05, Figures 3.6A and B respectively). Co-incubation with GW4064 reversed the effect of 
high glucose on mRNA expression of fibronectin and collagen IV (p < 0.01, Figures 3.6A 
and B). Similarly, protein expression of both fibronectin and collagen IV was reduced (p < 
0.05, Figures 3.6C and D). 
 
To confirm this finding, protein expression of fibronectin and collagen IV was examined in 
HK-2 cells after 48 hours incubation with high glucose in the presence or absence of 
GW4064. Fibronectin protein expression was nearly doubled compared to the control cells 
when exposed to high glucose (p < 0.01, Figure 3.6C). Similarly, type IV collagen production 
was also significantly increased in the HK-2 cells by high glucose exposure (p < 0.05, Figure 
3.6D). GW4064 suppressed high glucose-induced fibronectin and type IV collagen 
production in the HK-2 cells (p < 0.01, Figure 3.6C and p < 0.05, Figure 3.6D respectively).  
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Figure 3.6. Suppression of high glucose-induced fibronectin and collagen-IV expression by 
GW4064 in HK-2 cells. 
mRNA and protein expression of fibronectin (A and C) and Type IV collagen (B and D) 
exposed to high-glucose with and without the presence of GW4064 in HK-2 cells. N = 4 per 
group, * p<0.05; ** p < 0.01. 
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3.4.7 FXR agonist inhibits high glucose-induced TGF-1 and MCP-1 
expression 
 
TGF-β1 mRNA expression was significantly increased following 24 hours exposure to high 
glucose compared to the control group (p <0.05; Figure 3.7A), which was inhibited by 
GW4064 (p < 0.01). MCP-1 mRNA expression was also significantly increased by high 
glucose, but not ameliorated by additional GW4064 co-incubation (Figure 3.7B). 
 
3.4.8 FXR silenced cells had increased fibronectin, type IV collagen and 
SREBP-1 expression 
 
FXR silencing was confirmed by both mRNA and protein expression of FXR. A 50-60% 
reduction of FXR protein expression was achieved in all experiments compared to the control 
(data not shown). 
 
There was increased extracellular matrix markers in FXR silenced HK-2 cells compared to 
cells transfected with non-specific siRNA. Both fibronectin and type IV collagen expression 
were increased in FXR silenced cells (p < 0.01, p < 0.05, Figure 3.8A and B, respectively). 
Exposure to high glucose conditions (30 mM D-glucose for 72 hours) increased fibronectin 
expression in both normal and FXR-silenced cells but significantly more so in the FXR-
silenced cells (p < 0.05, FXR-silenced vs. normal). Similarly, type IV collagen expression 
was increased in HK-2 when FXR was silenced (p < 0.05) or exposed to high glucose (p < 
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0.05), which was further increased to in FXR silenced cells exposed to high glucose (p<0.05, 
Figure 3.8B).  
 
Increased SREBP-1 expression was found in FXR silenced cells compared to cells treated 
with non-specific siRNA (p < 0.05, Figure 3.8C). Exposure to 30 mM D-glucose further 
increased SREBP-1 expression in cells with silenced FXR, confirming that FXR can inhibit 
the expression of SREBP-1 (Figure 3.8C).  
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Figure 3.7 Exposure of HK-2 cells to high glucose increases TGF- β and MCP-1 mRNA 
expression and GW4064 ameliorates this effect.  
mRNA expression of TGF-β (A) and MCP-1 (B) in HK-2 cells exposed to high glucose with 
and without the presence of GW4064. N = 4-5 per group, * p < 0.05, ** p < 0.01. 
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Figure 3.8 FXR silenced cells exhibit increased ECM and SREBP-1 expression, further 
upregulated by exposure to high glucose conditions. 
Protein levels of fibronectin (A), type IV collagen (B), and SREBP-1c (C) in FXR silenced 
cells exposed to 5 mM D-glucose (black solid bar) and 30 mM D-glucose (white empty bar) 
for 72 hours. N = 4-5 per group, * p < 0.05, ** p < 0.01. 
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3.5 Discussion 
 
This study demonstrates that maternal obesity has significant adverse effects on the 
offspring’s kidneys and may increase the risk of kidney damage later in life. This study 
suggests that suppressed renal FXR is critical for maternal obesity-induced nephropathy in 
offspring, which has not been reported previously. 
 
Growing evidence has suggested that dysregulation in glucose as well as lipid metabolism 
may play a major role in the pathogenesis of obesity-related nephropathy (250, 252, 263, 264, 
285, 289-291). Despite the known relationship between obesity-related nephropathy and 
glucose dysregulation and dyslipidaemia, the contribution of FXR regulation to renal damage 
has not been well characterized. Our in vivo study showed that offspring of obese mothers 
have reduced renal expression of FXR until at least weaning in rats. FXR is mainly expressed 
in the tubules, but not in the glomeruli, as shown in this study and reported previously by 
others (281). In vitro study using human proximal tubule epithelial cell line demonstrated that 
high ambient glucose inhibits FXR expression and that the activation of FXR mitigates the 
effects of high ambient glucose to increase pro-inflammatory, pro-fibrotic mediators and 
extracellular matrix accumulation of collagen IV and fibronectin, which are the first step 
towards the development of CKD. Furthermore, FXR silencing markedly enhanced the effect 
of high glucose on inflammatory, fibrotic and lipid pathways in PTCs. These results suggest a 
significant role of FXR in modulating inflammation and fibrosis within PTCs under high 
glucose conditions. This is not surprising given FXR has already been shown to play a role in 
the development of hepatic fibrosis (261, 262, 292).  
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Bile acids can cross the blood-placenta barrier. In addition, foetal and maternal bile acid 
levels are well correlated. Bile acid accumulation in the bloodstream induces intrahepatic 
cholestasis of pregnancy (ICP). A recent study by Papacleovoulou et al. showed that children 
born to pregnant women with ICP had higher body mass indices and increased fasting 
hyperinsulinaemia at age 16 despite normal birth weight (293). The offspring of mothers with 
ICP were more prone to obesity and diabetes (293). In our study, offspring were exposed to 
overnutrition due to maternal obesity including increased fatty acids, cholesterol, glucose and 
other nutrients, all of which may impact upon FXR expression in the kidney.  
 
The role of inflammation in the development of CKD is increasingly appreciated. We 
recently reported that inflammatory mediators are important for the development of fibrosis 
within PTCs (294). We showed that in the presence of high glucose, transforming growth 
factor-β1 (TGF-β1) expression is induced and in particular, TGF-β1 plays a major role in 
upregulating other proinflammatory cytokines, including MCP-1 (295). These cytokines 
directly regulate the activity of pro-fibrotic markers, including fibronectin and collagen IV 
(295). FXR has been shown to negatively interfere with the inflammatory response (296). 
Wang et al. showed that obese mice had increased expression of MCP-1 and reduced 
expression of anti-inflammatory cytokine Kruppel-like factor 4 within their kidneys (264). In 
this study, offspring of obese mothers had increased MCP-1 and TGF-β1 despite no 
difference in their body weight at postnatal Day 1 suggesting an intrauterine programming. 
Our in vitro model demonstrated that activation of FXR using agonist can reduce expression 
of MCP-1 and TGF-β1 as well as fibrotic markers fibronectin and collagen IV while 
silencing FXR had the opposite effect. Similarly, the FXR ligand (6-ethyl chenodeoxycholic 
acid) has been shown to have anti-fibrotic, anti-inflammatory and anti-apoptotic effects in 
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cisplatin-induced HK-2 cells (266). Interestingly, here in rats, despite in utero exposure to 
high-fat diet there appeared to be minimal effects on pro-fibrotic markers. It is likely that 
fibrotic changes would be evident at later time points as it was demonstrated in the study 
performed by Hao et al. showing significant extracellular matrix (ECM) changes after 3 
months post-birth (251). 
 
Previous studies have suggested that FXR activation has beneficial effects on the kidney by 
altering the expression of SREBP-1 and its lipogenic target genes (297). SREBP-1 is a known 
key transcriptional factor linking fatty acid and lipid accumulation to ECM deposition (255, 
290). In SREBP-1 transgenic mice, overexpression of SREBP-1 in the kidney caused lipid 
accumulation and increased expression of profibrotic cytokines, which induced ECM 
accumulation, mesangial expansion, glomerulosclerosis and proteinuria (291). SREBP-1c lies 
downstream of FXR (288). SREBP-1c is known to be expressed in human and animal tissues, 
in particular kidneys (298, 299). Although mRNA expression of FXR in mouse PTCs is five 
times more than in glomeruli, there is a lack of evidence linking FXR with SREBP-1c in 
kidney PTCs (263).  In our HK2 PTCs, high glucose was associated with downregulation of 
FXR and SHP with upregulation of SREBP-1c. Similarly, the downregulation of FXR was 
associated with an upregulation of SREBP1c protein expression in offspring from obese rats 
at weaning. 
 
Suckling from obese mothers may confound the maternal effects incurred in utero. Previous 
studies addressed this confounding problem by cross-fostering techniques (275), thereafter to 
conclude that in utero exposure has independent effects on organ development and 
metabolism. Interestingly changes in FXR were demonstrated at Day 1 before significant 
neonatal milk consumption. In addition, changes in MCP-1, TGF-β1 and collagen IV were 
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also evident at Day 1. These changes had mostly normalized by postnatal Day 20, suggesting 
postnatal milk intake may have ameliorated the intrauterine effect due to maternal HFD 
consumption. It is well documented that breastfeeding has significant protective effects 
against obesity and its related metabolic effects (60, 61, 63) possibly due to increased 
amounts of antioxidants in the breast milk (300). Nevertheless, we postulate that the future 
development of CKD may require a second insult such as HFD consumption. Early metabolic 
changes and changes in renal inflammatory and fibrotic markers at birth in the absence of 
overt renal functional changes may suggest increased risk of future CKD in adulthood. 
 
Offspring of obese mothers had glucose intolerance at weaning; therefore we pursued the role 
of FXR in glucose-mediated renal damage in our in vitro model. Indeed, we showed that 
FXR is linked to glucose-mediated inflammatory and fibrotic changes in PTCs. Taken 
together, basal FXR expression is important in maintaining ECM homeostasis and high 
glucose suppresses FXR expression. In addition, an FXR agonist can abrogate high glucose-
induced ECM production. However, the offspring of obese mothers also had impaired lipid 
metabolism at Day 20. We did not investigate the role of FXR in lipid/cholesterol-mediated 
damage to PTCs here. Other nuclear hormone receptors such as vitamin D receptor (VDR) 
and peroxisome-proliferator-associated receptors (PPARs) are known to play a role in renal 
inflammation, oxidative stress, fibrosis and renal lipid deposition and their activation may 
mitigate nephropathy in diabetic animals (301). Nuclear receptor activation of FXR, VDR 
and PPAR tend to have common pathways leading to modulation of glucose metabolism, 
lipid metabolism and immune response (301-303). 
 
FXR is a potential pharmacological target for the treatment of obesity and metabolic 
syndrome due to its regulation of bile acids, lipids and glucose metabolism (255, 258, 259, 
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261, 264). Weight reduction induced by sleeve gastrectomy was recently demonstrated to be 
critically dependent upon FXR activation (304). Indeed, FXR knockout mice with dietary 
obesity failed to lose significant weight with sleeve gastrectomy compared to their wild-type 
counterparts. The therapeutic benefit of FXR agonists is only just being explored. A clinical 
trial investigating the effect of the FXR agonist INT-747 in patients with type 2 diabetes and 
non-alcoholic fatty liver disease, concluded that FXR activation improved insulin sensitivity 
and reduced markers of liver inflammation and fibrosis (305).  More clinical trials are 
underway to determine the effect of FXR agonist in the setting of diabetes and non-alcoholic 
fatty liver disease (306).  
 
Several studies have shown that FXR activation can ameliorate diabetic nephropathy by 
modulating lipid metabolism, fibrosis, inflammation, and oxidative stress in animals and in 
glomerular and mesangial cells in vitro (263, 307, 308). This study suggests that this process 
also occurs in PTCs. Furthermore, maternal obesity can change renal FXR expression 
associated with dysregulated glucose and lipid levels in the offspring. Our study is the first to 
report the effect of maternal obesity, which is a global health issue in humans, on the 
offspring’s kidney, and linked it to FXR as a critical regulator of the developmental 
programming effect of maternal obesity on kidney health. The long-term effect of a reduction 
of FXR level in early post-natal life on the development of CKD requires further 
investigation. If proven, the relative benefits of modifying FXR in the offspring of obese 
mothers will necessitate future study 
 
In summary, maternal obesity downregulates renal FXR expression in the offspring kidney, 
which is associated with increased inflammation and early fibrotic change in the kidney at 
birth. Given the role that FXR plays in regulating lipid and glucose metabolism, with 
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downstream activation of inflammatory and fibrotic pathways, the potential exists for FXR 
modulation to prevent and ameliorate kidney damage associated with maternal obesity.   
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4.1 Abstract 
 
Background: Maternal obesity is associated with an increased risk of chronic disease in 
offspring, including type 2 diabetes (T2D). Exendin-4 (Exd-4) activates the glucagon like 
peptide-1 (GLP-1) receptor thereby decreasing serum glucose levels and body weight. In 
addition, Exd-4 has been shown to reduce renal and cardiac complications in experimental 
models of T2D. We hypothesized that treatment with Exd-4 would ameliorate the detrimental 
effects of maternal and diet-induced obesity on renal characteristics in offspring.  
Methods: Female Sprague-Dawley rats were fed either normal or high-fat diet (HFD) for 6 
weeks prior to pregnancy, during pregnancy and lactation, and their offspring were weaned to 
normal or HFD. The offspring were randomized to Exd-4 or placebo from weaning and their 
kidneys harvested at Week 9.  
Results: We found that the kidneys of offspring from obese mothers, regardless of postnatal 
diet, had significantly increased markers of inflammation, oxidative stress and fibrosis. Exd-4 
ameliorated the negative renal effects of maternal obesity and in particular, reduced renal 
inflammation, oxidative stress and fibrosis.  
Conclusions: In conclusion, maternal obesity has persisting effects on renal structure in the 
offspring. GLP-1 analogues are potentially useful for protecting against the deleterious 
effects of maternal obesity on renal physiology in offspring. 
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4.2 Introduction 
 
The metabolic consequences of obesity have been well described and include type 2 diabetes, 
insulin resistance, non-alcoholic fatty liver disease, dyslipidaemia and hypertension. 
Furthermore, obesity has been shown to be an independent risk factor for both cardiovascular 
and cerebrovascular events (309, 310). Chronic kidney disease (CKD) is less often 
considered as part of the metabolic syndrome or an end-organ complication of obesity. 
However, epidemiological evidence suggests that CKD is increasing in parallel to the rising 
epidemic of obesity (311). A recent study showed that the risk of CKD was over 2.5 times 
higher in obese individuals compared with normal-weight individuals after adjusting for 
confounding factors including diabetes and hypertension (224). Postulated 
pathophysiological mechanisms of obesity-related CKD include renal lipid accumulation and 
increased expression of proinflammatory factors, oxidative stress and profibrotic growth 
factors, which in turn lead to renal hyperfiltration, podocyte damage and mesangial 
expansion (177, 222, 252, 284, 312). 
 
Obesity affects all stages of the lifespan including women of childbearing age. Maternal 
obesity in pregnancy is associated with lifelong metabolic consequences in the offspring, 
including obesity, dyslipidaemia, insulin resistance and type 2 diabetes (313, 314). Maternal 
obesity and its effects on offspring have raised considerable public interest, especially 
considering that adult progeny of obese mothers have a 22% increased risk of cardiovascular 
disease, stroke, and all-cause mortality independent of their own weight (21). This, along 
with similar other associations, gives precedence to the theory of the developmental origins 
of health and disease, which states that offspring’s health is integrally related to maternal 
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health as a result of long-lasting effects of in utero and early postnatal exposure (275). The 
effect of maternal obesity on the offspring risk of renal disease is less well characterized.  
 
Weight reduction by conservative management alone has been repeatedly shown to be 
difficult to achieve and sustain (315). Therapeutic options to assist with weight loss and 
maintenance are limited and would be a useful adjunct to lifestyle change. Glucagon like 
peptide-1 (GLP-1) receptor agonists, such as Exendin-4 (Exd-4) are a class of medications 
used in the management of type 2 diabetes as they have potent glucose-lowering effects. 
GLP-1 is a naturally occurring incretin hormone secreted from the L-cells in the lower gut; 
which stimulates endogenous insulin secretion in a physiological and glucose-dependent 
manner. In addition, GLP-1 receptor agonists promote weight loss through a reduction in 
appetite and increased satiety. Of note, it is increasingly understood that GLP-1 receptor 
activation has renoprotective properties beyond glucose lowering, as demonstrated in both 
animal models and preliminary data from human studies (316).  
 
We have previously shown that offspring of obese rat dams display increased fat mass, 
elevated blood triglyceride levels and glucose intolerance compared with those from lean 
rats, which is further exaggerated by consuming a high fat diet (HFD) after weaning (317). 
The current study utilized a rodent model to investigate whether maternal obesity has 
detrimental renal effects on the offspring; in particular promoting CKD by altering glucose 
and lipid metabolism, oxidative stress, inflammation, and fibrosis within the kidney. We 
hypothesized that the treatment of offspring with Exd-4 would reduce renal inflammation, 
oxidative stress and fibrotic changes induced by maternal obesity. 
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4.3 Methods 
 
4.3.1 Animal experiments 
 
Virgin outbred female Sprague Dawley rats (aged 9 weeks) were sourced from Animal 
Resource Centre (WA, Australia). The study protocol has been previously described (317). 
Briefly, dams were fed standard rodent chow (11kJ/g, 14% fat, Gordon’s Specialty 
Stockfeeds, NSW, Australia) or pellet HFD (20kJ/g, 43% fat; SF03-020, Speciality Feeds, 
WA, Australia) for 6 weeks prior to mating, throughout gestation and lactation. Only male 
offspring were studied given that previous studies have shown male gender to be more 
susceptible to renal damage (318). All procedures were approved by the Animal Care and 
Ethics Committee (ACEC) of University of New South Wales (ACEC#09/3A) and complied 
with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. 
At postnatal day 20 (normal weaning age), pups from lean dams were fed standard rodent 
chow diet (CC). Half of the pups from the obese dams within the same litter were fed chow 
(HC), while the other half was fed HFD (HH). Within each dietary cohort, half the rats were 
treated with daily injections of Exd-4 (15µg/kg/day i.p. Auspep, VIC, Australia) and the 
other half were treated with saline. This resulted in 6 experimental groups, CC, CCE, HC, 
HCE, HH, and HHE.  
 
An intraperitoneal glucose tolerance test (IPGTT) was performed on offspring at 8 weeks of 
age. After 5 hours fasting, a baseline glucose level was measured at time 0 using a blood 
glucose meter (Accu-Chek®, Roche Diagnostics, NJ, USA). Animals were then administered 
glucose (2g/kg i.p.) and blood glucose levels were measured at 15, 30, 60, and 90 minutes 
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post-injection as previously described (19). Area under the curve (AUC) of the glucose levels 
over the time was calculated for each rat. 
 
At 9 weeks of age, the rats were fasted for 5 hours before being deeply anesthetized with 
Pentothal® (0.1mg/g, i.p. Abbott Australasia PTY. LTD, NSW, Australia) and weighed. 
Blood was collected via cardiac puncture and kidneys were harvested at the time of death.  
 
4.3.2 Quantification of inflammatory and oxidative stress markers 
 
Expression levels of inflammatory markers, including monocyte chemotactic protein-1 
(MCP-1) and interleukin-6 (IL-6), were measured in serum using a rat specific ELISA kit 
(Thermo, Rockford, IL, USA). Serum transforming growth factor-beta 1 (TGF-β1) was 
measured using a multispecies ELISA kit (Invitrogen, California, USA). Plasminogen 
Activator Inhibitor-1 (PAI-1) was quantified as part of a Rat Diabetes 5-Plex Kit (Bio-Rad 
Laboratories, Hercules, CA, USA). 8-iso-Prostaglandin F2 was measured by ELISA in 
kidney lysate as a marker of oxidative stress according to the manufacturer’s protocol (Cell 
Biolabs, San Diego, USA).  
 
4.3.3 Quantitative real-time PCR 
 
RNA was extracted from kidney tissue using RNeasy mini kit (Qiagen, Valencia, CA, USA). 
cDNA was generated using Transcriptor First Strand cDNA Synthesis Kits (Roche 
Diagnostics, Mannheim, Germany). RT-PCR was performed using SYBR Green primers 
(Table 4A) with GreenER qPCR Supermix (Life Technology, Foster City, CA, USA) in an 
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ABI Prism 7900 HT Sequence Detection System (Life Technology), except preoptimised 
TaqMan® probe/primer was used to measure mRNA expression of GLP-1 receptor 
(NM_012728.1, Life Technology). Results are presented as fold change against the control 
after normalization to the housekeeping gene 18s. 
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Table 4.A Primers used in quantitative real time PCR 
Gene Primer sequences 
MCP-1 F: GTTGTTCACAGTTGCTGCCT 
 R: CTCTGTCATACTGGTCACTTCTAC 
TGF-β1 F: AGGACCTGGGTTGGAAGTGG 
 R: AGTTGGCATGGTAGCCCTTG 
iNOS F: TGGTGGTGACAAGCACATTT 
 R: CTGAGTTCGTCCCCTTCTCC 
PPAR-α F: CCTCTTCCCAAAGCTCCTTCA 
 R: GTACGAGCTGCGCATGCTC 
FAS F: GGCCACCTCAGTCCTGTTAT 
 R: AGGGTCCAGCTAGAGGGTACA 
FN F: CAGCCCCTGATTGGAGTC 
 R: TGGGTGACACCTGAGTGAAC 
CIV F: CCATTCTCAGGACTTGGGTA 
 R: AAGGGCATGGTGCTGAACT 
18S F: GAGGTGAAATTCTGGACCGG 
 R: CGAACCTCCGACTTTCGTTCT 
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4.3.4 Analysis of renal structural changes  
 
Formalin-fixed hemisected kidneys were embedded in paraffin and stained with Masson’s 
trichrome or Periodic Acid Schiff (PAS).  They were examined using a light microscope 
(Leica photomicroscope linked to a DFC 480 digital camera) and five non-overlapping fields 
were captured for each kidney. Tubulointerstitial fibrosis was graded on a scale of 0 to 4 in a 
blinded manner by two independent pathologists (0 - normal; 1 - involvement of < 10% of 
the cortex; 2 - involvement of 10 –25% of the cortex; 3 - involvement of 25–75% of the 
cortex; and 4 - extensive damage involving > 75% of the cortex). In a similar manner, PAS 
staining was used to grade glomerulosclerosis (0 - normal, 1 - < 25% involvement, 2 < 50% 
involvement, 3 - < 75%, and 4 - > 75% sclerosis) and then the glomerulosclerosis index 
(GSI) calculated as GSI = [(1 x N1) + (2 x N2) + (3 x N3) + (4 x N4)]/(N0 + N1 + N2 + N3 + 
N4), where Nx is the number of glomeruli with each given score for a given section. 
 
Immunohistochemistry staining was performed as previously described (319). Briefly, 
primary antibodies against fibronectin (dilution 1:1,000, Abcam, Cambridge, UK), collagen 
IV (dilution 1:1,000, Abcam, Cambridge, UK), fatty acid synthase (FAS, dilution 1:50, Cell 
Signalling, Danvers, USA), 8-Oxo-2'-deoxyguanosine (8-OHdG, 1:200, Cell Signalling) and 
nitrotyrosine (1:200, Abcam) were applied followed by biotinylated secondary anti-rabbit 
IgG antibodies and finally horseradish peroxidase (HRP)-conjugated streptavidin (Dako). 
The tissue specimens were examined by bright field microscopy (Leica photomicroscope). 
For fibronectin, collagen IV, FAS, 8-OHdG and nitrotyrosine, five consecutive 
nonoverlapping fields from each section of renal cortex were photographed under high 
magnification. Areas of brown staining were quantified using a computer-aided manipulator, 
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Image J (National Institutes of Health, US). The percentage of the stained area relative to the 
whole area in each vision field was determined. 
 
Oil Red O staining was performed on frozen sections to determine renal accumulation of 
neutral lipids. Frozen sections were place in Oil Red O-saturated solution (0.5:100 
isopropanol) for one hour and then observed under phase-contrast microscopy. Oil Red O-
stained lipid was examined by light microscopy and quantified with Image J. 
 
In order to examine effects on renal function, Cystatin C was measured by immunoassay as 
per manufacturer’s instructions (R&D Systems, Minneapolis, USA). 
 
4.3.5 Statistical methods 
 
All results are expressed as mean ± SEM. Data were analysed using analysis of variance 
(ANOVA), followed by post hoc Bonferroni tests (GraphPad Prism 6.0, GraphPad Software, 
San Diego, CA, USA). A p value of < 0.05 was considered statistically significant. 
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4.4 Results 
 
4.4.1 Effect of maternal obesity, HFD consumption and Exd-4 on weight 
and glucose tolerance in offspring 
 
We have previously shown that maternal obesity and diet-induced obesity have important 
consequences on offspring metabolic outcomes (317). In the present sub-study, despite no 
difference in total body weight, offspring of obese mothers had increased retroperitoneal and 
epididymal fat deposition (Figure 4.1A-C). Conversely, the body weight of offspring fed 
HFD was significantly increased at 9 weeks alongside increased fat deposition (p < 0.0001, 
Figure 4.1A-C). Exendin-4 treatment significantly reduced body weight in all groups, 
regardless of maternal or offspring diet (p < 0.0001, Figure 4.1A).  
 
Glucose tolerance was not affected by maternal obesity alone. However, HFD consumption 
in the offspring in conjunction with maternal obesity was associated with glucose intolerance 
as shown by increased AUC (p < 0.0001, Figure 4.1D). At 15- and 30- minute during IPGTT, 
there was a significant rise in blood glucose levels in the HFD-fed offspring group (HH), 
compared with the control group (CC) (p < 0.05 at both time-points, Figure 4.1E). Insulin 
resistance, measured by HOMA-IR, was increased in offspring of the obese mothers 
regardless of postnatal diet (HC vs. CC; p < 0.05 and HH vs. CC; p < 0.0001), however, 
HOMA-IR was significantly higher in the offspring of obese mothers fed HFD compared 
with those fed normal chow (HH vs. HC; p < 0.0001, Figure 4.1F). 
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Figure 4.1 Biometric measurements in the offspring at Week 9 
(A) Total body weight (N= 17-21); (B) Retroperitoneal fat deposition represented as 
percentage of total body weight; (C) Epididymal fat deposition represented as percentage of 
total body weight; (D) Blood glucose levels at Time 0, 15, 30, 60 and 90 minutes during 
IPGTT at Week 8 (2g/kg i.p) (N = 9-15) and, (E) AUC of IPGTT  (n = 6-9). (F) HOMA-IR 
scores at Week 9 (n = 9-15). *p< 0.05, ** p < 0.01, **** p < 0.0001.  
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4.4.2 Effect of maternal obesity, HFD consumption and Exd-4 on tubular 
and glomerular damage in the offspring   
 
Using Masson’s trichome staining, proximal renal tubules of control offspring demonstrated 
a normal appearance with back-to-back distribution and epithelial cells were cuboidal in 
shape (Figure 4.2A). In the offspring of obese mothers, there was flattening of the tubular 
epithelium, diminishment of the total thickness of the cortex and medulla, thickened 
basement membrane, a widened tubulointerstitial space, and increased cellular infiltrate 
compared with the control group, regardless of postnatal diet (composite endpoint; HC vs. 
CC p < 0.001, HH vs. CC p < 0.0001, Figure 4.2A and B). The kidneys of HFD-fed offspring 
of obese mothers had more extensive tubular damage compared with their chow-fed 
littermates (HH vs. HC p < 0.01). Furthermore, PAS staining demonstrated significant 
glomerular structural changes including glomerulomegaly, mesangial expansion and tubular 
distortion in the HFD-fed offspring of obese mothers (p < 0.05, Figure 4.2C and D). Exd-4 
treatment prevented the development of interstitial fibrosis (p < 0.001, Figures 4.2A and B) 
and significantly ameliorated the detrimental effects of overnutrition on the glomerulus (p < 
0.05, Figure 4.2C and D).  
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Figure 4.2 Structural changes in the kidney of offspring at 9 weeks 
(A) Representative images of interstitial fibrotic changes; (B) Interstitial fibrosis scores; (C) 
Representative images of glomerular damage; (D) Glomerulosclerosis scores (n = 4-8 per 
group). * p < 0.05, *** p < 0.001, **** p < 0.0001. 
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Immunohistochemistry staining for fibronectin confirmed that postnatal HFD consumption 
increased renal cortical fibronectin levels (p <0.0001, Figure 4.3A and B). mRNA expression 
of fibronectin was also increased in the offspring of obese mothers regardless of postnatal 
diet (p < 0.05 and p < 0.001 vs. CC respectively, Figure 4.3C). Treatment with Exd-4 
significantly reduced fibronectin protein and mRNA expression levels (p < 0.0001 and p < 
0.05 respectively, Fig 4.3B and C). Similarly, levels of collagen IV were elevated by both 
maternal obesity and postnatal HFD-consumption, as measured by immunohistochemistry 
and mRNA expression (P < 0.05, Figures 4.4D, E and F). However, there was no effect of 
Exd-4 treatment on collagen IV expression in either the HCE or HHE groups (Figure 4.4E 
and F). To further explore the above findings, renal function in the offspring was assessed by 
measurement of serum cystatin C. (320) Interestingly, neither maternal obesity nor diet-
induced obesity impaired renal function in offspring (Figure 4.5). Of note, treatment with 
Exendin-4 did not affect renal function in any of the groups. 
 
GLP-1 receptor expression was not altered by maternal obesity, diet-induced obesity or 
Exendin-4 therapy itself (Figure 4.6). 
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Figure 4.3 Fibronectin expression in the kidney of offspring at 9 weeks  
(A) Representative images of immunohistochemistry; (B) Protein expression of fibronectin; n 
= 4-6 per group for protein analysis, n = 6-9 per group for RT-PCR). * p < 0.05, *** p < 
0.001, **** p < 0.0001. 
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Figure 4.4 Collagen IV expression in the kidney at 9 weeks 
(D) Representative images of Collagen IV protein by immunohistochemistry; (E) 
Quantification of Collagen IV protein; (F) mRNA expression of fibronectin (n = 4-6 per 
group for protein analysis, n = 6-9 per group for RT-PCR). * p < 0.05, *** p < 0.001, **** p 
< 0.0001. 
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Figure 4.5 Serum cystatin C levels in offspring at 9 weeks 
Serum cystatin C was measured as a marker of renal function. No significant difference was 
found between groups (N=5-6 per group). 
 
 
  
Figure 4.6 GLP-1 receptor mRNA expression at 9 weeks 
There was no difference in GLP-1 receptor mRNA expression between groups (N = 4 per 
group).  
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4.4.3 Effect of maternal obesity, HFD consumption and Exd-4 on renal 
inflammatory markers in the offspring 
 
MCP-1 mRNA expression in the kidney was increased by maternal obesity in both chow- and 
HFD-fed offspring (HC vs. CC, p < 0.05 and HH vs. CC p < 0.01 respectively, Figure 4.7A). 
Similarly, mRNA expression of TGF-β1 was greater in offspring of obese mothers and those 
fed a HFD from weaning (Figure 4.7B). CD68 protein expression was increased by maternal 
obesity regardless of offspring diet (HC vs. CC, p < 0.01 and HH vs. CC p < 0.0001 
respectively, Figure 4.7C and D). Taken together, these results demonstrate that maternal and 
diet-induced obesity give rise to inflammation in the kidney. 
 
Exd-4 ameliorated the inflammatory effects of HFD and maternal obesity in offspring, as 
seen by a reduction in MCP-1 mRNA expression (p < 0.05, Figure 4.7A). There was a trend 
towards lower MCP-1 expression following Exd-4 treatment in chow-fed offspring of the 
obese mothers; however this difference was not statistically significant. Interestingly, Exd-4 
reduced TGF-β1 expression in the chow-fed but not HFD-fed offspring of the obese mothers 
(p < 0.05, Figure 4.7B), suggesting that diet-induced obesity in postnatal life outweighs the 
beneficial effect of Exd-4 therapy on TGF-β1 levels. CD68 protein level was reduced by 
Exd-4 in chow- and HFD-fed offspring of the obese mothers (p < 0.05, Figures 4.7C and D). 
 
To determine whether maternal obesity leads to a systemic inflammatory state or renal-
specific inflammation, circulating inflammatory markers were quantified. Similar to what 
was observed in the kidney, serum MCP-1 was increased in the offspring of obese mothers 
by 1.5 fold compared to the control group (HC vs. CC p < 0.05, Figure 4.7E). In addition, 
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serum MCP-1 levels were greater in the HFD-fed offspring of obese mothers (p < 0.01) and 
treatment with Exd-4 ameliorated this rise (HHE vs. HH p < 0.001). Likewise, circulating 
levels of TGF-β1 were higher in the offspring of obese mothers compared to control, 
regardless of postnatal diet (p < 0.05, Figure 4.7G), which again was reduced by Exd-4 (HCE 
vs. HC p < 0.05, HHE vs. HH p < 0.05). HFD feeding in the offspring of obese mothers gave 
rise to increased serum IL-6 levels, which was ameliorated by Exd-4 (p < 0.01, p < 0.05, 
respectively, Figure 4.7H). Furthermore, serum PAI-1 was increased by more than threefold 
when offspring of obese mothers were fed HFD (HH vs. HC p < 0.0001, Figure 4.7F), which 
was normalised by Exd-4 (p < 0.0001). Taken together, these results suggest that maternal 
and diet-induced obesity give rise to a systemic inflammatory state in the offspring, which is 
also evident in the kidney and is improved by treatment with Exd-4. 
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Figure 4.7. Renal and serum inflammation markers at 9 weeks 
(A) MCP-1 mRNA expression (n = 6-9), (B), TGF-β1 mRNA expression (n = 6-9), (C) and 
(D) immunohistochemistry staining of CD68 (n = 4-6), serum level of (E) MCP-1, (F) PAI, 
(G) TGF-β1, (H) IL-6 (n = 5-8). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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4.4.4 Effect of maternal obesity, HFD consumption and Exd-4 on renal 
oxidative stress in the offspring  
 
To further characterise the molecular mechanisms contributing to structural changes in the 
kidneys of offspring exposed to maternal and diet-induced obesity, quantitative analysis of 
oxidative stress markers was carried out. mRNA expression of iNOS was increased by almost 
threefold in the kidneys of offspring of obese mothers irrespective of postnatal diet, 
suggesting that maternal obesity gives rise to renal oxidative stress in the subsequent 
generation (HC vs. CC p < 0.05, HH vs. CC p < 0.01, Figure 4.8A). Exd-4 reduced iNOS 
mRNA expression to similar levels in both chow- and HFD-fed offspring of the obese 
mothers (HHE vs. HH p < 0.05, Figure 4.8A). 
 
In addition, the concentration of 8-iso PGF2α in kidney lysate were increased by almost 
threefold in both chow and HFD-fed offspring of the obese mothers (p < 0.05, p < 0.01 
respectively, Figure 4.8B), which was reduced by Exd-4 treatment (p < 0.05, Figure 4.8B).  
 
Furthermore, 8-OHdG expression was greater in the offspring of obese mothers with or 
without HFD; with a fourfold and threefold increase observed, respectively (p < 0.01, p < 
0.0001, Figure 4.8C and D). A reduction in 8-OHdG was seen in HFD-fed offspring of obese 
mothers treated with Exd-4 but no effect was observed for chow-fed controls (p < 0.001).  
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Figure 4.8 Renal oxidative stress markers in the offspring at 9 weeks  
(A) iNOS mRNA expression, (B) 8-iso PGF2a protein expression; (C and D) 
Immunohistochemistry staining for 8-OHDG (n = 4-7 per group). *p < 0.05, **p< 0.01, *** - 
< 0.001, **** p < 0.0001. 
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4.4.5 Effect of maternal obesity, HFD consumption and Exd-4 on lipid 
profile in the offspring  
 
As previously described, maternal obesity gave rise to hypertriglyceridemia irrespective of 
offspring diet which was ameliorated by treatment with Exd-4 (317). Furthermore, serum free 
fatty acid levels were increased in HFD-fed offspring of the obese mothers and again a 
reduction was observed following Exd-4 therapy (p < 0.05, p < 0.001 respectively, Figure 
4.9A).  
 
Oil red O staining demonstrated significant lipid deposition in the kidneys of HFD-fed 
offspring, which was ameliorated by Exd-4 (p < 0.01, Figure 4.9B and C). Renal FAS mRNA 
expression was increased by two fold by maternal obesity (HC vs. CC p < 0.01, Figure 4.9D), 
suggestive of upregulated fatty acid production. Furthermore, HFD consumption in the 
offspring of obese mothers was associated with a 7-fold increase in FAS mRNA expression. 
Similarly, FAS protein was increased by both maternal obesity and exposure of offspring to 
postnatal HFD (Figure 4.9E and F). Exd-4 reduced FAS protein levels in the offspring kidney 
(p < 0.001, Figure 4.9F), however mRNA expression was not significantly lowered (Figure 
4.9D). 
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Figure 4.9 Lipid and free fatty acid accumulation at 9 weeks 
 (A) Serum free fatty acid concentrations (n = 9-13 per group); (B and C) renal Oil red O 
staining (n = 4-6 per group); (D) mRNA expression of fatty acid synthase (n = 6-9 per group) 
and (E and F) Fatty acid synthase protein by immunohistochemistry (n = 4-6 per group). * p 
< 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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4.5 Discussion 
 
The results of the present study demonstrate that maternal obesity leads to detrimental effects 
on kidney health in the offspring, including increased inflammation, oxidative stress and 
fibrotic changes. Strikingly, these outcomes are observed even in the absence of HFD-
induced obesity in postnatal life. This suggests a powerful effect of developmental 
programming on kidney health as a consequence of maternal obesity. In addition, treatment 
with Exd-4 is associated with protection against the deleterious effects of maternal obesity on 
the renal physiology of offspring. As such, this study is the first to show a beneficial effect of 
a GLP-1 analogue on the modulation of kidney health in adolescence in the setting of 
maternal obesity. 
 
Obesity is a key player in the development of metabolic syndrome and is associated with a 
multitude of chronic complications. Of note, several recent studies have suggested that 
obesity, independent of diabetes, can cause renal damage (224, 321). We found that maternal 
obesity gives rise to inflammatory, oxidative stress and fibrotic changes within the offspring 
kidney, which collectively, are likely to lead to the development of CKD later in life. 
Interestingly, the deleterious effects of maternal obesity on the kidneys of rat offspring were 
observed irrespective of postnatal diet. Furthermore, these adverse effects are independent of 
the body weight or glucose tolerance, which were not altered by maternal obesity at Week 9 
in chow-fed offspring (317). Thus, developmental programming makes an important 
contribution towards kidney health. 
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Adipose tissue secretes chemokines and cytokines which induce an overall pro-inflammatory 
state in the body (237). Many of these chemokines and cytokines have known associations 
with renal fibrosis (211, 322-324). Our model of both maternal obesity and diet-induced 
obesity shows increased fat accumulation in fat depots (retroperitoneal and gonadal fat) as 
well as in the kidney. We found increased systemic inflammatory markers including: (1) 
MCP-1, an important chemokine secreted by the macrophages and key inflammatory 
mediator of renal fibrosis, (2) PAI-1, a known mediator of renal fibrosis in obesity, and (3) 
TGF-β1 which is an important regulator of inflammation and fibrosis in the kidney. The 
results of our study suggest that increased inflammation is a significant mediator of maternal 
obesity-induced kidney changes in the offspring. Given that the direct effect of the maternal 
milieu in utero and in early postnatal life has well passed by Week 9 in the rat offspring, we 
postulate that the effects of developmental programming on inflammatory pathways must be 
sustained to adult life. 
 
Recent studies suggest that oxidative stress in utero may be a key event in response to 
abnormal maternal nutrition (325, 326). Nutrient excess leads to mitochondrial dysfunction 
that in turns leads to obesity related pathologies, in part due to the harmful effects of 
oxidative stress (327). Oxidative stress has been reported early on during embryogenesis in 
offspring of obese mice, with the oocytes and zygotes having increased mitochondrial 
membrane potential, higher levels of oxidative phosphorylation and increased ROS 
production (328). Oxidative stress plays a critical role in the pathophysiology of several 
kidney diseases (329). Our study is the first to report the influence of maternal obesity on 
renal markers of oxidative stress suggesting that maternal obesity induces sustained 
activation of deleterious oxidative stress pathways in the offspring, rendering them 
vulnerable to develop kidney diseases. 
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GLP-1 receptors (GLP-1Rs) are predominantly expressed in the β-cells of the pancreas, but 
are also expressed in many other tissues including the kidney, where they have been localized 
to the glomeruli and endothelial cells within the kidney (330). A recent study used 
autoradiographic labelling to demonstrate that the GLP-1R is predominantly located in the 
renal microvasculature in rats, namely afferent arterioles (331). Thus, GLP-1R modulation 
may have beneficial effects in the kidney. We found that GLP-1R was expressed in the rat 
kidney and importantly its expression was not altered by maternal obesity, diet-induced 
obesity or Exendin-4 treatment. It was previously shown that treatment with the GLP-1R 
agonist liraglutide suppresses the progression of diabetic nephropathy in mice, as 
demonstrated by reduced markers of renal fibrosis and decreased glomerular oxidative stress 
(330). In the present study, Exd-4 therapy significantly reduced many of the adverse effects 
of maternal obesity and HFD consumption on inflammation, oxidative stress and fibrotic 
changes in the kidney. We did not see overt nephropathy, most likely due to the animals’ 
young age at the time of harvest, which is equivalent to late adolescence. Further studies are 
required to investigate the long-term outcome of maternal obesity on the renal outcomes in 
such offspring.  
 
A limitation of this study is that we were unable to fully determine whether the detrimental 
changes in the offspring’s kidneys induced by maternal obesity correlates with an alteration 
in kidney function and whether Exd-4 minimized this potential effect. Renal function as 
measured by circulating cystatin C was not altered by maternal obesity or Exd-4. In this 
study, the kidneys of rat offspring were studied at postnatal Week 9. It is possible that with 
longer exposure time, renal functional changes may have been seen. This would be an 
interesting focus for future studies. However, increased inflammation, oxidative stress and 
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fibrosis are all known precursors to the development of CKD and are integrally part of renal 
disease pathogenesis (332). In addition, recent evidence has suggested that structural kidney 
damage may preface frank impairment in kidney function, as evidenced by increased early 
interstitial fibrotic changes and podocyte damage in the absence of microalbuminuria (333). 
We found evidence of early renal fibrosis, increased oxidative stress and inflammation within 
the kidneys of offspring exposed to maternal obesity. This detrimental effect on renal 
parameters was further exacerbated by diet-induced obesity in the offspring. Thus, our results 
strongly suggest that maternal obesity induces pathophysiologic changes in the kidneys, 
which may predispose offspring to renal disease in later life.  
 
In the current model, there are two possible explanations for the protective renal effects of 
Exd-4 treatment: (1) direct pleiotropic effects of GLP-1 receptor activation on the kidney by 
reduction in pro-inflammatory and antioxidant effects ameliorating fibrotic changes induced 
by HFD; or (2) alterations in whole body metabolic profile including weight loss, reduced 
blood lipids and improved glucose metabolism. To further explore the above possibilities, a 
systemic or kidney-specific GLP-1 receptor knockout animal could be utilized to determine 
whether the effect observed was due to a systemic or kidney specific mechanism. Regardless 
of whether the effect is directly or indirectly mediated, our study has clinical relevance given 
it shows the beneficial renal outcomes of treatment with Exendin-4. An overview of the 
potential mechanisms of Exd-4 therapy on kidney health in offspring exposed to maternal 
obesity with or without diet-induced obesity is provided in Figure 4.10. 
 
To conclude, obesity-related nephropathy is an important complication of overnutrition. 
Maternal obesity has a detrimental impact on kidney health. As the prevalence of obesity 
increases worldwide, it is of clinical significance to better understand the effect of maternal 
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obesity on kidney health and find therapies that may ameliorate such detrimental effects. Our 
findings point towards GLP-1 receptor agonists as a potential novel therapy for the reduction 
of kidney damage associated with maternal obesity. 
 
 
 
 
Figure 4.10 Potential mechanism of Exendin-4 activity  
The potential mechanisms of Exendin-4 activity in the reduction of deleterious structural 
changes in kidneys of offspring of obese mothers. 
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5.1 Abstract 
 
Background: Maternal obesity is known to increase the risk of obesity and diabetes in 
offspring. Though diabetes is a key risk factor for the development of chronic kidney disease 
(CKD), the relationship between maternal obesity and CKD has not been clearly defined. In 
this study, a mouse model of maternal obesity was employed to determine the impact of 
maternal obesity on development of diabetic nephropathy in offspring.  
Methods: Female C57/BL6 mice were fed high-fat diet (HFD) for six weeks prior to mating, 
during gestation and lactation. Male offspring were weaned to normal chow diet. At postnatal 
Week 8, offspring were randomly administered low dose streptozotocin (STZ, 55 mg/kg/day 
for five days) to induce diabetes. Assessment of renal damage took place at postnatal Week 
32.  
Results: We found that offspring of obese mothers had increased renal fibrosis, inflammation 
and oxidative stress. Importantly, offspring exposed to maternal obesity had increased 
susceptibility to renal damage when an additional insult, such as STZ-induced diabetes, was 
imposed. Specifically, renal inflammation and oxidative stress induced by diabetes was 
augmented by maternal obesity.  
Conclusion: Our findings suggest that developmental programming induced by maternal 
obesity has implications for renal health in offspring. Maternal obesity should be considered 
a risk factor for CKD.  
.  
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5.2 Introduction 
 
Diabetic nephropathy is an important complication of diabetes and is the leading cause of 
end-stage kidney disease worldwide (334). In type 1 diabetes, the risk of diabetic 
nephropathy is associated with longer duration of diabetes, poor glycaemic control, 
hypertension and dyslipidaemia (335). Yet, it is poorly understood why, despite multiple risk 
factors for renal disease, some individuals appear to be unaffected by renal complications 
while others seem to be highly susceptible to diabetic nephropathy (336). Moreover, there 
appear to be less well-defined precipitating factors for diabetic nephropathy. Interestingly, 
recent studies have suggested that maternal factors impacting foetal exposure in utero may 
contributes to increased risk of kidney disease in adulthood (337-339). This concept of 
developmental programming is increasingly understood to have long-lasting consequences on 
renal health. 
 
Developmental programming due to foetal exposure to maternal obesity significantly 
increases the risk of metabolic syndrome and its sequelae in offspring (33, 340). Metabolic 
syndrome is a cluster of multiple medical comorbidities underpinned by obesity and insulin 
resistance (46). A retrospective case control study of over 1 million person years found a 
35% increased risk of mortality and 29% greater risk of cardiovascular death in offspring 
born to obese mothers compared to non-obese mothers (21). Both rodent and primate models 
of maternal high-fat diet (HFD) feeding have identified that offspring of obese mothers are at 
increased risk of obesity, glucose intolerance and diabetes, hepatic steatosis and endothelial 
injury (67, 275). Though the kidney is a highly vascular organ that is very responsive to 
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hemodynamic, metabolic and inflammatory changes (210), the link between maternal obesity 
and CKD has not clearly been made. 
 
Our recent studies have identified that rodent offspring of obese mothers have increased renal 
damage including fibrosis, inflammatory and oxidative stress changes (341). As such, 
exposure to maternal obesity in utero may propagate renal dysfunction in offspring through 
increasing the risk of metabolic syndrome, which can further be compounded by the 
development of diabetes later in life. Thus, the aim of this study was to determine whether 
maternal obesity increases diabetic nephropathy in rodent offspring with diabetes. 
Specifically, we aimed to determine whether maternal obesity: (1) leads to changes in renal 
physiology in offspring at adulthood and, (2) exacerbates renal damage in diabetic offspring, 
and importantly explore the mechanisms of these effects. 
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5.3 Materials And Methods 
 
5.3.1 Animal experiments 
 
A schematic representation of the animal model is shown in Figure 5.1. Female C57BL/6 
mice were fed either high fat diet (HFD, 20kJ/g, 43% fat; SF03-020, Specialty Feeds, WA, 
Australia) or standard rodent chow (11kJ/g, 14% fat, Gordon’s Specialty Stockfeeds, NSW, 
Australia) for six weeks prior to mating (n = 12). They were mated for 24 hours, pregnancy 
confirmed by vaginal plug and then maintained on the same diet throughout gestation and 
lactation.  Litters were adjusted to 4-6 pups at postnatal Day 1. Male pups were weaned at 
postnatal day 20 (normal weaning age) and fed chow. At postnatal week 8, mice were 
assigned to receive either low-dose streptozotocin (STZ) or placebo. Mice receiving low-dose 
STZ were fasted for 5 h prior to injection. STZ (55 mg/kg, Sigma, MO, USA) was prepared 
fresh in 0.1 M citrate buffer, pH 4.5 and administered over 5 consecutive days. Animals in 
the control group were administered citrate buffer.  
 
After fasting for 6 h, mice were weighed and their blood glucose levels were measured 
fortnightly using an Accuchek glucometer (Roche Diagnostics). Animals with blood glucose 
>16 mmol/L were considered diabetic. Diabetic mice received insulin treatment (Glargine, 
Sanofi, Germany) to control ketosis if their blood glucose level was > 25 mmol/L; following 
insulin treatment, their blood glucose readings were performed twice weekly.  
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Figure 5.1 Schematic representation of the mouse model of maternal obesity and offspring 
diabetes 
Offspring from lean mothers (control): CC-ctrl, type 1 diabetic offspring from lean mothers: 
CC-T1D, offspring from obese mothers: HC-ctrl and offspring from obese mothers with type 
1 diabetes: HC-T1D. 
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Mice were placed in metabolic cages and 24-h urine collection was performed one week prior 
to animal sacrifice.  Urine albumin levels were determined using the Murine 
Microalbuminuria ELISA kit (Exocell, Inc., Philadelphia, PA, USA).  
 
Animal sacrifice took place at Week 32 under fasting conditions. The body was perfused with 
PBS, and the kidneys, liver, pancreas and fat were weighed and collected, either snapped 
frozen for RNA and protein quantification or fixed in 10% buffered formalin for histological 
examination.  
 
All animals were housed in the Kearns Animal Facility of Kolling Institute, Royal North 
Shore Hospital and maintained at 22±1°C with a 12/12-h light–dark cycle. All procedures 
were approved by the Animal Ethics Committee (AEC) of Royal North Shore Hospital (AEC 
1309-007A) and complied with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes. 
 
5.3.2 Serum measures 
 
Glycosylated haemoglobin (HbA1c) was measured using a DCA Vantage Analyser (Siemens 
Medical Solutions Diagnostics, Tarrytown, NY). To measure serum triglycerides, plasma 
samples as well as glycerol standards (Sigma-Aldrich, St Louis, MO, USA) were incubated 
with triacylglycerol reagent (Roche Diagnostics) and concentration was determined using the 
colorimetric method on a Bio-Rad 680 XR (Hercules, CA, USA). Plasma non-esterified fatty 
acid (NEFA) was measured using a NEFA kit (WAKO, Osaka, Japan). Serum creatinine was 
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measured using the Architect C16000 Clinical Chemistry Analyser (Abbott Laboratories, 
Abbott Park, Il, USA). 
 
5.3.3 Analysis of renal structural changes  
 
Formalin-fixed hemisected kidneys were embedded in paraffin and stained with Masson’s 
trichrome or Periodic Acid Schiff (PAS). They were examined using a light microscope 
(Leica photomicroscope linked to a DFC 480 digital camera) and five non-overlapping fields 
were captured for each kidney. Tubular interstitial injury was an aggregate measure of 
tubular dilatation, separation, atrophy and interstitial fibrosis as measured by a blinded 
independent nephrologist. Images were analysed using an Olympus microscope (Olympus, 
Japan) and Image J software. 
 
5.3.4 Protein extraction and western blotting 
 
In order to extract protein, 10 mg kidney tissue was washed with phosphate buffered saline 
(PBS, pH 7.4, containing 0.16 mg/ml heparin to remove any red blood cells and clots) then 
the tissue was extracted with a Qiagen TissueRuptur (Qiagen, Limburg, Netherlands) in 1.5 
ml of cold 20 mM HEPES buffer (pH 7.2, containing 1 mM EGTA, 210 mM mannitol, 70 
mM sucrose) and quantified (BioRad, CA, USA). A total of 20µg of protein sample was 
loaded onto a NuPAGE SDS-PAGE gel (Life Technologies, CA, USA) and electroblotted to 
Hybond Nitrocellulose membranes (Amersham Pharmacia Biotech, Bucks, UK). The 
membranes were incubated overnight at 4°C with the following primary antibodies: 
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fibronectin (dilution 1:1000, Abcam, Cambridge, UK), collagen IV (1:1000, Abcam), and 
MnSOD (1:1000, Merck Millipore Ltd., Darmstadt, Germany), followed by horseradish 
peroxidase conjugated secondary antibody (Life Technologies, CA, USA). Proteins were 
visualized using Luminata Western HRP Substrate (Millipore, MA, USA) in a LAS 4000 
image reader (Fujifilm, Tokyo, Japan). All membranes were re-probed with β-actin 1:1000 
(Santa Cruz, CA, USA) and results were expressed as percentage of protein expression 
relative to β-actin. Analysis was performed using Image J software (Java based software 
program, National Institutes of Health). 
 
5.3.5. Immunohistochemistry 
Formalin-fixed paraffin kidney sections were deparaffinised and incubated overnight with the 
polyclonal primary antibody against fibronectin (dilution 1:1,000, Abcam Ltd, Cambridge), 
collagen IV (dilution 1:1,000, Abcam), CD68 (1:100, ABD Serotec, USA), F4/80 (1:100, 
ABD Serotec), 8OHdg (1:200, Cell Signalling Ltd) followed by horseradish peroxidase anti-
rabbit Envision system (Dako Cytochemistry, Tokyo, Japan) the following day. Staining was 
developed with 3.3diaminobenzidine tetrahydrochloride (Dako Cytochemistry, Tokyo, Japan) 
before counterstaining with Mayer’s haematoxylin stains. Antibody against rabbit IgG was 
used as a negative control. Images were analysed as described above. 
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5.3.6. Relative quantitative real-time PCR (RT-PCR) 
 
RNA was extracted using RNeasy mini kit (Qiagen, Valencia, CA, USA). cDNA was 
generated using Transcriptor First Strand cDNA Synthesis Kits (Roche Diagnostics, 
Mannheim, Germany). RT-PCR was performed using an ABI Prism 7900 HT Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA). SYBR GreenER qPCR 
Supermix (Invitrogen) with PCR primers was used (Table 5A). Results are presented as fold 
change compared to control after normalization to β-Actin. 
 
5.3.7. Statistical methods 
 
All results are expressed as mean ± SEM. Data were analysed using analysis of variance 
(ANOVA), followed by post hoc Bonferroni tests using GraphPad Prism 6.0 (GraphPad 
Software, San Diego, CA, USA). A p value of < 0.05 was considered statistically significant. 
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Table 5.A Mouse specific primers used in quantitative real time PCR 
Gene Forward or 
Reverse 
Primer Sequence 
FN 
 
F 
R 
5'ACAGAAATGACCATTGAAGG 
5'TGTCTGGAGAAAGGTTGATT 
Col IV 
 
F 
R 
5'TTAAAGGACTCCAGGGGACCAC 
5'CCCACTGAGCCCCTGTCACAC 
MCP 
 
F 
R 
5'CTTCTGGGCCTGCTGTTCA 
5'CTTCTGGGCCTGCTGTTCA 
iNOS 
 
F 
R 
5'GACGAGACGGATAGGCAGAG3' 
5'GTGGGGTTGTTGCTGAACTT3' 
β-Actin 
(Housekeeping 
gene) 
F 
R 
5'- CAAAGCAAAGGCGAGG 
5'- ACGGAGCGAAACTGGC 
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5.4 Results 
5.4.1 Serum metabolic measures 
 
To confirm the diabetic phenotype of mice treated with STZ, indices of glycaemia were 
assessed. As expected, at endpoint fasting glucose levels and HbA1c were significantly 
higher in offspring treated with STZ compared to controls (p < 0.01, Table 5B). Thus, STZ 
induced diabetes in treated animals. There was no difference in fasting glucose or HbA1c 
between non-diabetic offspring of lean versus obese mothers. Serum insulin levels were 
increased in offspring of obese mothers; however they were significantly lowered in the 
offspring with diabetes, in keeping with STZ treatment-induced pancreatic β-cell depletion. 
Serum triglycerides and NEFA were higher in offspring of obese mothers at postnatal Week 
32. Diabetes significantly increased triglycerides in the offspring of the lean mothers, but 
reduced in the offspring of the obese mothers (p < 0.01, Table 5B). 
 
5.4.2 Biometric parameters 
 
Total body weight was reduced in offspring with diabetes at 32 weeks of age, irrespective of 
maternal weight, although kidney/total body weight was similar in all groups (Table 5B). 
Maternal obesity alone did not have a sustained effect on body weight or fasting glucose 
levels in chow-fed offspring. However, there was significantly increased retroperitoneal and 
epididymal fat deposits in offspring of obese mothers (p < 0.01). As expected, fat deposits 
were reduced in diabetic animals, more so in offspring of the obese mothers (Table 5B). 
Liver size was non-significantly increased by diabetes.  
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Table 5.B Body/metabolic parameters at 32 weeks of age 
 CC-ctrl CC-T1D HC-ctrl HC-T1D 
Body weight (g) 26.97 ± 0.37 23.79 ± 0.62** 26.84 ± 0.83 24.20 ± 0.54** 
Kidney weight (g) 0.85 ± 0.39 0.80 ± 0.74 0.76 ± 0.70 0.75 ± 0.53 
Kidney /Body (%) 5.52 ± 0.06 2.85 ± 0.03 6.02 ± 0.01 4.19 ± 0.02 
Liver mass (g) 5.42 ± 0.24 5.48 ± 0.12 5.35 ± 0.19 5.88 ± 0.19 
Liver/Body (%) 20.10 ± 0.43 23.03 ± 0.01 19.93 ± 0.01 24.30 ± 0.01 
Epididymal mass 
(% total) 
1.59 ± 0.11 1.48 ± 0.15 2.12 ± 0.20# 1.33 ± 0.13** 
Retroperitoneal fat 
(% total) 
0.54 ± 0.05 0.46 ± 0.06 0.81 ± 0.07## 0.39 ± 0.05** 
Glucose (mmol/L) 14.11 ± 0.46 22.23 ± 0.97** 15.43 ± 0.51 20.28 ± 1.10** 
HbA1c (%) 4.51 ± 0.06 5.85 ± 0.24** 4.36 ± 0.11 5.65 ± 0.25** 
HbA1c (mmol/mol) 25.76 ± 0.82 40.44 ± 2.97 ** 24.15 ± 2.00 38.21 ± 3.02 ** 
Insulin (pmol/L) 67.72 ± 1.97 8.46 ± 3.10** 21.10 ± 5.10# 4.57 ± 2.30** 
NEFA 
(mmol/L) 
0.81 ± 0.06 1.06 ± 0.10 1.06 ± 0.23# 1.66 ± 0.18** 
Trigs (mmol/L) 0.25 ± 5.54 0.67 ± 2.01* 0.93 ± 3.49***## 0.43 ± 0.72** 
Creatinine 
(µmol/L) 
24.00 ± 0.55 28.67 ± 1.28* 28.00 ± 0.72* 28.00 ± 1.844* 
Urine volume 
(mL/24h) 
0.50 ± 0.11 1.67 ± 0.57* 0.89 ± 0.16 1.62 ± 0.34* 
24 h urinary 
albumin (mg/24h) 
7.71 ± 1.87 31.01 ± 7.00* 30.07 ± 3.87# 42.66 ± 7.55 * 
 
n= 6-12, *P<0.05, **P<0.01, compared with non-diabetic littermates. # P < 0.05, ## P < 0.01. 
Compared with the control mice with the same treatment, results are expressed as mean ± 
SEM, n=6-12.  
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5.4.3 Renal functional and structural changes 
 
The renal function of offspring from obese mothers was considerably worse in comparison to 
non-obese mothers, especially when they developed diabetes. Both diabetes and maternal 
obesity increased serum creatinine (CCT1D vs. CC-ctrl, HC vs. CC-ctrl and HCT1D vs. CC-
ctrl, P < 0.05, Table 5B). 24h urinary albumin excretion was significantly increased by 
maternal obesity independent of the development of diabetes and the 24h urinary albumin 
excretion was significantly increased in diabetic mice, regardless of the maternal diet (P < 
0.05, Table 5B). In addition, diabetic animals had polyuria as evidenced by more than three-
fold increase in urine output over 24 h (CCT1D vs. CC-ctrl and HCT1D vs. CC-ctrl, P < 
0.05, Table 5B). There was no significant difference in urine output between offspring of 
obese mothers compared to control.  
 
Objective increases in tubular injury score, determined by Masson trichrome staining, were 
found in offspring with diabetes regardless of maternal diet (P < 0.01, CC-ctrl vs. CC-T1D; P 
< 0.01, HC-ctrl vs. HC-T1D) and non-diabetic offspring by maternal obesity (P < 0.05, CC-
ctrl vs. HC-ctrl, Figure 5.2A-B). Similarly, the glomerulosclerosis score obtained by PAS 
staining was significantly increased by diabetes (P < 0.01, CC-ctrl vs. CC-T1D; P < 0.01, 
HC-ctrl vs. HC-T1D) and maternal obesity (P < 0.05 CC-ctrl vs. HC-ctrl, Figure 5.2C-D). 
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Figure 5.2. Renal structural changes associated with maternal obesity and diabetes 
 (A) Masson trichrome staining representative image at x20 magnification, (B) Periodic acid 
Schiff staining (PAS) representative image at x20 magnification  (C) Interstitial fibrosis score 
assessed by Masson trichrome staining, and (D) Glomerulosclerosis score assessed by PAS 
staining. Results are expressed as mean ± SEM, n=12. *P< 0.05, **P<0.01, ***P<0.001, 
****P<0.0001; offspring from lean mothers (control): CC-ctrl, type 1 diabetic offspring from 
lean mothers: CC-T1D, offspring from obese mothers: HC-ctrl and offspring from obese 
mothers with type 1 diabetes: HC-T1D. 
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5.4.4 Maternal obesity induced renal fibrosis in the presence of diabetes in 
offspring  
 
To determine whether maternal obesity impacted upon renal fibrosis in offspring, quantitative 
western blotting and immunohistochemistry were carried out. Protein expression of collagen 
IV by both Western blotting was increased by maternal obesity in combination with diabetes 
(P<0.05, CC-ctrl vs. HC-T1D, P<0.05, CC-T1D vs. HC- T1D, Figure 5.3A). 
Immunohistochemistry confirmed diabetes increased collagen IV expression compared to 
control though there was no exacerbating effect of maternal obesity in addition to diabetes (P 
< 0.05, CC-ctrl vs. HC-T1D, Figure 5.3B-C). Likewise, fibronectin protein level measured by 
western blotting was greater in the diabetes group (P < 0.01, CC-ctrl vs. CC-T1D) and also in 
mice from obese mothers (P < 0.05, CC-ctrl vs. HC-ctrl, Figure 5.4A). There was no 
significant difference in fibrosis markers when diabetic offspring from lean and obese 
mothers were compared, suggesting that maternal obesity does not potentiate fibrosis in the 
presence of diabetes. This finding was confirmed by immunohistochemistry staining (Figure 
5.4B-C). 
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Figure 5.3 Renal fibrotic changes as measured by Collagen IV 
 (A) Collagen IV protein expression measured by Western blotting (n=3-5) (B) 
immunohistochemistry representative image of CIV staining at x20 magnification 
representative blot (C) area % CIV expression (n=4-6), *P< 0.05, **P<0.01, ***P<0.001; 
offspring from lean mothers (control): CC-ctrl, type 1 diabetic offspring from lean mothers: 
CC-T1D, offspring from obese mothers: HC-ctrl and offspring from obese mothers with type 
1 diabetes: HC-T1D.  
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Figure 5.4. Renal fibrotic changes as measured by fibronectin 
 (A) Fibronectin protein expression by Western blotting, gels have been run at the same time 
under the same experimental conditions, (B) immunohistochemistry representative image of 
fibronectin staining at x20 magnification representative blot, (C) area % fibronectin 
expression. Results are expressed as mean ± SEM, n=4-6 per group. *P< 0.05, **P< 0.01: 
offspring from lean mothers (control): CC-ctrl, type 1 diabetic offspring from lean mothers: 
CC-T1D, offspring from obese mothers: HC-ctrl and offspring from obese mothers with type 
1 diabetes: HC-T1D. 
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5.4.5 Maternal obesity exacerbates the impact of diabetes on renal 
inflammation 
 
Inflammatory changes in the kidney are a hallmark of renal dysfunction in diabetic 
nephropathy. In keeping with this observation, MCP-1 mRNA expression was greater in the 
kidneys of offspring with diabetes (P < 0.05, CC-ctrl vs. CC-T1D and HC-T1D, Figure 
5.5A). Furthermore, levels of the macrophage marker CD68 were significantly increased by 
diabetes (P < 0.01, HC-ctrl vs. HC- T1D) and maternal obesity (P < 0.05, CC-ctrl vs. CC-
T1D, Figure 5.5B-C). Similarly, levels of the inflammatory marker F4/80 were higher in the 
presence of diabetes (P < 0.05, CC-ctrl vs. CC-T1D, P < 0.05, HC-ctrl vs. HC-T1D) and 
maternal obesity (P < 0.05, CC-ctrl vs. HC-ctrl, Figure 5.5 D-E). Moreover, the combination 
of maternal obesity and diabetes gave rise to significantly increased levels of F4/80 compared 
to diabetes alone (P < 0.01, CC- T1D vs. HC-T1D). Therefore, though maternal obesity in the 
presence of diabetes had no effect on MCP1 expression, it significantly increased CD68 and 
F4/80. 
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Figure 5.5. Renal inflammation associated with maternal obesity and diabetes 
(A) MCP-1 mRNA expression, (B-C) CD68 immunostaining, and (D-E) F4/80 
immunostaining. Results are expressed as mean ± SEM, n=4-6 per group. *P < 0.05; ** P < 
0.01, ***P<0.001; offspring from lean mothers (control): CC-ctrl, type 1 diabetic offspring 
from lean mothers: CC-T1D, offspring from obese mothers: HC-ctrl and diabetic offspring 
from obese mothers: HC-T1D. 
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5.4.6 Maternal obesity exacerbates the effect of diabetes on renal oxidative 
stress 
 
Enhanced levels of oxidative stress were observed in the kidneys of offspring of obese 
mothers, as well as those with diabetes. iNOS mRNA expression was significantly 
potentiated in offspring of obese mothers with diabetes compared to diabetes alone (P < 0.05, 
CC-T1D vs. HC-T1D, P < 0.05, HC-ctrl vs. HC-T1D, Figure 5.6A). Mitochondrial 
antioxidant, MnSOD was increased in response to oxidative stress in the kidneys of offspring 
from obese mothers with diabetes (P < 0.05, CC-T1D vs. HC-T1D, P < 0.05, HC-ctrl vs. HC-
T1D, Figure 5.6B). Furthermore, immunohistochemistry staining showed 8-OHdg, the major 
product of DNA oxidation, was significantly increased by diabetes (P < 0.01 CC-ctrl vs. CC-
T1D) and maternal obesity (P < 0.001, CC-ctrl vs. HC-ctrl, Figure 5.6C-D). Maternal obesity 
increased 8OH-dg expression. T1D also increased 8-OHdg to similar levels. Interestingly, 
T1D in the presence of maternal obesity significantly increased 8-OHdg compared to T1D 
alone (p < 0.01, CC-T1D vs. HC-T1D, Figure 5.6C-D).  
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Figure 5.6 Oxidative stress measures associated with maternal obesity and diabetes 
(A) iNOS mRNA expression, (B) MnSOD protein expression by Western blotting, gels have 
been run at the same time under the same experimental conditions, and (C-D) 8OHdg 
immunohistochemistry staining. Results are expressed as mean ± SEM, N=3-6 per group. *P 
< 0.05; ** P < 0.01, ***P<0.001; offspring from lean mothers (control): CC-ctrl, type 1 
diabetic offspring from lean mothers: CC-T1D, offspring from obese mothers: HC-ctrl and 
offspring from obese mothers with type 1 diabetes: HC-T1D. 
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5.5 Discussion 
 
The results of this study indicate that maternal obesity is associated with renal damage in 
rodent adult offspring, which is further amplified when diabetes supervenes. Functional and 
structural changes were seen in the kidneys of diabetic offspring consistent with a model of 
diabetic nephropathy. Maternal obesity was associated with reduced renal function as 
measured by serum creatinine and increased renal fibrosis as measured by renal structural 
changes and fibronectin. Both renal inflammation and oxidative stress were exacerbated in 
offspring born to obese mothers, further amplified by diabetes, suggesting an important role 
of developmental programming in the kidney.  
 
The mechanisms underpinning developmental programming of metabolic disease are 
complex and yet to be fully elucidated, however inflammation and oxidative stress have an 
integral role in the propagation of metabolic dysfunction between generations (342, 343). In 
addition, there is considerable evidence to support the hypothesis that maternal obesity has 
significant effects on central pathways for energy homeostatic regulation and reward-driven 
behaviour ((65, 325, 344-347). As a consequence, maternal overnutrition increases 
adipogenesis and lipogenesis in offspring and leads to adipocyte hyperplasia and hypertrophy 
due to excessive lipid accumulation, with steatosis occurring in the hepatocytes (80, 93, 348-
353). In this study, we found no difference in total adult body weight between offspring of 
obese versus lean mothers. This is perhaps due to the fact that the offspring were only 
exposed to a balanced and non-obesogenic diet after weaning. However, the offspring of 
obese mothers still had increased retroperitoneal and epididymal fat deposits, suggesting 
body weight does not accurately reflect adiposity. In fact, the concept of normal weight 
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obesity has been proposed, which link this phenomenon to a significantly higher risk of 
metabolic syndrome, cardiovascular dysfunction and higher mortality rate (354, 355). This 
clearly can be exaggerated by the additional ad libitum HFD consumption (346). However 
the impact of maternal obesity on kidney pathology in the setting of renal lipid accumulation 
has not been well studied.   
 
Adipocytes are key secretors of pro-inflammatory cytokines. Indeed, we have previously 
shown that inflammatory cytokines including IL-6, MCP-1 and TGFβ are increased in the 
serum of rat offspring of obese mothers, as well as in their kidneys (341, 356). Thus, 
exposure to maternal obesity may prime offspring towards a pro-inflammatory state, thereby 
increasing their susceptibility to complications of obesity and kidney disease at a later stage. 
Diabetes itself, even type 1 diabetes in the absence of obesity, is known to foster a pro-
inflammatory state and the pathophysiological mechanisms underlying the development of 
diabetic nephropathy is increasingly being recognized to involve inflammatory processes 
(283, 357). Herein, we report that renal inflammation is exacerbated in the kidneys of 
diabetic offspring, as a consequence of early exposure to maternal obesity. We found that 
MCP-1 and macrophage markers CD68 and F4/80 were increased. MCP-1 is an important 
chemokine, playing a key role in monocyte/macrophage recruitment and contributing to 
inflammation in diabetic nephropathy (358, 359). We further observed that maternal obesity 
together with diabetes exaggerated inflammatory cell accumulation in the kidney, as seen by 
increases in both CD68 and F4/80. The inflammatory cells (i.e. macrophages) recruited from 
the circulation into the interstitium play an active role in tubulointerstitial fibrogenesis,(360) 
which was also well represented in the offspring’s kidneys at 32 weeks.  
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Oxidative stress plays a critical role in the pathophysiology of several kidney diseases and 
has been implicated in the development of diabetic kidney disease in humans and mice (329, 
361-363). Furthermore, recent studies suggest that production of reactive oxidative species 
(ROS) in the liver and adipose tissue may precede the onset of foetal weight gain in response 
to abnormal maternal nutrition in utero (325, 326). Nutrient excess leads to mitochondrial 
dysfunction, which in turns gives rise to obesity related pathologies, in part due to the 
harmful effects of ROS (327). Mitochondrial dysfunction has been reported as early as 
embryogenesis in offspring of obese mice, with the oocytes and zygotes having increased 
mitochondrial membrane potential, higher levels of oxidative phosphorylation and increased 
ROS production (328). Mitochondrial DNA (mtDNA) is highly sensitive to the deleterious 
effects of ROS (364). The kidney is also highly susceptible to the effects of oxidative stress 
and mitochondrial dysfunction due to their high metabolic throughput. Indeed, mice with 
mtDNA mutations die prematurely due to renal failure, suggesting a link between 
mitochondrial dysfunction and renal disease (365). To date, no studies have examined the 
influence of maternal obesity on renal markers of oxidative stress in the context of diabetes. 
Our findings in this study represent the first evidence of the powerful additive effect of 
maternal obesity and diabetes on oxidative stress and tissue damage within the kidney. Not 
only were oxidative stress markers iNOS and 8-OHdg increased but the antioxidant MnSOD 
was increased; MnSOD is a mitochondrial enzyme that scavenges reactive oxygen species 
and is known to be upregulated in the context of cellular stress (366). 
 
In this study we found only mild to moderate glomerulosclerosis and interstitial fibrosis and 
there was no extensive proteinuria or frank renal sclerosis. Collagen IV expression was 
variable between western blotting and immunohistochemistry, likely due to the pattern of 
expression of collagen IV. Specifically, collagen IV is expressed in both the medulla and 
  
 
147 
cortex of the kidney (367).  Therefore, immunohistochemistry analysis better reflects cortical 
collagen IV expression, known be relevant to renal fibrosis. Our data clearly showed that 
collagens IV as well as fibronectin were significantly increased in offspring of obese mothers 
with diabetes. The Animal Models of Diabetic Complications Consortium have set forth 
guidelines for the use of animal models of diabetic nephropathy. They have recommended 
against the usage of C57/BL6 mice as a model of diabetes and its complications due to the 
relative resistance of the strain to diabetic nephropathy (368). However, though genetically 
manipulated animals models such as the eNOS knockout mouse are good models for diabetic 
nephropathy, they are resistant to the effects of HFD-feeding and this makes them less useful 
as a model of maternal obesity.  Despite the known limitations of the model employed in the 
present study, there was still significant renal damage in term of fibrosis in the offspring. This 
well suggests the potent impact of maternal obesity and diabetes to induce renal disorders 
that can ultimately lead to the development of CKD. 
 
In summary, maternal obesity increases fibrotic, inflammatory and oxidative stress changes 
in offspring kidneys. As expected, diabetes is associated with renal damage involving similar 
underlying changes. Maternal obesity potentiates the deleterious effects of insulin-
insufficient diabetes on offspring kidney health, particularly renal inflammation and oxidative 
stress. Thus, maternal weight in pregnancy is an important modifiable risk factor for the 
development of renal disease in offspring later in life. 
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6.1 Abstract 
 
Background: Multiple rodent models have been used to study diabetic kidney disease 
(DKD). The purpose of the present study was to compare models of diabetes and obesity-
induced metabolic syndrome and determine differences in renal outcomes.  
Methods: C57BL/6 male mice were fed either normal chow or high fat diet (HFD). At 
postnatal week 8, chow-fed mice were randomly assigned to low-dose streptozotocin (STZ, 
55 mg/kg/day, five consecutive days) or vehicle control, whereas HFD-fed mice were given 
either one high-dose of STZ (100 mg/kg) or vehicle control. Intraperitoneal glucose tolerance 
tests were performed at Week 14, 20 and 30. Urinary albumin to creatinine ratio (ACR) and 
serum creatinine were measured, and renal structure was assessed using Periodic Acid Schiff 
(PAS) staining at Week 32.  
Results: Results showed that chow-fed mice exposed to five doses of STZ resembled type 1 
diabetes mellitus (T1D) with a lean phenotype, hyperglycaemia, microalbuminuria and 
increased serum creatinine levels. Their kidneys demonstrated moderate tubular injury with 
evidence of tubular dilatation and glycogenated nuclear inclusion bodies. HFD-fed mice 
resembled metabolic syndrome, as they were obese with dyslipidaemia, insulin resistance, 
and significantly impaired glucose tolerance. One dose STZ, in addition to HFD, did not 
worsen metabolic features (including fasting glucose, non esterified fatty acid, and 
triglyceride levels). There were significant increases in urinary ACR and serum creatinine 
levels, and renal structural changes were predominantly related to interstitial vacuolation and 
tubular dilatation in HFD-fed mice.  
Conclusion: The C57BL/6 mouse model utilising either STZ or HFD resembles T1D or 
metabolic syndrome respectively with important renal consequences.  
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6.2 Introduction 
 
Diabetes is the leading cause of chronic kidney disease (CKD) worldwide not only in 
Western countries, but also in low- or middle-income countries (369). Type 2 diabetes 
mellitus (T2D), together with its related kidney disorders, is increasing in pandemic 
proportions largely driven by the exponential rise in obesity (370, 371). An important and 
growing complication of T2D is diabetic kidney disease (DKD) (372, 373). Moreover, 
obesity itself has been shown to have detrimental effects on renal outcomes independent of 
diabetes (219-221). Advanced CKD is associated with a huge personal burden given that 
kidney transplantation and dialysis are the only options for late stages of CKD, and these 
renal replacement therapies are costly and have significant ramifications for healthcare 
expenditure (374). Hence, a greater understanding of CKD and how it relates to diabetes and 
obesity is imperative, in order to devise better diagnostic and treatment strategies for the 
prevention and treatment of CKD.  
 
In humans, renal biopsy is invasive and costly and is not routinely performed in patients with 
known diabetes, obesity and renal functional changes. Although DKD is typically associated 
with the histological features of diabetic nephropathy including diffuse mesangial thickening, 
glomerular basement membrane thickening and tubulointerstitial fibrosis, a significant 
portion of individuals with diabetes and impaired renal function do not have classic 
histological signs of diabetic nephropathy (375). Classic renal features associated with severe 
obesity in humans include glomerulopathy and focal segmental glomerulosclerosis (FSGS) 
(376).  However, FSGS associated with extreme obesity alone is quite uncommon whereas 
renal damage in the context of obesity together with other features of the metabolic syndrome 
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is frequently seen (370, 377). In order to study obesity-induced renal disease mimicking 
human pathophysiology, it is important to establish animal models of obesity together with 
glucose dysregulation, hyperlipidaemia, and hypertriglyceridaemia.  
 
Compared to human studies, animal models have the advantage of controlled experimental 
designs to systematically assess the value of therapeutic interventions. Consumption of a 
high-fat diet (HFD) in rodents, sheep and primates typically yields obesity (378). The 
C57BL/6 mouse model is advantageous given its short gestational period and long lifespan, 
ease of availability and the animal’s tendency to over-consume HFD, thus mimicking human 
behaviour resulting in an obese phenotype. Furthermore, the wild type C57BL/6 mouse is 
particularly susceptible to weight gain when fed HFD compared to other genetically 
manipulated mouse models (379). Over time, C57BL/6 mice typically exhibit features 
commonly associated with the complex metabolic syndrome in humans, which include 
obesity, insulin resistance, glucose intolerance, hyperlipidaemia, hypertriglyceridaemia and 
hypertension (380, 381). They are susceptible to glucose intolerance, non-alcoholic fatty liver 
disease and endothelial damage commonly associated with cardiovascular disease (380-382). 
With respect to renal outcomes, mice on a HFD showed albuminuria, glomerulomegaly, 
mesangial expansion, increased type IV collagen, renal lipid accumulation, increased 
macrophage infiltration and elevated markers of oxidative stress (381). 
 
The type of diabetes that is of interest should influence the animal model utilised to study 
DKD. In comparison to T2D with its associated metabolic features, type 1 diabetes mellitus 
(T1D) is an autoimmune form of diabetes characterised by progressive destruction of the 
pancreatic beta cell and insulin deficiency (383). Relative beta cell depletion and loss of beta 
cell function are also thought to be important factors in the development of T2D, although in 
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the case of T2D, the process is not thought to be autoimmune in nature (384). One method of 
inducing diabetes using a wild-type animal is by administering streptozotocin (STZ), a 
pharmacological agent that induces beta cell destruction by intracellular alkylation of DNA 
and subsequent beta cell necrosis (385-387). There is variability in the timing, dosage and 
frequency of STZ injections and different protocols can be employed to mimic T1D or T2D 
in a variety of species/strains (385, 388-390). The mouse model utilising five doses of STZ at 
low dose (50-60 mg/kg/day) has been extensively used to mimic T1D due to the progression 
destruction of beta cell mass (385). In comparison, HFD together with one high dose of STZ 
has been suggested as a useful model of T2D, encompassing both the features of obesity and 
insulin resistance due to HFD and moderate beta cell reduction (391)  
 
In the present study, we aimed to characterise the metabolic and renal outcomes in a mouse 
model of insulin deficiency mimicking T1D and diet-induced obesity associated with 
metabolic dysregulation representing T2D. Specifically, we compared the metabolic features 
and renal outcomes in a C57BL/6 mouse model using five low doses of STZ (55 mg/kg/day), 
HFD alone or HFD together with one high dose of STZ (100 mg/kg). 
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6.3 Materials and Methods 
 
6.3.1 Animal experiments 
 
The animal models utilised in the present study included a control group fed normal chow 
diet (Chow group), a group fed chow diet and given five low doses of STZ (Chow_lowSTZ 
group), a group fed HFD (HFD group) and a group fed HFD together with a single high dose 
of STZ (HFD_hiSTZ group). A schematic representation of the animal model used in this 
study is presented in Figure 6.1. All animals were housed in the Kearns Animal Facility of 
Kolling Institute, Royal North Shore Hospital with a stable environment maintained at 
22±1°C with a 12/12-h light–dark cycle. All procedures were approved by the Animal Ethics 
Committee (AEC) of Royal North Shore Hospital (AEC 1309-007A) and complied with the 
Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. 
 
Male pups were weaned from C57BL/6J dams (sourced from Kearns Facility, Kolling 
Institute, Royal North Shore Hospital, St Leonards, NSW, Australia) at postnatal day 20 
(normal weaning age) and fed standard rodent chow (11kJ/g, 14% fat, Gordon’s Specialty 
Stockfeeds, NSW, Australia) or pellet HFD (20kJ/g, 43% fat; SF03-020, Speciality Feeds, 
WA, Australia). At postnatal week 8, mice fed chow diet were assigned to either low-dose 
streptozotocin (STZ, 55 mg/kg, ip for five consecutive days) or vehicle control (citrate 
buffer) whereas mice fed HFD were assigned to either high-dose STZ (100 mg/kg, i.p., once) 
or vehicle control. To deliver STZ, mice were fasted for 5 h prior to injection. STZ (in 0.1 M 
citrate buffer, pH 4.5, Sigma, MO, USA) was freshly prepared.   
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Figure 6.1 Schematic representation of the animal model utilised in this study  
Chow represents control group fed normal chow diet; Chow_lowSTZ depicts the group 
exposed to normal chow diet and low-dose streptozotocin (STZ) for five consecutive days; 
HFD depicts the group fed HFD; HFD_hiSTZ depicts the group fed HFD in conjunction with 
high-dose STZ (one dose only). 
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Mice were weighed fortnightly and their blood glucose levels were measured using an Accu-
Chek glucometer (Roche Diagnostics) following 6 h fasting period. Only animals with fasting 
blood glucose >16 mmol/L were considered to be diabetic. Diabetic mice received insulin 
(2U glargine, Germany) to prevent ketosis if their blood glucose level was above 25 mmol/L 
and subsequently blood glucose readings were performed twice weekly. Tissue harvesting 
took place at Week 32 under fasting conditions. Organ perfusion was performed with PBS 
after cardiac puncture for blood collection. The kidneys, liver, and fat were collected and 
weighed then the kidney was fixed in 10% buffered formalin for histological examination.  
 
Mice were placed in metabolic cages and 24-h urine collection was performed one week prior 
to sacrifice.  Urine albumin levels were determined using the Murine Microalbuminuria 
ELISA kit (Exocell, Inc., Philadelphia, PA, USA) and urine creatinine levels were 
determined using the Microcreatinuria ELISA kit (Exocell, Inc., Philadelphia, PA, USA). 
 
Intraperitoneal glucose tolerance tests (IPGTTs) were performed at Week 14, Week 20 and 
Week 30.  Mice were fasted for 6 h prior to the test. At baseline, the blood glucose level was 
measured. Glucose was administered at Time 0 (2 g/kg, Phebra, Australia) and then blood 
glucose levels recorded at Time 15 min, 30 min, 60 min and 90 min. Animals were fully 
conscious throughout the IPGTT.  
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6.3.2 Bioassays 
 
Glycosylated haemoglobin (HbA1c) was measured using a DCA Vantage Analyser (Siemens 
Medical Solutions Diagnostics, Tarrytown, NY, USA) (392). Serum creatinine and lipid 
profile including total serum cholesterol, triglycerides and LDL were measured using the 
Architect C16000 Clinical Chemistry Analyser (Abbott Laboratories, Abbott Park, Ill, USA) 
available through the affiliated hospital pathology service. Plasma non-esterified fatty acids 
(NEFA) were measured using a NEFA kit (WAKO, Osaka, Japan) [13]. Serum insulin was 
measured using a mouse-specific ELISA method (Merck, Darmstadt, Germany). The density 
was detected on a Bio-Rad 680 XR (Hercules, CA, USA) [13, 18]. HOMA-IR was quantified 
as blood glucose level multiplied by serum insulin level divided by 22.5. 
 
6.3.3 Analysis of changes to renal structure 
 
Formalin-fixed hemisected kidneys were embedded in paraffin and stained with Periodic 
Acid Schiff (PAS). Two independent, blinded observers including an anatomical pathologist 
and a nephrologist performed histological analyses using a light microscope (Olympus 
photomicroscope linked to a DFC 480 digital camera).  
 
One kidney hemisection was examined at 100x magnification for foci of tubulointerstitial 
fibrosis and graded using a scale of 0 to 4 (0 - normal; 1 - involvement of < 10% of the 
cortex; 2 - involvement of 10 –25% of the cortex; 3 - involvement of 25–75% of the cortex; 
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and 4 - extensive damage involving > 75% of the cortex).  Tubular injury was determined 
using ten random non-overlapping high power fields (HPFs) of renal cortex at 400x 
magnification and assessment of four categories of damage was made including: (A) tubular 
vacuolation, (B) tubular dilatation, C) glycogenated nuclei, and (D) tubular cast. For tubular 
dilatation: 0, absence, 1, <5 dilated cortical tubules were observed per high power field 
(HPF), 2, 5-10 dilated cortical tubules were observer per HPF, 3, >10 dilated tubules were 
observed per HPF. For tubular vacuolation: 0, absence, 1, <25% of the cortical tubules have 
vacuoles 2, 25-50% cortical have vacuoles, 3, >50% cortical tubules have vacuoles. For 
glycogenated nuclei in tubular epithelium, 0, absence, 1, only 1 glycogenated nuclear 
observed per HPF; 2- 2to 3 nuclei observed per HPF, 3, > 3 glycogenated nuclei observed per 
HPF. For cast appearance, 0, absence, and 1, present.  
 
For glomerulosclerosis, the first 20 randomly selected glomeruli at the kidney cortex were 
examined and graded as previously described (319, 356). The sections were scored as 0 - 
normal, 1 - < 25% involvement, 2 < 50% involvement, 3 - < 75%, and 4 - > 75% sclerosis 
and then the average of 20 individual scores was calculated to generate the 
glomerulosclerosis score. 
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6.3.4 Statistical methods 
 
All results are expressed as mean ± SEM. Data were analysed using analysis of variance 
(ANOVA), followed by post hoc Bonferroni tests when the difference between groups was 
being considered. The trapezoidal rule was used to determine the area under the curve (AUC) 
during IPGTT results. For differences in plasma glucose levels during the IPGTT, an 
ANOVA with repeated measures was performed and significance determined using Tukey’s 
post hoc test. All analyses were carried out using GraphPad Prism 6.0 (GraphPad Software, 
San Diego, CA, USA) and a P value of < 0.05 was considered statistically significant. 
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6.4 Results 
 
6.4.1 Anthropometric parameters 
 
Body weight was expected to be reduced in a model with multiple STZ injections and higher 
in HFD-induced obesity. The group exposed to five doses of STZ had a significantly lower 
body weight compared to the control Chow group at Week 32 (P < 0.01, Chow vs. 
Chow_lowSTZ; Table 6A). Moreover, they showed significantly less weight gain between 
the induction of diabetes at Week 8 and Week 32 (P < 0.05, Chow_lowSTZ vs. Chow; Table 
6A). In addition, three of the 14 animals in the Chow_lowSTZ group lost weight between 
Week 8 and Week 32. In comparison, both HFD and HFD_hiSTZ groups were significantly 
heavier compared to the Chow group (P < 0.0001, Chow vs. HFD, and Chow vs. 
HFD_hiSTZ, Table 6A), over the course of 24 weeks concordant with the human obese T2D 
phenotype. The HFD group was significantly heavier than the HFD_hiSTZ group (P < 
0.0001, Table 6A). 
 
To determine the impact of diet and/or STZ treatment on kidney size, the left and right 
kidney masses were averaged for each animal. Kidney size as percentage of body weight was 
similar among the groups (Table 6A). The liver was significantly heavier in the HFD group 
compared to the Chow group (P < 0.0001 vs. Chow) and HFD_hiSTZ group (P < 0.001 vs. 
control). As expected in a model of obesity, animals fed HFD had significantly more 
percentage of fat mass at Week 32 as measured by both retroperitoneal and epididymal fat 
deposits (P < 0.0001, HFD vs. Chow for both fat measures). There was significantly less fat 
deposition in the retroperitoneal and epididymal regions in the HFD_hiSTZ versus HFD 
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group, as a consequence of the one dose of STZ at Week 8 presumably due to the adverse 
effects induced by STZ (P < 0.01, P < 0.05 respectively, Table 6A).  
 
 
Table 6.A. Anthropometric measures at 32 weeks of age 
 Chow Chow_lowSTZ HFD HFD_hiSTZ 
BW (g) 27.26 ± 
0.27 
24.02 ± 0.72 * 42.06 ± 1.21** 33.02 ± 1.56**### 
Weight gain (g) 
from Week 8  
5.52 ± 0.40 2.85 ± 0.76* 13.67 ± 1.27 
** 
8.50 ± 1.31 ### 
Kidney (g) 0.22 ± 0.01  0.19 ± 0.01 0.29 ± 0.01** 0.24 ± 0.01# 
Kidney  
(% BW) 
0.80 ± 0.02 0.79 ± 0.03 0.74 ± 0.02 0.77 ± 0.05 
Liver  
(% BW) 
5.40 ± 0.27 5.53 ± 0.14 8.01 ± 0.48 ** 6.03 ± 0.36## 
Retroperitoneal  
fat (% BW) 
0.52 ± 0.06 0.64 ± 0.16 2.35 ± 0.28 ** 1.37 ± 0.22 ** ## 
Epididymal fat  
(% BW) 
1.68 ± 0.10 1.53. ± 0.16  5.34 ± 0.34 ** 4.24 ± 0.48 ** # 
 
BW: body weight. Compared with control *P<0.01, **P<0.0001; HFD_hiSTZ compared 
with HFD # P < 0.05, ## P < 0.001, ### P < 0.0001. Results are expressed as mean ± SEM, 
n=9-12. Control: Chow; Chow diet and five low-dose STZ: Chow_lowSTZ; High fat diet: 
HFD; and HFD and one high-dose STZ: HFD_hiSTZ.  
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6.4.2 Glucose tolerance test results 
 
To characterise the impact of HFD and exposure to one dose of STZ, glucose tolerance was 
measured by performing an IPGTT in Chow, HFD and HFD_hiSTZ groups at postnatal 
Week 14, 20 and 30 (corresponding to 6 weeks, 12 weeks and 22 weeks post STZ injection).  
 
At Week 14 (6 weeks post-STZ injection), fasting glucose at Time 0 was greater in the HFD 
and HFD_hiSTZ groups than the Chow group (P < 0.0001, Chow vs. HFD_hiSTZ; Chow vs. 
HFD, P < 0.0001, Figure 6.2A). From 15 to 90 minutes, the glucose levels in the 
HFD_hiSTZ, and HFD groups were significantly higher than the Chow fed mice (P < 0.0001 
for both, Figure 6.2A), with no significant difference between HFD and HFD_hiSTZ at these 
time points.  
 
At Week 20 (12 weeks post-STZ injection), higher fasting glucose levels were observed at 
Time 0 in the HFD_hiSTZ group compared to the Chow group (P < 0.05, Figure 6.2B). There 
were no differences between the 3 groups at 15 minutes. At Time 30 and beyond, both HFD 
and HFD_hiSTZ had higher glucose readings in comparison to the Chow fed mice (P < 0001, 
Chow vs. HFD; P < 0.0001, Chow vs. HFD_hiSTZ, at Time 30, 60 and 90). When the HFD 
and HFD_hiSTZ groups were compared, there were no significant differences at any time 
point. 
 
At Week 30 (20 weeks post-STZ injection), both the HFD and HFD_hiSTZ groups still 
demonstrated significant glucose intolerance compared to the Chow group (Figure 6.2C). 
Despite no statistical difference in fasting glucose levels, both groups had higher glucose 
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readings at Time 30, 60 and 90 (P < 0.001, Chow vs. HFD, Chow vs. HFD_hiSTZ, at Time 
30; P < 0.0001 at Time 60 and 90). There was no difference in blood glucose level between 
HFD and HFD_hiSTZ groups at any time point. 
 
The AUC value was elevated at Week 14, Week 20 and Week 30 in both HFD and 
HFD_hiSTZ groups compared to the Chow group (P<0.0001, Figure 6.2D-F). The AUC 
value was significantly higher in the HFD_hiSTZ versus HFD group at Week 20 but not at 
Week 14 or Week 30 (p < 0.01, HFD vs. HFD_hiSTZ at Week 20).  
 
Interestingly, at Week 30 in both the HFD and HFD_hiSTZ the shape of the IPGTT curve 
was dissimilar to the shape of the curve at Week 14 and Week 20 due to persistence of 
hyperglycaemia and failure to recover normoglycaemia by 90 minutes. This suggests 
impaired second phase insulin response.  
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Figure 6.2 Intraperitoneal glucose tolerance tests performed at postnatal Week 14, 20 and 31 
in C57BL/6J mice  
Blood glucose levels were measured at 0,15,30,60 and 90 minutes as seen in A-C. Area under 
the curve was calculated using the trapezoid rule and is shown in D-F. Results are expressed 
as mean ± SEM, n = 7-14. *P< 0.05, **P<0.01 compared to control, # compared to HFD. 
Control: Chow; High fat diet: HFD; and HFD and one high-dose STZ: HFD_hiSTZ. 
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6.4.3 Serum metabolic measures 
 
Glycosylated haemoglobin (HbA1c) was significantly elevated in the Chow_lowSTZ group 
alone suggesting that this group had the most significant impairment in glucose control 
consistent with a model of T1D (P < 0.0001, Chow_lowSTZ vs. Chow). Nonetheless, HbA1c 
was lower in the C57BL/6 diabetic mouse compared to both humans and other mouse strains, 
consistent with previously described data (392). 
 
Fasting insulin levels in the Chow_lowSTZ group were significantly lower compared to 
Chow (P < 0.05, Table 6B), likely due to STZ-induced destruction of pancreatic β-cells 
similar to T1D. In the HFD group, there was evidence of fasting hyperinsulinaemia (P < 0.01, 
HFD vs. Chow), and insulin resistance measured by HOMA-IR was increased (HFD vs. 
Chow P < 0.01). There was no difference in insulin levels or HOMA-IR between the 
HFD_hiSTZ and Chow group at Week 32. Interestingly serum insulin and HOMA-IR were 
two to three fold lower in the HFD_hiSTZ versus HFD groups, presumably as a consequence 
of one high dose of STZ at Week 8 (P < 0.05 respectively).  
 
Hyperlipidaemia was assessed by measuring fasting total serum cholesterol, triglycerides, 
low-density lipoproteins (LDL), and NEFA. Total cholesterol was significantly elevated in 
the HFD and HFD_hiSTZ groups (HFD vs. Chow and HFD_hiSTZ vs. Chow < 0.0001, 
Table 6B). Fasting total cholesterol was higher in the HFD versus HFD-hiSTZ groups (P < 
0.0001). Likewise, serum LDL level was markedly higher in the HFD versus Chow group by 
five folds (P < 0.0001) and also elevated in the HFD_hiSTZ group compared to the Chow 
group (P < 0.01). However, the LDL concentration in the HFD_hiSTZ group was 
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significantly lower than that in the HFD group (HFD_hiSTZ vs. HFD, P < 0.0001). 
Furthermore, the levels of NEFA were raised in the HFD and HFD_hiSTZ groups (P<0.01, 
P< 0.05 respectively). There was no difference in either triacylglycerol or NEFA between 
HFD and HFD_hiSTZ groups. 
 
As anticipated, in each of the three models of diabetes/obesity, fasting glucose was 
significantly elevated compared to control at Week 32 (Chow_lowSTZ, HFD, HFD_hiSTZ 
vs. Chow P < 0.0001, Table 6B). Interestingly, there were no significant differences in 
fasting glucose levels between any of the three models. 
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Table 6.B. Metabolic measures at 32 weeks of age 
 Chow Chow_lowSTZ HFD HFD_hiSTZ 
Fasting Glucose 
(mmol/L) 
14.11 ± 0.47 22.23 ± 1.09 *** 19.92 ± 0.74 
*** 
22.14 ± 1.18 *** 
HbA1c (%) 4.51 ± 0.07 5.85 ± 0.27 *** 4.82 ± 0.17 4.67 ± 0.09 
Serum insulin 
(mIU/L) 
8.01 ± 1.31 3.38 ± 0.70* 16.89 ± 4.77* 5.99 ± 1.61### 
HOMA-IR 0.18 ± 0.03 0.14 ± 0.03 0.59 ± 0.17* 0.34 ± 0.09# 
Serum total 
cholesterol 
(mmol/L) 
2.33 ± 0.08 2.40 ± 0.19 6.40 ± 0.45**** 4.42 ± 0.09****#### 
Serum 
triglycerides 
(mmol/L) 
0.70 ± 0.12 0.50 ± 0.15 1.08 ± 0.13* 0.84 ± 0.10 
Serum LDL 
(mmol/L) 
0.60 ± 0.07 0.88 ± 0.07 3.25 ± 0.38**** 1.57 ± 0.20*#### 
Serum NEFA 
(mmol/L) 
0.85 ± 0.04 0.95 ± 0.06 1.10 ± 0.07 ** 1.00 ± 0.05* 
 
* P < 0.05, ** P < 0.01, *** P < 0.001, ****P<0.0001 Compared with control; # P < 0.05, 
### P < 0.001,#### P < 0.0001 HFD_hiSTZ compared with HFD. Results are expressed as 
mean ± SEM, n=6-12. Control: Chow; Chow diet and five low-dose STZ: Chow_lowSTZ; 
High fat diet: HFD; and HFD and one high-dose STZ: HFD_hiSTZ.  
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6.4.4 Measures of renal function 
 
The urinary ACR was measured after collecting urine for 24 h whilst mice were placed in a 
metabolic cage. Urinary ACR was elevated in the Chow_lowSTZ group compared to the 
controls (P < 0.05, Figure 6.3A). Additionally, both HFD and HFD_hiSTZ groups had higher 
ACR compared to the controls (HFD, HFD_hiSTZ vs. Chow, P < 0.05). To further examine 
renal function, serum creatinine was measured and importantly was elevated in all three 
groups of diabetes/obesity at Week 32 (Chow_lowSTZ, HFD, HFD_hiSTZ vs. Chow, P < 
0.05, Figure 6.3B). 
 
 
Figure 6.3. Renal function measured at postnatal Week 31 and 32 
(A) Urinary albumin to creatinine ratio (ACR) collected at Week 31 from metabolic cage, (B) 
Serum creatinine at Week 32. Results are expressed as mean ± SEM, n=9 for ACR, n = 6-9 
for 24 h albumin. *P< 0.05, **P<0.01 compared to Ctrl; # P < 0.05 compared to 
Chow_lowSTZ. Control: Chow; Chow diet and five low-dose STZ: Chow_lowSTZ; High fat 
diet: HFD; and HFD and one high-dose STZ: HFD_hiSTZ. 
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6.4.5 Renal structural changes 
 
Glomerulosclerosis was demonstrated by PAS staining which contributed to a higher 
glomerulosclerosis index score in the HFD group (HFD vs. Chow, p < 0.05, Figure 6.4A and 
C). There were no differences in the glomerulosclerosis score between Chow_lowSTZ or 
HFD_hiSTZ versus Chow group. For the purpose of this study, tubulointerstitial fibrosis is 
strictly referred to as a combination of widening of the interstitium, accumulation of 
inflammatory cells, tubular atrophy, and wrinkling and/or thickened of the tubular basement 
membrane. Perivascular areas were excluded during scoring. Tubulointerstitial fibrosis was 
evident in the HFD-fed groups (HFD, HFD_hiSTZ vs. Chow, P < 0.0001, Figure 6.4B and 
D). Interestingly, there was no difference in the tubulointerstitial fibrosis score seen between 
Chow_lowSTZ and Chow.   
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Figure 6.4. Periodic acid Schiff (PAS) staining at Week 32 
PAS staining was used to demonstrate: (A) Representative images at high magnification of 
glomerular changes,  (B) Representative images at high magnification of tubular damage, (C) 
Tubular interstitial fibrosis score, and (D) Glomerulosclerosis score. Results are expressed as 
mean ± SEM, n=6. *P< 0.05, **P<0.01 compared to Chow_lowSTZ. Control: Chow; Chow 
diet and five low-dose STZ: Chow_lowSTZ; High fat diet: HFD; and HFD and one high-dose 
STZ: HFD_hiSTZ.  
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The Chow_lowSTZ group demonstrated features of tubular injury including tubular dilatation 
(Chow_lowSTZ vs. Chow, P < 0.05, Figure 6.5A) and glycogen intranuclear inclusions 
within the nuclei of the proximal tubules (Chow_lowSTZ vs. Chow, P < 0.0001, Figure 
6.5A). To confirm that the intranuclear inclusions were glycogenated, PAS staining was 
performed with or without the addition of diastase, an enzyme that breaks down glycogen. 
With the addition of diastase, the intranuclear inclusions were no longer observed confirming 
the content of the intranuclear inclusions as glycogen (Figure 6.5E and F).  There was 
minimal evidence of glycogen intranuclear inclusions in the proximal tubules of the HFD or 
HFD_hiSTZ groups. In contrast, the most striking features in the kidneys of the HFD and 
HFD_hiSTZ groups were tubular vacuolation and marked tubular dilatation (vacuolation 
score for HFD or HFD_hiSTZ vs. Chow, P < 0.0001 and dilatation score for HFD or 
HFD_hiSTZ vs. Chow, P < 0.001 and P < 0.0001 respectively, Figure 6.5A and B). There 
was no difference between the tubular vacuolation or dilatation scores between the HFD and 
HFD_hiSTZ groups. Tubular casts were also present in the HFD and HFD_hiSTZ groups 
whereas they were barely noticed in either the Chow or Chow_lowSTZ groups (HFD vs. 
Chow, P< 0.01, HFD_hiSTZ vs. Chow, P < 0.05, Figure 6.5D). 
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Figure 6.5. Tubular injury score at Week 32 
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Periodic acid Schiff (PAS) staining was used to demonstrate tubular injury scored according 
to: (A) Tubular dilation,  (B) Tubular vacuolation, (C) Glycogenated nuclei, and (D) Tubular 
casts. (E) Representative image of nuclear inclusion bodies (due to glycogenation) with PAS, 
(F) Representative image of the absence of glycogenated nuclei with PAS and diastase (an 
enzyme used to degrades glycogen). Results are expressed as mean ± SEM, n=6. *P< 0.05, 
**P<0.01 compared to Chow_lowSTZ. Control: Chow; Chow diet and five low-dose STZ: 
Chow_lowSTZ; High fat diet: HFD; and HFD and one high-dose STZ: HFD_hiSTZ.  
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6.5 Discussion 
 
The present study has utilised the C57BL/6 mouse to characterise models of diabetes and 
obesity, and thereafter demonstrate their renal characteristics. In particular, normal diet 
together with five low doses of STZ resembles T1D with marked hyperglycaemia and 
functional and structural renal changes. In comparison, HFD feeding induces many features 
of the metabolic syndrome including increased body weight, adiposity, hyperinsulinaemia, 
insulin resistance, hyperlipidaemia and glucose intolerance. Renal effects include functional 
changes demonstrated by albuminuria and higher serum creatinine. Marked structural 
changes distinct from the normal kidney were seen in the HFD-fed animals including 
glomerulosclerosis and tubular injury. The addition of a single dose of STZ together with 
HFD mitigates the effect of HFD on adiposity and hyperinsulinaemia. There was no lasting 
effect on glucose tolerance beyond that induced by HFD alone by Week 32. In addition, there 
was very little differential effect of one dose of STZ and HFD on renal changes, particularly 
structural changes induced by HFD. These results suggest that the short-term insult of one 
dose of STZ is not sufficient to worsen either the metabolic or the renal changes seen by HFD 
alone.  
 
The model of multiple low doses of STZ employed in this study using the C57BL/6 strain 
and low-dose STZ adequately demonstrated the key features of T1D including a lean 
phenotype, hypoinsulinaemia and hyperglycaemia as demonstrated by both raised fasting 
glucose and HbA1c. The kidney damage seen in the Chow_lowSTZ group was sufficient to 
demonstrate function changes as evidenced by increased urinary ACR and serum creatinine. 
Moreover, the renal structural changes were in keeping with known histological changes 
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associated with diabetic nephropathy in relation to tubular injury (393). Of interest is the 
finding of glycogenated nuclei seen only in the Chow_lowSTZ group. Nuclear inclusion 
bodies are rarely seen on histological examination and are the result of the accumulation of 
substances not normally found in the nucleus, one of which includes glycogen (394, 395). 
Kang and colleagues previously described marked glycogenated nuclei in the rat kidney 
several months after induction of diabetes with alloxan (396). Moreover, in a rat model of 
STZ-induced diabetes, hyperglycaemia was associated with large glycogen deposits in renal 
tubular cells nine months later (397). The presence of nuclear inclusion bodies is likely to 
reflect hyperglycaemia and lead to cellular damage (398). In our study, the histopathological 
changes seen in the Chow_lowSTZ group were clearly juxtaposed against those changes seen 
in the HFD and HFD_hiSTZ groups. 
 
T2D is characterised by insulin resistance and β-cell failure (399). The C57BL/6 mouse strain 
is highly susceptible to the metabolic effects of high fat feeding and this model has the 
advantage of being easily accessible (391).  The concept of using STZ to provide the “second 
hit” to reduce β-cell mass and further emulate T2D has been previously explored (389, 400, 
401). Of note, Gilbert et al. found that islet mass was not affected by diet but was reduced by 
50% in mice that received STZ injections. Furthermore, another study demonstrated that one 
dose of STZ with HFD resulted in metabolic features of T2D and induced interstitial fibrosis 
and glomerulosclerosis in the kidney (401). They further found evidence of renal lipotoxicity, 
inflammation and oxidative stress. However in this study, one dose of STZ in addition to 
HFD feeding did not show significant advantage to model diabetic renal pathology. In 
addition, the HFD_hiSTZ group was less obese than the HFD alone group. We speculate that 
increased glomerulosclerosis is a result of HFD induced obesity/metabolic syndrome, which 
was less evident in the STZ treated mice. Furthermore, the HFD_hiSTZ group did not have 
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elevated HOMA-IR (evidence of insulin resistance). We postulate that it is due to the 
suppressive effect of STZ on β-cell production of insulin, thereby preventing increased 
insulin secretion. Thus, high insulin levels were not observed in the HOMA-IR test for this 
group of animals. 
 
Obesity-propagated metabolic syndrome is associated with increased visceral adiposity, 
insulin resistance, hyperlipidaemia, hypertriglyceridaemia and insulin resistance; all key 
features that were most clearly demonstrated in the HFD group in the present study. The 
glucose tolerance test is an important indicator of glucose intolerance and diabetes in rodent 
models and the test is essential when carrying out metabolic research using rodents (402). 
Our results demonstrate that glucose tolerance becomes severely impaired as the mice 
become older and more obese on HFD irrespective of treatment with STZ. Interestingly, 
HbA1c was not elevated in either group fed HFD despite significant glucose intolerance 
demonstrated by IPGTT. It has been suggested that 6-h fasting glucose correlates more 
closely with HbA1c than overnight-fasted blood glucose (392). Indeed, the baseline glucose 
levels during IPGTT (after 6-h fasting) were similar among groups. 
 
The effect of HFD in the wild type mouse on body habitus and renal damage is insidious and 
is due to a multitude of pathophysiologic changes including hormonal, metabolic and 
vascular effects driven by changes in inflammation, oxidative stress and endothelial function 
(222). Though genetically manipulated models can be useful for interrogating a particular 
aspect of renal pathophysiology, they are less useful for exploring the whole body effects of 
metabolic syndrome and associated kidney disease. Although HFD feeding in C57BL/6 mice 
did not cause profound diabetic nephropathy in previous studies, our study shows sufficient 
renal damage to offer this model as a useful one when examining metabolic syndrome and 
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renal outcomes. The length of the modelling, 24 weeks, can be the key to induce such 
meaningful renal changes due to obesity and insulin resistance. 
 
The most striking feature seen in the kidneys of the HFD group was tubular vacuolation and 
tubular dilatation with moderate effects on the glomerular structure. This observation of 
tubular vacuolisation has been reported previously in the setting of HFD-induced obese 
mouse models and is associated with CKD (194, 248, 403, 404). In fact, this finding has been 
shown to relate to lysosome accumulation secondary to altered lysosomal system function 
and altered lipid metabolism characterised by cholesterol and phospholipid accumulation in 
the kidney (248). Tubular lipid accumulation has been previously shown to relate to CKD 
development in both humans and mice (285, 405). There was certainly evidence of 
hyperlipidaemia, hypertriglyceridaemia and hepatomegaly seen in the HFD group in the 
present study, and we have shown increase kidney lipid deposition in a rat model of obesity 
using the same diet (341, 356).  Furthermore, abnormal autophagy in the setting of obesity 
has been implicated to lead to tubulointerstitial changes which may also have played a role in 
the tubular abnormalities seen (404).  
 
In summary, the use of HFD in the C57BL/6 mouse is a suitable model to induce whole body 
and metabolic effects commonly seen in the human metabolic syndrome and is associated 
with renal damage likely to lead to progressive renal disease. The use of one dose STZ in 
addition to HFD does not provide added advantage in terms of either metabolic or renal 
characteristics related to T2D. The T1D model utilising five doses of STZ to induce insulin 
deficiency over a time interval of 24 weeks is associated with significant functional and 
structural renal damage.  Therefore, both the T1D and HFD models using the C57BL/6 
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mouse strain are simple, effective models by which to understand diabetes and obesity related 
kidney disease and develop new diagnostic and treatment strategies. 
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7.1 Abstract 
 
Background: Maternal obesity has implications for the offspring’s risk of chronic disease. In 
particular, developmental programming induced by maternal obesity is known to influence 
the future development of obesity, type 2 diabetes, non-alcoholic fatty liver disease and even 
cardiovascular disease in offspring. Recently, the effect of maternal obesity on chronic 
kidney disease (CKD) has gained increased attention. In the present study, we aimed to 
determine whether maternal obesity exaggerates the effect of obesity-related kidney disease 
using a C57BL/6 mouse model.  
Methods: Female C57/BL6 mice were fed high-fat diet (HFD) for six weeks prior to mating, 
during gestation and lactation. Male offspring were weaned to normal chow diet or HFD. At 
postnatal Week 8, HFD-fed offspring were administered one dose streptozotocin (STZ, 100 
mg/kg i.p.) or vehicle control. Metabolic parameters and renal functional and structural 
changes were observed at postnatal Week 32.  
Results: HFD-fed offspring had increased adipose tissue, glucose intolerance, and a deranged 
lipid profile, associated with increased albuminuria and serum creatinine levels. The kidneys 
displayed tubulointerstitial fibrosis, tubular dilatation and marked vacuolation. Moreover, 
HFD-induced obese offspring expressed increased levels of fibrotic, inflammatory and 
oxidative stress markers. STZ administration did not potentiate the renal effects of HFD 
alone. Maternal obesity had a sustained effect on increased offspring adiposity and impaired 
glucose tolerance, especially as offspring aged. Increased lipid and free fatty acid 
concentrations were observed in offspring of obese mothers fed HFD independently of 
whether they were given STZ. Though maternal obesity had a sustained effect on serum 
creatinine and oxidative stress markers in lean adult offspring, the renal consequences of 
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maternal obesity were overwhelmed by the powerful effect of diet-induced obesity on renal 
fibrosis, inflammation and oxidative stress.  
Conclusion: In conclusion, maternal obesity portends significant risks for metabolic and 
renal health in adult offspring. However, diet-induced obesity is an overwhelming and potent 
stimulus for the development of CKD that is not potentiated by maternal obesity. 
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7.2 Introduction 
 
Obesity is a known independent risk factor for the development and progression of chronic 
kidney disease (CKD) (221, 312). Additionally, obesity is strongly associated with the 
development of type 2 diabetes (T2D), which in turn accounts for the majority of CKD in 
most countries worldwide (406).  As such, globally the incidence of CKD has been 
increasing in the setting of rising rates of obesity. Identification of individuals with a 
predisposition to the development of CKD may enable targeted and early intervention in 
order to prevent progression of kidney damage and reduce known complications of CKD 
including cardiovascular disease and future end-stage kidney disease.  
 
Maternal obesity has sustained effects on the risk of chronic disease in offspring. Evidence 
from both human and animal studies suggests that maternal obesity ‘programs’ the offspring 
towards obesity, dysglycaemia, diabetes and hypertension, all key features of the metabolic 
syndrome (18, 19). This observation evokes the concept of the developmental origins of 
health and disease (DOHaD); a concept first explored by Barker and colleagues, which 
suggests that foetal exposure to factors inherent to the maternal milieu during gestation may 
influence programming towards chronic disease (20). There is substantial evidence that 
maternal obesity increases the risk of metabolic-related complications including 
cardiovascular disease and even premature death in adult offspring (21-24). The effect of 
maternal obesity on the risk of CKD in offspring is less well appreciated though a large 
population-based study of 1994 young people with CKD (age < 21 years) found a 
disproportionate number of children were born to mothers who were overweight or obese 
during their gestation (268).  
  
 
182 
Animal models of obesity are important to enable better understanding of the 
pathophysiologic pathways specific to obesity-related kidney disease. In contrast to 
genetically manipulated rodent models often used to study CKD, models susceptible to diet-
induced obesity, induced by ad libitum high fat diet (HFD) feeding, are likely to more closely 
resemble the human situation with insidious onset of adiposity, insulin resistance and 
metabolic derangement. Moreover, we have previously demonstrated that diet-induced 
obesity in rodents can be utilised to study the developmental programming effects of 
maternal obesity on offspring’s kidney health (356). We found that offspring born to obese 
mothers have upregulation of inflammatory and oxidative stress markers up until Week 9, 
equivalent to late adolescence in humans (341, 356). Further, we have previously shown the 
biometric, metabolic and neural effects of maternal obesity on offspring health (317).  
 
Most recently, we found that offspring of obese mothers had increased renal fibrosis, 
inflammation and oxidative stress which persist into adulthood (407). Importantly, when 
given an additional insult, five low doses of streptozotocin (STZ, 55 mg/kg/day for 5 
consecutive days) to induce diabetes, offspring exposed to maternal obesity had increased 
susceptibility to renal damage. In particular, renal inflammation and oxidative stress induced 
by diabetes was augmented by maternal obesity. However, induction of diabetes with STZ in 
this fashion is analogous to a model of type 1 diabetes with marked insulin depletion from 
pancreatic beta cells. Others have reported that one dose of STZ with HFD resulted in 
metabolic features of type 2 diabetes and induced interstitial fibrosis and glomerulosclerosis 
in the kidney (401). Given that the increased rates of obesity and type 2 diabetes are 
responsible for the rising rates of CKD in our community, we hypothesised that maternal 
obesity may also augment the effect of diet-induced obesity-related renal damage especially 
when combined with one dose of STZ. Therefore, the aim of this study was to determine, 
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using a C57BL/6 mouse model, whether maternal obesity increases obesity-related kidney 
disease in offspring. We aimed to determine whether maternal obesity exacerbates renal 
damage in high-fat diet (HFD)-induced obese offspring, specifically related to known 
mechanisms involved in obesity-related kidney disease including renal fibrosis, inflammation 
and oxidative stress.  
 
7.3 Methods 
7.3.1 Animal experiments 
 
The animal model of maternal obesity employed in this study has been previously described 
(407). In short, C57BL/6 female mice were fed high fat diet (HFD) or normal chow diet for 
six weeks prior to mating, during gestation and lactation (sourced from Kearns Facility, 
Kolling Institute, Royal North Shore Hospital, St Leonards, NSW, Australia). At Day 1, litter 
size was adjusted to 4-6 pups per mother. Offspring were weaned to either normal chow or 
HFD at postnatal Day 20. At postnatal Week 8, offspring fed HFD were assigned to either 
high-dose STZ (100 mg/kg, ip., once) or vehicle control (citrate buffer). STZ was 
administered to mice after fasting for 5 h prior to injection. STZ was freshly prepared by 
diluting it in citrate buffer (0.1 M, pH 4.5, Sigma, MO, USA) 15 minutes prior to injection. 
The model yielded six groups: CC: offspring of lean mothers fed a chow diet post-weaning, 
HC: offspring of obese mothers fed a chow diet post-weaning, CH: offspring of lean mother 
fed a HFD post-weaning, HH: offspring of obese mothers fed a HFD post-weaning, CH-STZ: 
offspring of lean mothers fed a HFD post-weaning together with one dose of STZ at postnatal 
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Week 8, and HH-STZ: offspring of obese mothers fed a HFD post-weaning together with one 
dose of STZ. 
 
This animal study was approved by the Animal Ethics Committee (AEC) of Royal North 
Shore Hospital (AEC 1309-007A) and complied with the Australian Code of Practice for the 
Care and Use of Animals for Scientific Purposes. All animals were housed in the Kearns 
Facility of the Kolling Institute, Royal North Shore Hospital with a stable environment 
maintained at 22±1°C with a 12/12-h light–dark cycle.  
 
 
Following a 6 h fasting period, mice were weighed and blood glucose levels measured using 
an Accu-Chek glucometer (Roche Diagnostics). If an animal developed fasting 
hyperglycaemia > 25 mmol/L they received insulin (2U glargine, Germany) to prevent 
ketosis and thereafter blood glucose readings were performed twice weekly.  
 
Intraperitoneal glucose tolerance tests (IPGTTs) were performed in fully conscious animals at 
Week 14, Week 20 and Week 30 after 6 h of fasting, as previously described (407). Mice 
were placed in metabolic cages and a 24-h urine collection was performed one week prior to 
sacrifice.   
 
Tissue harvesting took place at Week 32 under fasting conditions. Organ perfusion was 
performed with PBS after cardiac puncture for blood collection. The kidneys, liver, and fat 
were collected and weighed then the kidney was fixed in 10% buffered formalin for 
histological examination or snap frozen by immersing into liquid nitrogen as soon as possible 
after collection. 
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7.3.2 Serum measurements 
 
Serum insulin was measured using a mouse-specific ELISA method (Merck, Darmstadt, 
Germany). HOMA-IR was calculated using the formula: serum insulin (ng/mL) multiplied by 
the fasting glucose level (mmol/L) divided by 22.5, where the fasting glucose level was 
obtained at the time of tissue harvest using the Accu-Check glucometer. Glycosylated 
haemoglobin (HbA1c) was measured using a DCA Vantage Analyser (Siemens Medical 
Solutions Diagnostics, Tarrytown, NY, USA). Serum total cholesterol, triglycerides and LDL 
was measured using the Architect C16000 Clinical Chemistry Analyser (Abbott Laboratories, 
Abbott Park, Ill, USA) available through the affiliated hospital pathology service. Plasma 
non-esterified fatty acids (NEFA) were measured using a NEFA kit (WAKO, Osaka, Japan). 
The density was detected on a Bio-Rad 680 XR (Hercules, CA, USA) [13, 18].  
 
7.3.3 Analysis of renal function  
 
Urine albumin and creatinine concentrations were determined using the Murine 
Microalbuminuria ELISA kit (Exocell, Inc., Philadelphia, PA, USA) and Microcreatinuria 
ELISA kit (Exocell, Inc. These measurements enabled calculation of the urinary albumin to 
creatinine ratio. Serum creatinine was measured using the Architect C16000 Clinical 
Chemistry Analyser (Abbott Laboratories). 
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7.3.4 Analysis of changes to renal structure 
 
Formalin-fixed hemisected kidneys were embedded in paraffin and stained with Periodic 
Acid Schiff (PAS).  The whole kidney cortex was examined under the magnification of 400x 
using a light microscope (Olympus photomicroscope linked to a DFC 480 digital camera). 
Two independent assessors, including an anatomical pathologist and nephrologist, reviewed 
histological sections in a blinded manner and scored tubulointerstitial fibrosis, tubular injury 
and glomerulosclerosis.  
 
The characteristic features of tubulointerstitial fibrosis include tubular atrophy or dilatation, 
presence of mononuclear inflammatory cells, widening of interstitial spaces with deposition 
of extracellular matrix, interstitial cell proliferation and wrinkling or thickened tubular 
basement membrane (perivascular and periglomerular areas were discounted). Tubular 
interstitial fibrosis was scored using a scale of 0 to 4: 0 - normal; 1 - involvement of < 10% of 
the cortex; 2 - involvement of 10–25% of the cortex; 3 - involvement of 25–75% of the 
cortex; and 4 - extensive damage involving > 75% of the cortex (see Figure 7.1). 
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Further analyses of tubular injury were assessed by: (A) tubular dilatation, (B) tubular 
vacuolation, C) glycogenated nuclei, and (D) tubular casts (see Figure 7.2). Tubular dilatation 
was scored using a scale of 0 to 4: 0 – dilatation absent, 1 – less than five dilated cortical 
tubules were observed per high power field (HPF), 2 – five to ten dilated cortical tubules 
were observed per HPF, 3 – more than ten dilated tubules were observed per HPF. Tubular 
vacuolation was scored using a scale of 0 to 3: 0 – absent vacuoles, 1 – vacuoles seen in < 
25% cortical tubules per HPF, 2 – vacuoles evident in 25 - 50% cortical tubules per HPF, and 
3 – vacuolation present in > 50% PHF. For glycogenated nuclei in tubular epithelium, the 
scoring system was similar: 0 – absence, 1 – only one glycogenated nuclear observed per 
HPF, 2 – two to three nuclei observed per HPF, or 3 – greater than three glycogenated nuclei 
observed per HPF. Cast appearance was scored as either 0 – absence, or 1 – present.  
 
Glomerulosclerosis was scored as previously described (407, 408). In brief, PAS staining was 
used to grade glomerulosclerosis: 0 - normal, 1 - < 25% involvement, 2 < 50% involvement, 
3 - < 75%, and 4 - > 75% sclerosis) and then the average of 20 individual scores was 
calculated to generate the glomerulosclerosis score (see Figure 7.3). 
  
  
 
188 
 
 
Figure 7.1. Features of tubulointerstitial fibrosis 
The key features of tubulointerstitial fibrosis include A. Tubular atrophy, B. Tubular 
dilatation, C. Inflammatory infiltrate, D. Thickened basement membrane, and E. Widened 
interstitial space. Tubular interstitial fibrosis was scored using a scale of 0 to 4: 0 - normal; 1 
- involvement of < 10% of the cortex; 2 - involvement of 10–25% of the cortex; 3 - 
involvement of 25–75% of the cortex; and 4 - extensive damage involving > 75% of the 
cortex. 
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Figure 7.2. Tubular interstitial injury 
Tubular interstitial injury scoring was determined according to: (A) Tubular dilatation, (B) 
Tubular vacuolation, (C) Glycogenated nuclear inclusions, and (D) Casts. Tubular dilatation 
was scored using a scale of 0 to 4. Tubular vacuolation was scored using a scale of 0 to 3. For 
glycogenated nuclei in tubular epithelium, the scoring system was similar, 0 to 3. Cast 
appearance was scored as either 0 – absence, or 1 – present.  
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Figure 7.3. Glomerular sclerosis injury score 
Glomerular sclerosis is scored as: (A) 0 – no sclerosis, (B) 1-25% sclerosis, (C) 26-50% 
sclerosis, (D) 51-75% sclerosis, (E) >75% sclerosis. 
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7.3.5 Immunohistochemistry and semi-quantification 
 
Paraffin-embedded hemisected kidneys were cut into 2µm sections. For specific antibody 
detection, the sections were de-waxed in xylene and rehydrated in graded concentrations of 
ethanol. Antigen retrieval was performed by incubating the sections in citrate buffer (99°C, 
pH 6.0) for 30 minutes, followed by washing in running water, then blocked for 15 minutes 
in 10% blocking solution (Dako, Glostrup, Denmark). Next, sections were incubated with 
primary antibodies against collagen IV (dilution 1:1000, Abcam Ltd, Cambridge, MA, USA), 
fibronectin (dilution 1:500, Abcam), or 8-hydroxy-2' –deoxyguanosine (8-OHdg) (dilution 
1:200, Cell Signaling Technology, Beverly, MA, USA) at 4°C overnight in a humid chamber 
and washed three times in buffered PBS before incubating with a secondary biotinylated 
antibody for 1 hour at room temperature (ABD Serotec, USA; dilution 1:200), and then 
treated with peroxidase-conjugated streptavidin for 15 minutes (Dako Glostrup, Denmark) 
followed by the LSAB+ detection system (Dako Glostrup, Denmark). Antigen-antibody 
reactions were visualized with chromogen diaminobenzidine and counter staining was 
performed using Mayer’s Haematoxylin followed by Scott’s Blue staining (Fronine, NSW, 
Australia). Control sections were also prepared whereby the authentic primary antibodies 
were replaced with an irrelevant isotope matched antibody. 
 
Alternatively, frozen tissue was cut into 4-µm frozen sections and fixed in acetone for 10 
minutes immediately and did not undergo heat retrieval. Sections were washed in PBS three 
times, 5 min each, pre-incubated in a blocking solution (10% goat serum in PBS) for 30 min 
and washed in PBS three times. They were then incubated in the widely used markers of 
murine macrophage populations, rat anti-mouse F4/80 monoclonal antibody (dilution 1:100, 
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ABD Serotec, USA) or rat anti-mouse CD68 antibody (dilution 1:100, ABD Serotec, USA) 
for one hour. Each section was washed three times in PBS and then incubated with a 
secondary HRP labelled goat anti-rat antibody for 30 min (ABD Serotec, USA; dilution 
1:200). Antigen-antibody reactions were then visualized with chromogen diaminobenzidine 
and counter staining was performed using Mayer’s Haematoxylin followed by Scott’s Blue 
staining (Fronine). 
 
The tissue specimens were examined by light microscopy using the Olympus 
photomicroscope and images retained using the DFC 480 digital camera. For fibronectin, 
collagen IV, 8-OHdg, CD68, and F4/80, six consecutive non-overlapping fields from each 
section of renal cortex were photographed under high magnification (x400). Stained areas 
were quantified using Image J software (Java based software program, NIH, UK). The 
percentage of the stained area relative to the whole area in each visual field was determined. 
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7.3.6 Relative quantitative real-time PCR 
 
RNA was extracted using the RNeasy mini kit (Qiagen, Valencia, CA, USA) and then cDNA 
was generated using the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, 
Mannheim, Germany). RT-PCR was performed using an ABI Prism 7900 HT Sequence 
Detection System (Applied Biosystems, Foster City, CA, USA) and SYBR GreenER qPCR 
Supermix (Invitrogen) with PCR primers (Table 7A). Results are presented as fold change 
compared to control after normalisation to β-actin. 
 
  
  
 
194 
 
Table 7.A. Details of primers used for pro-fibrotic, pro-inflammatory and oxidative stress 
markers 
Gene Primer sequence 
Fibronectin 
 
Forward: 5'ACAGAAATGACCATTGAAGG 
Reverse: 5'TGTCTGGAGAAAGGTTGATT 
Collagen IV 
 
Forward: 5'TTAAAGGACTCCAGGGGACCAC 
Reverse: 5'CCCACTGAGCCCCTGTCACAC 
MCP-1 
 
Forward: 5'CTTCTGGGCCTGCTGTTCA 
Reverse: 5'CTTCTGGGCCTGCTGTTCA 
TGF-β 
 
Forward: 5'GCGGACTACTATGCTAAAGAGG3' 
Reverse: 5'GTAGAGTTCCACATGTTGCTCC3' 
iNOS 
 
Forward: 5'GACGAGACGGATAGGCAGAG3' 
Reverse: 5'GTGGGGTTGTTGCTGAACTT3' 
β-Actin  
 
Forward: 5'- CAAAGCAAAGGCGAGG 
Reverse: 5'- ACGGAGCGAAACTGGC 
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7.3.7 Statistical methods 
Results are expressed as mean ± SEM. Data were analysed using analysis of variance 
(ANOVA), followed by post-hoc Bonferroni tests to make between-group comparisons. The 
area under the curve (AUC) during glucose tolerance test results was calculated using the 
trapezoidal rule. To compare plasma glucose levels at different time points during the IPGTT, 
a two-way ANOVA was performed and between-group differences were determined using 
Tukey’s post hoc test. Analyses were carried out using GraphPad Prism 6.0 (GraphPad 
Software, San Diego, CA, USA) and P value < 0.05 was considered statistically significant. 
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7.4 Results 
7.4.1 Maternal obesity increases adiposity in the presence of obesity and 
STZ 
 
Feeding with HFD is known to consistently lead to diet-induced obesity in C57BL/6 mice 
(67). Therefore, as expected all groups fed HFD from weaning until Week 32 including CH, 
HH, CH-STZ and HH-STZ had increased body weight compared to control (P < 0.0001 for 
all groups vs. CC; Figure 7.4A). There was no difference in body weight of offspring of 
obese mothers weaned to a normal chow diet compared to control (HC vs. CC, N.S.). Though 
maternal obesity did not increase body weight of offspring fed HFD alone (CH vs. HH), 
maternal obesity was associated with increased body weight in offspring fed HFD and given 
a further diabetes-related insult with STZ (CH-STZ vs. HH-STZ, P < 0.01).  
 
Visceral adiposity, as measured by retroperitoneal and epididymal fat mass, was increased in 
all groups fed HFD (both retroperitoneal and epididymal fat CH, HH, CH-STZ, HH-STZ vs. 
control P < 0.0001; Figures 7.4B and C). Maternal obesity had no effect on either 
retroperitoneal or epididymal fat mass when offspring were fed normal chow or HFD. 
Similar to the observation for body weight, offspring of obese mothers fed HFD and given 
one dose of STZ had significantly increased adiposity as measured by both fat depots 
compared to similar offspring of lean mothers (CH-STZ vs. HH-STZ for both retroperitoneal 
and epididymal fat mass, P < 0.05).  
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Figure 7.4. Anthropometric measures performed at Week 32 
(A) Body weight, (B) Retroperitoneal fat mass relative to body weight, (C) Epididymal fat 
mass relative to body weight, and (D) Liver mass relative to body weight. Results are 
expressed as mean ± SEM, N = 9-20. *P< 0.05, **P<0.01, ***P<0.001, ****P<0.0001 
compared to CC. Control: CC, offspring from obese mothers fed chow: HC, offspring of lean 
mothers fed high fat diet (HFD): CH, offspring of obese mothers fed HFD: HH, offspring of 
lean mothers fed HFD and administered one dose of streptozotocin (STZ) at Week 8:CH-
STZ, and offspring of obese mothers fed HFD and administered one dose of STZ: HH-STZ. 
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All groups fed HFD demonstrated hepatomegaly except for the CH-STZ group whose liver 
mass was no different from control. Though there was no effect of maternal obesity on liver 
mass in offspring fed HFD, offspring fed HFD and given STZ had increased liver size (alone 
(CH vs. HH, N.S., CH-STZ vs. HH-STZ, P < 0.01, Figure 7.4D). Offspring fed normal chow 
diet had normal liver mass regardless of maternal diet.  
 
7.4.2 Maternal obesity worsens glucose intolerance in HFD-fed offspring  
 
Intraperitoneal glucose tolerance tests (IPGTTs) were performed at Week 14, Week 20 and 
Week 30, which corresponded to 6 weeks, 12 weeks and 22 weeks post-STZ induction of 
diabetes respectively (Figure 7.5). The between-group differences of relevance included the 
effect of HFD and maternal obesity on glucose tolerance. The area under the curve was 
calculated as a measure of overall glucose tolerance, as previously described (402). 
 
Week 14: At the commencement of the IPGTT, the HFD-fed groups had significant fasting 
hyperglycaemia compared to control (CH vs. CC, P < 0.05, CH-STZ vs. CC, P < 0.05, HH 
vs. CC, P < 0.05 and HH-STZ vs. CC, P < 0.01, Figure 7.5A). There was no effect of 
maternal obesity on fasting glucose levels regardless of the postnatal diet. At 15, 30, 60 and 
90 min post-commencement of the IPGTT, hyperglycaemia was sustained in the HFD-fed 
groups (Time 15: CH vs. CC, P < 0.05, CH-STZ vs. CC, P < 0.01, HH vs. CC, P < 0.05, HH-
STZ vs. CC, P < 0.001, Times 30, 60 and 90: CH, CH-STZ, HH, HH-STZ vs. CC, P < 
0.0001, Figure 7.5A). There was no added effect of maternal obesity in the HFD-fed groups 
on blood glucose values at any time point. Interestingly, at time-points 60 and 90 minutes of 
the IPGTT, one dose STZ significantly exacerbated hyperglycaemia in the offspring of obese 
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mothers fed HFD (HH-STZ vs. HH, P < 0.05).  As an overall measure of glucose tolerance 
the AUC was calculated, and in all groups fed HFD the AUC was increased (CH vs. CC, CH-
STZ vs. CC, HH vs. CC and HH-STZ, P < 0.0001). Compared to offspring born to lean 
mothers, offspring of obese mothers weaned to normal chow diet had impaired glucose 
tolerance as measured by AUC (HC vs. CC, P < 0.05, Figure 7.5B).  
 
Week 20: At commencement of the IPGTT only the HFD-fed groups given STZ continued to 
have significant fasting hyperglycaemia compared to control (CH-STZ vs. CC and HH-STZ 
vs. CC, P < 0.05, Figure 7.5C). At 15 minutes, maternal obesity potentiated hyperglycaemia 
in the offspring fed HFD and given STZ (HH-STZ vs. CH-STZ, P < 0.05). From 30 minutes, 
all HFD-fed groups had higher blood glucose levels compared to control and this was 
sustained until 90 minutes (P < 0.0001). The AUC was increased in all groups fed HFD (CH 
vs. CC, CH-STZ vs. CC, HH vs. CC and HH-STZ, P < 0.0001, Figure 7.5D). Though 
maternal obesity alone did not increase AUC (HC vs. CC), maternal obesity exacerbated 
glucose intolerance in the high-fat fed group though not with STZ (HH vs. CH, P < 0.05, 
HH-STZ vs. CH-STZ, N.S.).  
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Figure 7.5. Intraperitoneal glucose tolerance tests performed at postnatal Week 14, 20 and 31 
in C57BL/6J mice 
Blood glucose levels were measured at 0, 15, 30, 60 and 90 minutes post-glucose injection 
(A-C). AUC of A-C (D-F). Results are expressed as mean ± SEM, n = 8-13. *P< 0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 compared to CC. Control: CC, offspring from obese 
mothers fed chow: HC, offspring of lean mothers fed high fat diet (HFD): CH, offspring of 
obese mothers fed HFD: HH, offspring of lean mothers fed HFD and administered one dose 
of streptozotocin (STZ) at Week 8:CH-STZ, and offspring of obese mothers fed HFD and 
administered one dose of STZ: HH-STZ. 
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Week 30: At commencement of the IPGTT, there was no difference in fasting blood glucose 
levels between groups. By 15 minutes, some HFD-fed groups had higher blood glucose levels 
compared to control (CH vs. CC, P < 0.05, HH-STZ vs. CC, P < 0.001, Figure 7.5E). By 30 
minutes, all HFD-fed groups had higher blood glucose levels compared to control, which 
were sustained till 90 minutes (P < 0.0001). Furthermore, maternal obesity potentiated the 
effect of HFD on blood glucose levels at 30 minutes (HH vs. CH, P < 0.01). At 60 minutes, 
maternal obesity potentiated the effect of HFD with or without STZ (HH vs. CH, P < 0.05, 
HH-STZ vs. CH-STZ, P < 0.01). Finally, by 90 minutes, hyperglycaemia persisted in all 
HFD-fed groups (P < 0.0001) and maternal obesity continued to exacerbate the effect of HFD 
with or without STZ (HH vs. CH, P < 0.01, HH-STZ vs. CH-STZ, P < 0.05). The glucose 
intolerance measured by AUC resulting from HFD was sustained until Week 30 (CH vs. CC, 
CH-STZ vs. CC, HH vs. CC and HH-STZ, P < 0.0001, Figure 7.5F). Maternal obesity alone 
did not impair glucose tolerance (HC vs. CC). Although maternal obesity alone worsened 
glucose intolerance at Week 14, by Week 20 and Week 30 the effect was lost. There was 
greater glucose intolerance in groups given STZ (CH-STZ vs. CH and HH-STZ vs. HH, P < 
0.05, Figure 7.5F). 
 
7.4.3 Maternal obesity has modest effect on metabolic measures in the 
setting of obesity and diabetes 
 
At Week 32, fasting hyperinsulinaemia was observed in HFD fed offspring (CH vs. CC, P < 
0.01, HH vs. CC, P < 0.05, Figure 7.6A). STZ-treated offspring did not have HFD-induced 
hyperinsulinaemia, presumably because STZ depleted the beta cell capacity to increase 
insulin secretion in the setting of hyperglycaemia. There was no differential effect of 
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maternal obesity on insulin concentrations, regardless of group. Insulin resistance was 
measured by calculating HOMA-IR; there was evidence of insulin resistance in some HFD-
fed offspring (CH vs. CC, P < 0.05, HH vs. CC, P < 0.05, Figure 7.6B). In comparison, 
offspring given STZ did not demonstrate insulin resistance despite their higher weight, 
adiposity and hyperglycaemia and maternal obesity did not exacerbate insulin resistance in 
adulthood.  
 
HbA1c (%) was measured as a marker of overall glycaemic control and no statistical 
difference was detected between groups (CC: 4.51 ± 0.07, HC: 4.36 ± 0.18, CH: 4.82 ± 0.17, 
HH: 4.87 ± 0.23, CH-STZ: 4.66 ± 0.10, HH-STZ: 4.66 ± 0.07, data not shown). 
 
Hyperlipidaemia was evident in all HFD-fed offspring. Total cholesterol and LDL were 
increased in obese animals in all groups (total cholesterol: CH vs. CC, P < 0.0001, CH-STZ 
vs. CC, P < 0.01, HH vs. CC, P < 0.05, HH-STZ vs. CC, P < 0.001 and LDL: CH vs. CC, P < 
0.0001, CH-STZ vs. CC, P < 0.01, HH vs. CC, P < 0.05, HH-STZ vs. CC, P < 0.05, Figure 
7.6C and D). Maternal obesity potentiated hyperlipidaemia as measured by total cholesterol 
and LDL in HFD-fed offspring given STZ (P < 0.05). Serum triglyceride levels were 
increased in two of the HFD-fed offspring (CH vs. CC and HH-STZ vs. CC, P < 0.05, Figure 
7.6E). NEFA concentrations were elevated in HFD-fed offspring except in the CH-STZ 
group (CH vs. CC, P < 0.01, HH vs. CC, P < 0.0001, HH-STZ vs. CC, P < 0.0001, Figure 
7.6F). Maternal obesity significantly heightened NEFA levels in all groups regardless of 
postnatal diet (HC vs. CC, P < 0.05, HH vs. CH, P < 0.05, HH-STZ vs. CH-STZ, P < 
0.0001). 
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Figure 7.6. Metabolic measures at Week 32 
(A) Serum insulin, (B) HOMA-IR score, (C) Serum total cholesterol, (D) Serum triglyceride 
measure, (E) Low density lipoprotein (LDL) concentration, (F) Non-esterified free fatty acid 
(NEFA) concentration. Results are expressed as mean ± SEM, N = 6-10. *P< 0.05, **P<0.01, 
***P<0.001, ****P<0.0001 compared to CC. Control: CC, offspring from obese mothers fed 
chow: HC, offspring of lean mothers fed high fat diet (HFD): CH, offspring of obese mothers 
fed HFD: HH, offspring of lean mothers fed HFD and administered one dose of STZ at Week 
8:CH-STZ, and offspring of obese mothers fed HFD and given one dose of STZ: HH-STZ.  
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7.4.4 Obesity is associated with impaired renal function and maternal 
obesity does not exacerbate the effect 
 
HFD-induced obesity affected renal function. Specifically, an elevated urinary ACR was 
evident in almost all groups fed HFD (CH vs. CC, CH-STZ vs. CC, HH-STZ vs. CC, P < 
0.05, Figure 7.7A). In addition, serum creatinine was raised in all groups fed HFD (CH, HH, 
HH-STZ vs. CC, P < 0.01 and CH-STZ, HH vs. CC, P < 0.05, Figure 7.7B). Neither STZ-
induced injury nor maternal obesity worsened renal function at Week 32. 
 
7.4.5 Diet-induced obesity and renal structural changes are independent of 
maternal obesity and STZ injury 
 
Alongside the aforementioned renal functional changes, obese offspring had marked renal 
structural changes and in particular, demonstrated renal tubular injury (Figure 7.8). There was 
no impact of maternal obesity on renal structural changes beyond diet-induced obesity at 
Week 32.  
 
Tubular interstitial fibrosis is a frequently described renal consequence of diabetes. Scoring 
performed by two independent assessors demonstrated that all HFD-fed groups had evidence 
of tubular interstitial fibrosis, in particular tubular dilatation, widening of the interstitial space 
and inflammatory infiltrate (CH vs. CC, P < 0.0001, HH vs. CC, P < 0.0001, CH-STZ vs. 
CC, P < 0.01, HH-STZ vs. CC, P < 0.0001, Figure 7.8A and B). There was no effect of 
maternal obesity on the interstitial fibrosis score with or without HFD feeding.  
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Figure 7.7. Renal functional changes at Week 32 
(A) Urinary albumin to creatinine ratio (ACR) at Week 31, (B) Serum creatinine 
concentration at Week 32. Results are expressed as mean ± SEM, N = 9-20. *P< 0.05, 
**P<0.01 compared to CC. Control: CC, offspring from obese mothers fed chow: HC, 
offspring of lean mothers fed high fat diet (HFD): CH, offspring of obese mothers fed HFD: 
HH, offspring of lean mothers fed HFD and administered one dose of streptozotocin (STZ) at 
Week 8:CH-STZ, and offspring of obese mothers fed HFD and administered one dose of 
STZ: HH-STZ. 
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Figure 7.8. Renal structural changes at Week 32 
(A) Periodic acid Schiff staining (PAS) representative image at 400x magnification, (B) 
Interstitial fibrosis score, (C) Tubular dilatation score, (D) Tubular vacuolation score, (E) 
Nuclear inclusion body score, (F) Tubular cast score, and (G) Glomerulosclerosis score. 
Results are expressed as mean ± SEM, N = 6-7. *P< 0.05, **P<0.01, ***P<0.001, 
****P<0.0001 compared to CC. Control: CC, offspring from obese mothers fed chow: HC, 
offspring of lean mothers fed high fat diet (HFD): CH, offspring of obese mothers fed HFD: 
HH, offspring of lean mothers fed HFD and given one dose of streptozotocin (STZ) at Week 
8:CH-STZ, and offspring of obese mothers fed HFD and given one dose of STZ: HH-STZ. 
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Further characterisation of tubular injury was performed by assessing tubular dilatation, 
vacuolation, nuclear inclusion bodies and cast formation. Diet-induced obesity due to HFD 
consumption was significantly associated with marked tubular dilatation (CH vs. CC, P < 
0.01, HH vs. CC, P < 0.001, CH-STZ vs. CC, P < 0.0001, HH-STZ vs. CC, P < 0.01, Figure 
7.8A and C). Moreover, the most consistent and dramatic effect of HFD on renal structure 
was the appearance of marked vacuolation throughout the tubules (P < 0.0001 for all 
comparisons, Figure 7.8A and D). Nuclear inclusion bodies, specifically glycogenated nuclei 
have been previously reported in the setting of diabetes and obesity, and in addition renal 
tubular casts are occasionally reported (396). However, in our experiments, there was no 
difference in nuclear inclusions or casts demonstrated between the groups fed a postnatal 
HFD (Figures 7.8A, E-F). Renal structure was not influenced by maternal obesity regardless 
of post-weaning diet.  
 
Compared to the significant tubular damage demonstrated in HFD-fed animals, the 
glomerular changes were less marked. Assessment of glomerular injury was determined by 
calculating the glomerulosclerosis score. There was evidence of glomerular injury in both the 
CH and HH-STZ groups though not HH and CH-STZ groups (CH vs. CC, P < 0.05, HH-STZ 
vs. CC, P < 0.01, Figure 7.8A and G). Maternal obesity did not influence glomerular 
structure. 
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7.4.6 Diet-induced obesity has an overwhelming effect on extracellular 
matrix deposition independent of maternal obesity  
 
Extracellular matrix is a hallmark feature of renal fibrosis and is characterised by deposition 
of major constituents such as collagen IV and fibronectin. There was evidence of collagen IV 
and fibronectin accumulation in the kidneys of obese mice, evaluated by both 
immunohistochemistry staining (Figure 7.9A and B) and RT-PCR (Figure 7.9C). 
Specifically, collagen IV staining was increased in obese offspring (CH vs. CC, P < 0.05, 
CH-STZ vs. CC, P < 0.0001, HH-STZ vs. CC, P < 0.01, HH vs. CC, N.S., Figure 7.9A and 
B). In addition, Collagen IV mRNA expression was increased in all obese offspring (all 
groups vs. CC, P < 0.0001, Figure 7.9C). Likewise, fibronectin immunostaining was 
increased in HFD-fed offspring (CH vs. CC, P < 0.05, HH vs. CC, P < 0.05, CH-STZ vs. CC, 
P < 0.0001, HH-STZ vs. CC, P < 0.01, Figure 7.9D and E). Fibronectin mRNA expression 
was increased in all obese offspring (CH vs. CC, P < 0.05, HH vs. CC, P < 0.05, CH-STZ vs. 
CC, P < 0.01, HH-STZ vs. CC, P < 0.05, Figure 7.9F). There was no effect of maternal 
obesity either with or without HFD feeding on either collagen IV or fibronectin. Additionally, 
the administration of a single dose of STZ did not amplify collagen IV or fibronectin 
deposition. 
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Figure 7.9 Markers of extracellular matrix deposition at Week 32 
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(A) Collagen IV representative images at 400x magnification, (B) Area (%) of collagen IV 
staining, (C) Collagen IV mRNA expression, (D) Fibronectin representative images at 400x 
magnification, (E) Area (%) of fibronectin staining, (F) Fibronectin mRNA expression. 
Results are expressed as mean ± SEM, N = 4-6. *P< 0.05, **P<0.01, ***P<0.001, 
****P<0.0001 compared to CC. Control: CC, offspring from obese mothers fed chow: HC, 
offspring of lean mothers fed high fat diet (HFD): CH, offspring of obese mothers fed HFD: 
HH, offspring of lean mothers fed HFD and administered one dose of streptozotocin (STZ) at 
Week 8:CH-STZ, and offspring of obese mothers fed HFD and administered one dose of 
STZ: HH-STZ. 
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7.4.7 Renal inflammation is associated with diet-induced obesity 
 
Obesity is known to be a pro-inflammatory state and furthermore developmental 
programming by maternal obesity has been associated with upregulation of inflammatory 
processes. Therefore, we investigated whether maternal obesity would exacerbate renal 
inflammation.  
 
Immunohistochemistry staining for two macrophage markers, CD68 and F4/80 was 
evaluated. CD68 and F4/80 staining showed very similar patterns of expression and the semi-
quantification was almost identical demonstrating that HFD-induced obesity was associated 
with increased expression (CD68 and F4/80: CH vs. CC, P < 0.05, HH vs. CC, P < 0.01, CH-
STZ vs. CC, P < 0.01, HH-STZ vs. CC, P < 0.001, Figure 7.10A-D). TGF-β is a pro-
inflammatory and pro-fibrotic cytokine and its mRNA expression was increased in all obese 
groups (CH vs. CC, P < 0.01, HH vs. CC, P < 0.01, CH-STZ vs. CC, P < 0.0001, HH-STZ 
vs. CC, P < 0.0001, Figure 7.10E). Similarly the macrophage-mediated pro-inflammatory 
cytokine MCP-1 was also elevated in the HFD fed groups (CH vs. CC, P < 0.05, HH vs. CC, 
P < 0.05, CH-STZ vs. CC, P < 0.01, HH-STZ vs. CC, P < 0.05, Figure 7.10F). In these 
analyses, there was an overwhelming effect of diet-induced obesity on inflammatory markers 
and no superimposed effect of maternal obesity was demonstrated.  
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Figure 7.10. Markers of renal inflammation at Week 32 
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(A) CD68 representative images at 200x magnification, (B) Area (%) of CD68 staining, (C) 
Area (%) of F4/80 staining, (D) F4/80 representative images at 200x magnification, (E) TGF-
β mRNA expression, and (F) MCP-1 mRNA expression. Results are expressed as mean ± 
SEM, N = 4-6. *P< 0.05, **P<0.01, ***P<0.001, ****P<0.0001 compared to CC. Control: 
CC, offspring from obese mothers fed chow: HC, offspring of lean mothers fed high fat diet 
(HFD): CH, offspring of obese mothers fed HFD: HH, offspring of lean mothers fed HFD 
and administered one dose of streptozotocin (STZ) at Week 8:CH-STZ, and offspring of 
obese mothers fed HFD and administered one dose of STZ: HH-STZ. 
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7.4.8 Renal oxidative stress is induced by maternal obesity in lean offspring 
though diet-induced obesity has a stronger impact 
 
8-OHdg, a major product of DNA oxidation in the setting of oxidative stress, was measured 
by immunohistochemistry staining. 8-OHdg expression was increased in obese offspring (CH 
vs. CC, P < 0.01, HH vs. CC, P < 0.01, CH-STZ vs. CC, P < 0.0001, HH-STZ vs. CC, P < 
0.01, Figure 7.11A and B). Though maternal obesity did not exaggerate the effect of HFD on 
8-OHdg expression maternal obesity significantly increased 8-OHdg expression in offspring 
weaned to normal diet (HC vs. CC, P < 0.05). Diet-induced obesity in the CH-STZ group was 
more detrimental than the effect of maternal obesity (CH-STZ vs. HC, P < 0.05).  
 
The mRNA expression of iNOS, a further marker of oxidative stress, was measured using 
RT-PCR. Once again, iNOS mRNA expression was increased in the obese offspring (CH vs. 
CC, P < 0.001, HH vs. CC, P < 0.0001, CH-STZ vs. CC, P < 0.001, HH-STZ vs. CC, P < 
0.001, Figure 7.11C). Importantly, maternal obesity significantly increased iNOS expression 
in offspring weaned to a normal diet, though the overwhelming effect of diet-induced obesity 
mitigated any demonstrable effect of maternal obesity in obese offspring (HC vs. CC, P < 
0.05). Indeed, HFD had a more powerful effect on iNOS expression than did maternal obesity 
(HH vs. HC, P < 0.05). 
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Figure 7.11. Markers of oxidative stress in the kidney at Week 32 
(A) 8-OHdg representative images at 200x magnification, (B) Area (%) of 8-OHdg staining 
and (C) iNOS mRNA expression. Results are expressed as mean ± SEM, N = 4-6. *P< 0.05, 
**P<0.01, ***P<0.001, ****P<0.0001 compared to CC. Control: CC, offspring from obese 
mothers fed chow: HC, offspring of lean mothers fed high fat diet (HFD): CH, offspring of 
obese mothers fed HFD: HH, offspring of lean mothers fed HFD and administered one dose 
of STZ at Week 8:CH-STZ, and offspring of obese mothers fed HFD and administered one 
dose of STZ: HH-STZ.  
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7.5 Discussion 
 
In this study of maternal and diet-induced obesity, the results demonstrate that diet-induced 
obesity has multiple detrimental effects on glucose tolerance, metabolic regulation, renal 
function and renal structure in C57BL/6 mice. In relation to kidney injury, obesity is 
associated with functional changes including increased albuminuria and raised serum 
creatinine and structural changes including tubulointerstitial fibrosis, tubular dilatation, and 
marked vacuolation consistent with tubular damage. In addition, we found that extracellular 
matrix components including collagen IV and fibronectin and inflammatory and oxidative 
stress pathways are upregulated in the setting of obesity. . We found that the addition of STZ 
together with HFD had little impact on the renal effects demonstrated 24 weeks later, 
suggesting that one dose of STZ is insufficient to worsen chronic kidney damage. The results 
suggest that the HFD-induced model of obesity utilising the wild-type C57BL/6 mouse for 32 
weeks duration is an excellent model of obesity-related CKD.  
 
Our study also focused on the impact of maternal obesity on offspring kidney health. We 
found that diet-induced obesity has an overwhelming effect on renal structural, fibrotic, 
inflammatory and oxidative stress changes, mitigating any effect of maternal obesity beyond 
that induced by obesity itself. Nonetheless, in the current C57BL/6 animal model we 
demonstrate a sustained effect of maternal obesity on adiposity, glucose intolerance and lipid 
concentrations, including total cholesterol, LDL and NEFA. Moreover, maternal obesity 
continued to exert an effect on renal function with respect to increased albuminuria and 
raised serum creatinine. Importantly, markers of oxidative stress were elevated in offspring of 
  
 
217 
obese mothers who weaned to a normal chow diet. This suggests that oxidative stress is likely 
to be an important mediator of the developmental programming effect of maternal obesity.  
 
Oxidative stress markers, alongside inflammatory mediators are also known to be 
upregulated in the setting of obesity (243, 326). In addition, altered cellular programming 
leading to oxidative stress has previously been recognised as a mechanism underlying the 
developmental programming effects of maternal obesity on metabolic risk (136, 275). 
Increased reactive oxygen species that outweigh anti-oxidant defence mechanisms will lead 
to cellular injury initiating the inflammatory signalling cascade (192). Oxidative stress is 
known to play a key role in initiating and potentiating renal fibrosis and is known to act 
synergistically with pro-inflammatory cytokines to perpetuate renal damage (185-189, 193). 
Therefore, the findings in this study that maternal obesity and diet-induced obesity up-
regulate markers of oxidative stress in the kidney are in keeping with the known role of 
oxidative stress. 
 
 
A major strength of the present study is the detailed analysis of renal structural changes. 
Importantly, we observed significant tubulointerstitial fibrosis and tubular dilatation 
alongside overwhelming evidence of tubular vacuolation in the kidneys of HFD-fed 
offspring. This finding of tubular vacuolation is not universally associated with obesity-
related kidney disease. Moreover, a review of the literature found a handful of studies 
reporting this unique appearance of vacuoles in proximal tubular cells resulting from lipid 
accumulation (194, 249-251). This pattern of lipid vacuolation has been observed in proximal 
tubular cells in mice with 5' adenosine monophosphate-activated protein kinase (AMPK)-b1 
subunit deficiency, suggesting an interaction between the AMPK pathway and the 
  
 
218 
development of CKD (248). Recently, Mount and colleagues have showed that lipid 
accumulation is associated with reduced activity of AMPK in the kidney, leading to reduced 
phosphorylation and increased activity of acetyl CoA carboxylase which can thereby set forth 
increased oxidative stress (194). The HFD-fed offspring in the present study had marked 
hyperlipidaemia, with serum total cholesterol, triglycerides and LDL markedly raised 
consistent with the abovementioned association between deranged lipid metabolism and 
vacuolation. 
 
The results of the current study complement our previous studies demonstrating renal effects 
of maternal obesity until adolescence, related to renal inflammatory, oxidative stress and 
fibrotic markers (341, 356). Taken together with the current results, the detrimental effect of 
maternal obesity on renal health persists to adulthood though diet-induced obesity is a more 
powerful inducer of renal damage. The addition of STZ together with HFD in the present 
study was not successful in demonstrating a sustained effect of maternal obesity on renal 
fibrosis. This may possibly be due to an inadequate dose of STZ, and others have proposed 
using three low doses of STZ with HFD as an alternative (389). 
 
In summary, our study provides evidence of the marked glucose intolerance, metabolic, and 
kidney damage associated with diet-induced obesity in C57BL/6 mice. We demonstrate that 
inflammatory and oxidative stress markers are significantly elevated in the kidneys of obese 
mice and that they have altered functional and structural changes including tubulointerstitial 
fibrosis and tubular vacuolation. Maternal obesity had a sustained effect on glucose tolerance, 
serum free fatty acids and renal oxidative stress markers. The harmful effects of diet-induced 
obesity overpower the impact of maternal obesity on renal consequences.  
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     Chapter 8  
 
 
 
Summary And Future Directions 
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8.1 Summary of key findings 
 
The principal finding in my studies is that maternal obesity has a detrimental impact on 
kidney health in the offspring, demonstrated within weeks of birth and still evident in adult 
life in rodent models. Though maternal obesity is known to have significant ramifications for 
the offspring’s risk of chronic disease, underpinned by developmental programming, very 
little research has been conducted previously to determine whether maternal obesity affects 
kidney health in offspring. There is ample evidence to support diabetes as a significant risk 
factor for CKD and furthermore obesity-related kidney disease is appreciated as an 
independent cause of CKD (219, 221, 222). My data provide evidence of the powerful effect 
of obesity on renal health and strongly suggests that maternal obesity should be considered an 
independent risk factor for CKD in the offspring.  
 
As described in Chapter 3 and published in Nutrition and Metabolism (341), I used a rat 
model of maternal obesity to demonstrate that offspring of obese mothers were heavier with 
increased adiposity, higher plasma insulin and significantly higher triglyceride levels, 
highlighting maternal overnutrition as a potent factor to increase metabolic disorders in 
offspring. Offspring of obese mothers demonstrated glucose intolerance at weaning, with 
associated downregulation of renal FXR expression and upregulation of the inflammatory 
markers MCP-1 and TGF-β1. This finding was in keeping with in vitro data performed in 
HK2 cells, showing reduced FXR expression and increased MCP-1, TGF-β1, fibronectin and 
collagen IV expression in the presence of high glucose. This in vitro work provided support 
to the notion that maternal obesity specifically influences kidney health, separate to systemic 
whole-body effects that may at least in part by due to increased glucose levels. A limitation to 
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the studies performed in Chapter 3 was that the effects of maternal obesity on renal outcomes 
was assessed at weaning (postnatal Day 20) thereby precluding the ability to determine 
whether the effect of maternal obesity on renal outcomes was due to developmental 
programming or the diet-induced effects of suckling from mothers fed a HFD. 
 
In Chapter 4, published in Scientific Reports (356), I used the same rat model of maternal 
obesity to show that the impact of maternal obesity on renal health lasted well past weaning 
to adolescence. I found that the kidneys of offspring from obese mothers had significantly 
increased markers of inflammation, oxidative stress and fibrosis. I showed that the GLP-1 
agonist, Exendin-4 was able to ameliorate the negative renal effects of maternal obesity and 
in particular, reduced renal inflammation, oxidative stress and fibrosis. This data suggests 
that GLP-1 agonists may have a potential therapeutic role in protecting the kidney against the 
deleterious consequences of maternal obesity on renal physiology in offspring.  
 
Diabetes is a significant risk factor for the development of CKD, which is pathologically 
characterised by increased extracellular matrix and interstitial renal fibrosis (334). In Chapter 
5, I hypothesised that maternal obesity may exacerbate the effect of diabetes-related kidney 
damage in the offspring. Offspring of obese or lean mothers were exposed to the beta-cell 
toxic effects of STZ, in order to develop a mouse model of insulin-deficient diabetes, 
mimicking type 1 diabetes, which was observed until well into adulthood, at postnatal week 
32. I found that the offspring of obese mothers had impaired renal function alongside 
significant structural changes, including accelerated renal fibrosis. Both renal inflammation 
and oxidative stress were exacerbated in offspring born to obese mothers, further exaggerated 
by the deleterious effects of diabetes, suggesting an additive effect of programming by 
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maternal obesity when diabetes supervenes. The content of Chapter 5 has been published in 
Scientific Reports on 25th May, 2016 (407).  
 
In Chapter 6 I explored mouse models of obesity and diabetes. The C57BL/6 mouse had 
impaired glucose tolerance with weight gain induced by HFD-feeding. There were major 
perturbations in body fat distribution, glucose tolerance and lipid profiles in the mice fed 
HFD, which closely resembles the metabolic syndrome described in humans. Although I had 
considered that one dose STZ, in addition to HFD, may worsen metabolic features in the 
mice, one dose of STZ appeared to have little effect. As demonstrated in Chapter 5, chow-fed 
mice exposed to five doses of STZ developed characteristics of T1D with a lean phenotype, 
hyperglycaemia and microalbuminuria. Interestingly, the renal tubules of insulin-deficient 
mice demonstrated marked glycogenated nuclei, a finding which we found to be unique to the 
T1D model. Importantly, HFD-fed mice had increased urinary albumin and serum creatinine 
and there were features of structural damage with prominent interstitial vacuolation seen in 
HFD-fed mice. The kidneys also showed increased glomerular changes and tubular injury. 
Chapter 6 has been published in PLoS One on 31st August, 2016 (409). 
 
The results of Chapter 6 clearly identified that the C57BL/6 mouse model of HFD with or 
without STZ is an excellent model of metabolic derangements and obesity-induced kidney 
disease. Based on the results from Chapter 5 in the T1D model, I hypothesised that maternal 
obesity would also increase kidney damage in offspring with obesity-related renal injury. 
Contrary to my expectation, in Chapter 7 I found that maternal obesity did not worsen the 
renal damage induced by diet-induced obesity.  Renal function, structure and markers of 
inflammation, oxidative stress and fibrosis were massively increased by HFD-induced 
obesity. The only consistent alteration induced by maternal obesity appeared to be mild 
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elevation in serum creatinine and increased renal markers of oxidative stress. Chapter 7 is 
currently under review to publication with The International Journal of Biochemistry and 
Cell Biology. 
 
An important limitation of my studies was that male, and not female, offspring were 
examined. The developmental programing effects of maternal obesity appear to impact male 
offspring more significantly than female offspring (70, 410, 411). Furthermore, chronic 
kidney disease, specifically diabetic nephropathy, is known to be more prevalent and 
progressive in males compared to females (318, 412). This sexual dimorphism is likely due to 
the differential effect of hormones, including sex steroids (70-72). In particular, oestrogen 
positively impacts anti-inflammatory mediators and the renin-angiotensin system in the 
kidney. These effects may contribute to alterations in kidney haemodynamics and affect 
kidney disease progression.  
 
8.2 Future directions 
 
There is considerable evidence related to the pathways of inflammation, oxidative stress and 
fibrosis with regard to the pathogenesis of CKD (186, 210). Our results support the 
hypothesis that maternal obesity is an important modulator of these pathways and hence a 
contributor to future CKD risk in the offspring. Further studies are needed to explore the 
critical components of in utero exposure underlying the influence of maternal obesity on 
renal outcomes in both rodents and humans, and will guide future therapeutic intervention. 
One likely key player is the placenta, which acts as an important gatekeeper between the 
maternal and foetal circulations. An objective for future studies is to determine the role of the 
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placenta in orchestrating the effect of perturbations related to maternal obesity on metabolic 
programming within the foetal kidney. There are several unanswered questions related to this 
concept. Are all periods of gestation as important for the deleterious renal effects of maternal 
obesity? For example, is early gestation most important when placental implantation is 
occurring or is late gestation more important when final kidney maturation is taking place? 
Another question arises: If weight loss occurs prior to conception, will this resolve the 
negative programming effects of maternal obesity on the renal health of offspring? There is 
some evidence to suggest that this may not be the case and invokes the concept of permanent 
epigenetic modifications with the potential to lead to transgenerational propagation of obesity 
and renal disease (314, 413). Transmission of epigenetic modifications from mother to child 
requires further consideration and is the subject of a grant proposal submitted for NHMRC 
funding for which I am a collaborator. I have commenced a clinical project whereby maternal 
and foetal blood, placenta and amniotic fluid of obese versus normal-weight mothers will be 
collected to determine the transmission of methylated DNA transcripts related to the kidney.  
Importantly, amniotic fluid is mostly a by-product of kidney excretion at the end of gestation 
(414), making it an excellent fluid to examine renal transcripts. I intend to interrogate some 
of the known regulators of metabolism in the placenta, which will relate to renal outcomes 
and to the mechanisms underpinning developmental programming in general. I intend to 
perform more animal experiments utilising the rodent model of maternal obesity that we have 
developed. These may include manipulation of diet before and during pregnancy and 
examination of the placenta at various stages of gestation. 
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8.3 Therapeutic application 
 
Another avenue for future research is to investigate the off-target effects of GLP-1 
modulation. The primary role of GLP-1 is to modulate insulin secretion and regulate glucose 
homeostasis. Chapter 4 identified that renal inflammation and oxidative stress induced by 
maternal obesity were modulated by GLP-1 activation via Exendin-4 therapy. It remains 
uncertain if the advantageous renal effects are due to whole body weight loss of the organism 
or pleiotropic effects directly on the kidney. Studies investigating the renal effects of GLP-1 
agonist therapy in rodents and humans are generally confounded by the effect of weight loss 
associated with GLP-1 agonists. I have been the second author on a recent publication 
reviewing the neurological off-target effects of GLP-1 modulation which include anti-
inflammatory and anti-apoptotic effects on neural cells (415). Furthermore, I am currently an 
investigator of a randomised controlled trial examining the effects of GLP-1 agonist, 
liraglutide, on cardiac and neurological function. This project entitled “The Combined Effect 
of Liraglutide and Sleeve Gastrectomy on Metabolic, Cardiac, Neurological and Sleep 
Function in Obese Diabetes” (LIRASLEEVE) has been recruiting since the commencement 
of my PhD studies. I envisage its completion in the next 12 months. These off-target effects 
of GLP-1 modulation are likely to have broad clinical application and are likely related to its 
anti-inflammatory and anti-oxidative stress effects (416). The GLP-1 agonist liraglutide 
(Saxenda©) has been approved by the Australian Therapeutic Goods Administration (TGA) 
for primary use in obesity for weight loss. Its application may potentially be useful for 
preconception planning in obese women with the potential for improved pregnancy outcomes 
for both mother and offspring. Such therapy may reverse the potential deleterious effects of 
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maternal obesity on developmental programming. To date, there is insufficient data to 
recommend its use in pregnancy.  
 
Other targets to reduce renal inflammation and oxidative stress are needed to prevent the 
harmful effects of maternal obesity on renal health. Agents safe in human pregnancy, such as 
hydralazine, that can reverse adverse epigenetic modification, could be useful to prevent 
developmental programming of maternal obesity impacting on renal health in offspring. 
Furthermore, naturally occurring food stuffs may also have a potential role in reducing 
programming effects of maternal obesity and again, we are currently exploring these options. 
 
Finally, my project calls for unity of industry, academia and public health to come together 
with policymakers and governments to devise public health strategies to reduce obesity, 
particularly in women of reproductive age. I suggest that this is a particularly pertinent 
population to address given its far-reaching consequences for disease propagation to 
subsequent generations. My PhD has therefore generated many research questions requiring 
further targeted investigation. I am planning to pursue these areas of research in my 
postdoctoral studies with the aim of developing an academic career bridging the multifaceted 
aspects of obesity, diabetes and chronic kidney disease. 
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